



(43) International Publication Date
29 June 2017 (29.06.2017)

(10) International Publication Number
WO 2017/109227 A1

- (51) International Patent Classification:
A61K 39/12 (2006.01) *C07K 14/005* (2006.01)
- (21) International Application Number:
PCT/EP2016/082666
- (22) International Filing Date:
23 December 2016 (23.12.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
15202585.4 23 December 2015 (23.12.2015) EP
16161068.8 18 March 2016 (18.03.2016) EP
16176025.1 23 June 2016 (23.06.2016) EP
16176049.1 23 June 2016 (23.06.2016) EP
16182845.4 4 August 2016 (04.08.2016) EP
- (71) Applicant: **VALNEVA AUSTRIA GMBH** [AT/AT];
Campus Vienna Biocenter 3, 1030 Vienna (AT).
- (72) Inventors: **BARBERO CALZADO, Jana**; Valneva Austria GmbH, Mittersteig 20/21, 1050 Vienna (AT). **NEBENFÜHR, Mario**; Valneva Austria GmbH, Grimmelshausengasse 12/27, 1030 Vienna (AT). **SCHLEGL, Robert**; Valneva Austria GmbH, Rosenthal 63, 2500 Siegenfeld (AT). **WEBER, Michael**; Valneva Austria GmbH, Rechte Wienzeile 249/15, 1120 Vienna (AT). **WRUSS, Jürgen**; Valneva Austria GmbH, Dampfgasse 25/27-29, 1100 Vienna (AT).
- (74) Agent: **DEMPSTER, Robert**; Maschio & Soames IP Limited, 30 Carlton Crescent, Southampton Hampshire SO15 2EW (GB).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ZIKA VIRUS PURIFICATION

(57) Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.



WO 2017/109227 A1

ZIKA VIRUS PURIFICATION

FIELD OF THE INVENTION

5 The disclosure relates to methods for the purification of Zika viruses for use in vaccines and in particular relates to an improved sucrose gradient process step allowing the separation of impurities such as protamine sulphate.

BACKGROUND OF THE INVENTION

10

Adverse responses to protamine sulfate have been known for many years. Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug. Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may
15 experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Although there is no clear evidence for hypersensitivity reactions of protamine sulphate linked to vaccination, vaccines containing protamine impurities have a precaution and contraindication
20 warning in their labels stating that a serious allergic reaction after a previous dose of such a protamine containing vaccine (e.g. IXIARO®, see CDC site <http://www.cdc.gov/japaneseencephalitis/vaccine/>) is a contraindication to further doses. Thus elimination of said impurity is a medical request for an improved safety profile. On the other hand protamine sulphate is an excellent tool (and often better than other reagents such as benzonase) to
25 purify crude harvests of viruses grown on cell substrates.

In 2007, Zika virus was detected for the first time outside of the endemic regions of Asia and Africa since its discovery in a Rhesus monkey in Uganda in 1947. Since then, the virus has caused a large epidemic in French Polynesia, spreading through islands in the Pacific and into South and
30 Central America by 2015 (WHO “Zika Situation Report” February 5, 2016). Evidence suggests that in addition to being transmitted by *Aedes* species mosquitos, other vectors may exist, and the virus may be transmitted by blood transfusion, transplacentally, and through sexual transmission (WHO Zika Virus Fact Sheet, Feb. 2016). Though the symptoms of Zika virus infection include mild fever, rash, and conjunctivitis, there is a likely correlation between infection and neurological
35 disorders, including Guillain-Barré syndrome and microcephaly in fetuses/neonates subsequent to

infection during pregnancy. There is currently no specific treatment or vaccine for Zika virus and the only preventative measures involve control of the mosquito vector. Zika virus presents a substantial public health threat due to the wide circulation of the *Aedes* mosquito, multiple routes of transmission, and potentially severe neurological effects of infection.

5

A preventative vaccine against Zika virus is a pressing medical need in endemic areas and in geographical areas where the vector is spreading. Furthermore, as Zika infection has dire consequences on embryonic and fetal development, a safe and effective vaccine for women of child-bearing potential or pregnant women is needed. Vaccines administered during pregnancy must be very safe for both the mother and the developing fetus. While live attenuated viral vaccines are highly effective, they are often not considered safe enough for administration to pregnant women. In this regard, inactivated viral vaccines, which lack the ability to propagate in the vaccinated subject, are considered much safer. Development of an inactivated Zika virus vaccine for administration to at-risk patients would fill this need.

10

15

SUMMARY OF THE INVENTION

Zika virus is a flavivirus closely related to Dengue virus and is similarly transmitted by the *Aedes* species mosquito, although other arthropod vectors for Zika virus are possible. Since it was first isolated from a Rhesus monkey in the Zika forest of Uganda in 1947, there were very few reported incidents of human infection, especially outside of the endemic regions of Africa and Asia until a large outbreak in French Polynesia in 2007 (Haddow *et al. PLoS Neglected Tropical Diseases* (2012) 6(2), Malone *et al. PLoS Neglected Tropical Diseases* (2016) 10(3),). The virus has since spread through islands of the Pacific, including Oceania, and into South and Central America (WHO “Zika Situation Report” February 5, 2016).

20

25

In addition to being spread by the bite of an infected mosquito, evidence also suggests transmission may occur between individuals, such as from the blood of an infected individual, *in utero*/transplacental transmission from an infected mother to the fetus, sexual transmission between sexual partners, and possibly by other local transmission routes. There is a possible association between Zika virus infection during pregnancy and microcephaly in the fetus/neonate. Microcephaly is a rare condition in which a baby’s head circumference is significantly less than expected based on the average for their age, sex, and ethnicity. This is a result of the brain failing to undergo proper embryonic development, and in 90% of cases is associated with mental retardation (Rocha *et al. (2016) Bull World Health Organ* 8 Feb. 2016).

30

35

There is a probable association between individuals having had a prior Zika virus infection and the incidence of Guillain-Barré syndrome, a neurological disorder in which the individual's immune system destroys the myelin sheath surrounding axons of the peripheral nervous system (WHO
5 "Zika Situation Report" February 5, 2016).

No specific treatments or vaccines for Zika virus currently exist, and the only measures at this time to prevent infection are through vector control and avoiding travel to regions experiencing outbreaks.

10 Described herein are Zika virus vaccines and compositions comprising inactivated Zika virus that provide a safe method for generating an immune response to Zika virus, including virus-neutralizing antibodies, that may help protect against Zika virus infection.

15 During the course of virus purification, it was observed that addition of protamine sulfate to a Zika virus harvest produced on a cell substrate removed not only contaminating DNA derived from host cells, as expected, but surprisingly also virtually eliminated immature and otherwise non-infectious Zika virus particles from the preparation. This finding provided a streamlined, gentle and reproducible process for obtaining highly-purified Zika virus particles for applications such as
20 vaccine preparation. In addition, it was surprisingly found that said protamine sulfate can very efficiently be separated from the Zika virus fraction allowing for a safer vaccine produced at high yields.

Disclosed herein are Zika virus vaccines and compositions comprising inactivated Zika viruses,
25 and related methods of producing said vaccines and compositions. Also provided are methods of administering said Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus. In embodiments disclosed herein, "prevention" of a Zika virus infection is equivalent to "protection from" a Zika virus infection; i.e., the Zika virus vaccine of the invention
30 protects a vaccinated subject from noticeable or serious Zika virus infection and/or mild or serious sequelae of Zika virus infection. In particular, the invention is directed to a Zika virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability; i.e., to confer seroprotection. Another advantage
35 of the invention is that related methods of producing said Zika virus vaccines and compositions are

very efficient and provide pure compositions largely devoid of impurities, in particular protamine sulphate, allowing for high volume production of Zika virus vaccines. Examples illustrating the propagation, purification and inactivation of Zika virus are provided herein.

5 The herein disclosed in vivo data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was unexpectedly higher than the recently reported inactivated Zika virus vaccine candidate (Larocca, et. al, 2016, Nature doi:10.1038/nature18952.). Inactivated viruses are
10 among the safest vaccines and especially preferred for deliver to populations where safety is especially concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

15 Each of the limitations of the invention can encompass various embodiments of the invention. It is therefore anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth
20 in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

25 The accompanying drawings are not intended to be drawn to scale. The figures are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing, alignments were performed with the multi alignment package Jalview (Waterhouse et al., 2009, Bioinformatics 25 (9) 1189-1191). In the drawings:

30 **Figure 1:** Average distance tree (by % identity, nt), complete genomes.

Figure 2: Neighbor joining tree (by % identity, nt), complete genomes.

Figure 3: Pairwise alignment-Jalview (% identity, nt), complete genomes.

Figure 4: Average distance tree (by % identity, aa), E-protein.

Figure 5: Neighbor joining tree (by % identity, aa), E-protein.

5 **Figure 6:** Pairwise alignment-Jalview (% identity, aa), E-protein.

Figure 7: Alignment (shading: % identity, aa), E-protein.

10 **Figure 8:** An example of virus particle maturation in the host cell. As observed in flaviviruses, full maturation of the particles requires proteolytic cleavage of the precursor membrane glycoprotein (prM) by the host protease furin. Not all prM molecules are cleaved, resulting in the release of mature, mosaic or immature-like conformations from the cells. Mosaic and immature forms are generally not infectious—only mature virions are infective and have hemagglutinin (HA) / TCID50 activity. (Figure adapted from Plevka, et al., Maturation of flaviviruses starts from one or more
15 icosahedrally independent nucleation centres, EMBO reports (2011) 12, 602–606).

Figure 9: An exemplary downstream Zika virus purification process from the crude harvest to formulation of the drug substance (vaccine), a preferred embodiment of the process of the invention (A). A flow-chart of an exemplary Zika virus inactivation process is shown in (B).
20

Figure 10: PS treatment results in selective removal of Zika virus aggregates and Vero HCP and LMW impurities (SEC-HPLC of 30x concentrated Zika Virus harvest day 5).

Figure 11: SEC-HPLC of individual 30x concentrated Zika harvest prior to PS treatment at
25 different time points.

Figure 12: SEC-HPLC of individual 30x concentrated Zika harvest post PS treatment at different time points. The smaller graph indicates the observed cytopathic effect (CPE) over time.

30 **Figure 13:** Preparation of the sucrose gradient.

Figure 14: Representative SDS-PAGE from the sucrose gradient harvest of a Zika virus purification is shown.

35 **Figure 15:** Comparison of JEV and ZikaV harvest schedules/yields.

Figure 16: SEC-HPLC elution profile of ZikaV neutralized inactivated virus (NIV). Data were processed on Dionex Ultimate 3000 / Superose 6 Increase column. Both panels are from the same chromatogram. The upper graph is the complete elution profile; the lower graph is an enlargement of the ZikaV elution peak.

Figure 17: SEC-MALLS analysis of inactivated ZikaV.

Figure 18: Cumulative particle size distribution of Zika NIV.

Figure 19: Graphical representation of the neutralization of the Zika virus H/PF/2013 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

Figure 20: Graphical representation of the neutralization of the Zika virus MR766 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

Figure 21: Correlation between JEV antigen content in neutralized inactivated virus (NIV) analysed by ELISA and SEC-HPLC (Dionex Ultimate 3000, Superose 6 column).

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus. In particular, the invention is directed to a Zika virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle in an appropriate dose is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability, preferably an 80% probability, i.e., is able to confer seroprotection in at least 70% of vaccinated subjects. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely devoid of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided herein for Zika virus.

Disclosed herein are downstream processes for purifying Zika virus particles from a crude preparation. The downstream process can be applied to either a Zika virus which has not adapted for propagation on a particular cell substrate or for a partially / fully cell substrate adapted virus particle.

Aspects of the invention provide processes for the purification of infectious Zika virus particles comprising the steps of (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said Zika virus particles on a cell substrate; (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a Zika virus preparation (b); and further purifying the Zika virus preparation (b) by an optimized sucrose density gradient centrifugation to obtain a Zika virus preparation (c) comprising the infectious Zika virus particles.

In some embodiments, the concentration of protamine sulphate in step (b) is about 1 to 10 mg/ml, more preferably about 1 to 5 mg/ml, more preferably about 1 to 2 mg/ml. In one embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/mL. In one embodiment, the concentration of protamine sulphate is 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml. In a preferred embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/ml.

In some embodiments, the residual host cell DNA of the Zika virus preparation (c) is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL. In a preferred embodiment, the residual host cell DNA of the Zika virus preparation (c) is less than 10 ng/mL. In some embodiments, the residual host cell protein of the final Zika virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual host cell protein of the Zika virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual non-infectious Zika virus particles of the final Zika virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual non-infectious Zika virus particles of the Zika virus preparation (c) is less than 100 ng/mL.

In some embodiments, the residual protamine is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, more preferably is below the detection limit of HPLC, in particular below the detection limit in the final drug substance. In some embodiments, the PS content is tested by HPLC or size exclusion chromatography (SEC).

For example, HPLC is validated for PS determination in JEV sucrose gradient pool samples as a routine release assay and is very sensitive (i.e., LOQ 3µg/mL; LOD 1µg/mL). In the current invention, PS content in in Zika virus DS samples was <LOD. In one embodiment, the HPLC assessment of PS content can be performed on a Superdex Peptide 10/300GL column (GE: 17-5176-01) using 30% Acetonitrile, 0,1% Trifluoroacetic acid as solvent with a flow rate of 0,6 ml/min at 25°C and detection at 214 nm. A more sensitive method of measurement for residual protamine in a purified virus preparation is mass spectrometry (MS). In some embodiments, the residual PS levels in a Zika virus preparation are tested by MS or other such highly sensitive method, e.g. nuclear magnetic resonance (NMR). With this method, residual PS, as well as fragments and/or break-down products of PS, can be detected at trace amounts, such as levels as low as, for example, 10^6 , 10^7 or 10^8 molecules per typical sample load. In some embodiments, the PS levels are tested in the sucrose gradient pool. In some embodiments, the PS levels are tested in the drug product. In some embodiments, the PS levels are tested in the drug substance.

In some embodiments, the crude harvest (a) comprising the Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b). In some embodiments, the one or more pre-purification step(s) comprises digesting host cell genomic DNA in the crude harvest (a) comprising the Zika virus particles and impurities by enzymatic treatment. In some embodiments, the one or more pre-purification step(s) comprises filtration, ultrafiltration, concentration, buffer exchange and/or diafiltration. In some embodiments, the one or more pre-purification steps is filtration using a filter having a pore size equal to or less than 1 µm. In some embodiments, the filter has a pore size equal to or less than 0.2 µm. In a preferred embodiment, the filter has a pore size of 0.2 µm. In some embodiments, the concentration and/or ultra/diafiltration and/or buffer exchange is performed by tangential flow filtration (TFF). In some embodiments, ultra/diafiltration of the crude harvest (a) comprising the Zika virus particles and impurities is performed using a hollow fiber membrane having a cut-off of equal to or less than 300 kDa. In a preferred embodiment, the hollow fiber membrane has a cut-off of about 100 kDa.

The process according to the current invention may also comprise the use of a sucrose gradient, preferably an optimized sucrose gradient. The sucrose gradient is preferably optimized for the removal of protamine sulfate, also for the removal of immature viral particles or other viral particles which are non-infectious or host cell proteins or nucleic acids (DNA, RNA, mRNA, etc) or other host cell debris. In the current invention the optimized sucrose gradient comprises at least two, at least three, at least four layers of sucrose solutions with different densities. In one embodiment, the virus preparation to be purified is provided in a sucrose solution which has a

density of about 8%, about 9%, about 10%, about 11%, about 12% sucrose (w/w), preferably about 10%. In one embodiment, one sucrose solution in the gradient has a density of about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55% sucrose (w/w), preferably about 50%. In one embodiment, one sucrose solution in the gradient has a density of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40% sucrose (w/w), preferably about 35%. In one embodiment, one sucrose solution in the gradient has a density of about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20% sucrose (w/w), preferably about 15% sucrose. In a preferred embodiment, the sucrose gradient comprises three layers of sucrose solutions of about 50%, about 35% and about 15% (w/w) sucrose and the virus composition to be purified is contained in about 10% (w/w) sucrose. Because the invention provided for means to not only test for host cell DNA but also immature viral particles, the skilled person in the art is able to more precisely optimize the sucrose gradient for most efficient purification and include additional tools such as PRNT assay to monitor purification success.

In some embodiments, the Zika virus particle is a live virus, a chimeric virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In a further step, the Zika virus particles of the invention may be optionally inactivated. In some embodiments, the Zika virus particle is an attenuated form of the virus particle. For example, the virus may have reduced infectivity, virulence, and/or replication in a host, as compared to a wild-type Zika virus. In some embodiments, the Zika virus is a mutated or modified virus, for example the nucleic acid of the Zika virus may contain at least one mutation relative to the wild-type Zika virus. In some embodiments, the virus is a recombinant live Zika virus, meaning a virus that is generated recombinantly and may contain nucleic acid from different sources.

In a most preferred embodiment, the Zika virus is a Zika virus from the Asian lineage.

In some embodiments, the relative reduction of impurity of the final Zika virus preparation relative to the liquid medium (a) comprising the Zika virus particles and impurities is in a range from 60 to 95%. In some embodiments, the residual impurity of the final Zika virus preparation is less than 1%.

In some embodiments, the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a

293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line. In some embodiments, said cell line is a duck cell line. In some embodiments, said cell line is a diploid avian cell line. In some embodiments, said cell line is an EB66 cell line. In a preferred embodiment, said cell line is a Vero cell line.

Aspects of the invention provide a use of any of the processes described herein for manufacturing a composition for immunization against a Zika viral infection. In a preferred embodiment, the composition is a vaccine. In a preferred embodiment, the composition or vaccine directed against Zika virus is directed to a Zika virus of the Asian lineage.

Other aspects provide compositions comprising the Zika virus particles obtainable by any of the processes described herein for treating and/or preventing a Zika viral infection. In one embodiment, the Zika viral infection is caused by a Zika virus of the Asian lineage.

Furthermore, disclosed herein are vaccines and compositions comprising an inactivated Zika virus. Also provided are methods of administering the said vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus.

Any strain of Zika virus may be used in the methods and compositions described herein. In some embodiments, the Zika virus is an isolate from an infected subject during a Zika virus outbreak. In some embodiments, the Zika virus is a strain isolated from Africa or from the African virus lineage. In some embodiments, the Zika virus is a strain isolated from Asia or from the Asian lineage (includes also strains from French Polynesia). In some embodiments, the Zika virus is a strain isolated from the Americas (South America, Central America, or North America), such as a Suriname Zika virus strain. In some embodiments, the Zika virus has an RNA genome corresponding (but not limited) to the DNA sequences provided by GenBank Accession Nos., KU321639.1, KU497555.1, KU501215.1, KU509998.1, KU527068.1, KU681081.3, KU681082.3, KU707826.1, KU744693.1, KJ776791.1, KJ776791.2 or LC002520.1, AY632535.2 or an RNA genome disclosed partially or fully herein (SEQ ID NOs: 2 to 69 or 72).

In some embodiments, the process of the invention results in an enrichment of infectious Zika virus particles from the crude harvest comprising infectious Zika virus particles and non-infectious Zika

virus particles and other Zika virus products such that the enrichment of the infectious Zika virus particles is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, preferably at least 80%, especially at least 85% relative to the total virus particle content of the crude harvest (a) comprising the Zika virus particles and impurities.

5

In some embodiments, the residual impurity of the final Zika virus preparation with respect to all impurities in the crude harvest is less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, preferably less than 5% as determined by SEC-HPLC (Size Exclusion Chromatography – HPLC).

10

A unique aspect of the current invention is the realization that know-how related to the vaccine design and purification approach used for the Japanese Encephalitis Vaccine (JEV) IXIARO® (see Srivastava A.K. et al., 2001, Vaccine 19, 4557-4565, WO99/11762) may be employed and improved upon in order to expedite the development of a Zika virus vaccine and provide it to the subjects in need as soon as possible. The industrial process as disclosed for IXIARO®, providing a very effective vaccine against JEV, was complemented by further significant improvements disclosed herein in order to provide a more efficient (higher yield) and safer (less or no protamine sulphate with its allergic potential) Zika vaccine compared to the available JEV vaccine. A particular innovation of the herein disclosed vaccines is their greatly reduced protamine salt (SEQ ID NO: 1) content in the final drug substance facilitated by the development of an improved sucrose gradient. Said sucrose gradient not only allowed the separation of protamine sulphate but also allowed for a very effective inactivation by formaldehyde and resulted in over 90% yield of Zika virus with the improved process disclosed herein compared with about 35% yield with the published JEV process (see experimental part for comparison). Thus, the invention provides for a robust process for the preparation of Zika virus vaccines.

25

Aspects of the disclosure relate to methods of producing a Zika virus in Vero tissue culture cells. Vero cells are a commonly used tissue culture cell line derived from the kidney of an African green monkey. The Vero cells used in the methods described herein are the VERO (WHO) cell line, obtained from the Health Protection Agency general cell collection under catalogue number 88020401.

30

Vero cells can be grown to confluent monolayers, for example in tissue culture flasks; in suspension (on microcarriers), for example in roller bottles; or in any other cell culture system for Zika virus production. In some embodiments, the Vero cells are grown in a bioreactor for viral production. For plaque assays or the plaque reduction neutralization test (PRNT), Vero cells are

35

grown in monolayers in tissue culture flasks, dishes, or wells of a plate. To infect the Vero cells with the Zika virus, the culture medium is inoculated with Zika virus and the cells are incubated with the Zika virus for a period of time. The cells may be washed after inoculation to remove any Zika virus that did not adsorb to the cells in a given amount of time.

5

The methods provided herein involve passaging the Zika virus in Vero cells. As used herein, the terms “passage” or “passaging” refer to infecting a population of Vero cells with Zika virus and subsequently inoculating a second population of Vero cells with Zika virus produced by infection of the first Vero cell population. In some embodiments, a portion of the culture medium from the infected Vero cells (containing Zika virus that was released from the infected cells) is used to inoculate a second population of Vero cells. This is referred to as one passage or one round of passaging. The passaging may be performed serially, for example, a portion of the culture medium from the infected second population of Vero cells is used to inoculate a third population of Vero cells, and so on. In some embodiments, Zika virus obtained from a single plaque is used to inoculate another population of cells.

10

15

In some embodiments, the Zika virus is passaged in Vero cells several times, such as at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 times. In some embodiments, the Zika virus is passaged in Vero cells at least 4 times or 5 times. In some embodiments, the Zika virus is passaged in Vero cells at least 30 times. It is important that the virus population, i.e. the Zika virus sequence, stays as much as possible constant over said passaging. If adaption of the Zika virus occurs (i.e. appearance of mutated Zika viruses in the original Zika virus population), it is preferred that said passages are not used in the context of manufacturing of said virus, e.g. for Zika it was found that up to passage 3 and culturing to day 7 can be used without major shifts in virus population, i.e. introduction of virus population with mutations. However this observation needs to be done for each Zika virus strain and may be different.

20

25

In some embodiments, the Vero cells are incubated for at least 2 days after inoculation with the Zika virus at e.g. a typical 0.01 MOI (multiplicity of infection), to allow for Zika viral production, prior to passaging. In some embodiments, the Vero cells are incubated for at least 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days e.g. at least 7 days after inoculation with the Zika virus prior to passaging. The number of days the Vero cells are incubated after Zika viral inoculation may depend on factors such as the multiplicity of infection used to inoculate the cells and the viral titer desired in the

30

culture medium. Serial passaging of the Zika virus in Vero cells may result in generation of a Vero cell adapted Zika virus strain.

The culture medium from the infected Vero cells may be harvested (collected) to obtain the Zika virus. In some embodiments, the culture medium is harvested from infected Vero cells and is replaced with fresh culture medium, which is then harvested after another period of time. In some embodiments, the culture medium harvested from infected Vero cells is pooled from independent Vero cell cultures and/or from independent days. Harvesting can be repeated up to 4 times by 7 or 9 days post infection, for example, and result in a high yield of virus per unit cell culture. In order to minimize the adoption of Zika virus strain to Vero cells, it was found that Vero cell could be incubated for at least 7 days, more preferably 5 days, prior to passaging and subsequently supernatants could be harvested at days 2, 3, 5 and 7 or 2, 3, and 5 (see also experimental part). The harvested culture medium can be stored at +4°C prior to purification of the virus from the culture medium for up to 2 weeks.

In some embodiments, debris from infected and lysed Vero cells may be removed from the harvested culture medium, referred to as a “clarification” of the culture medium. The harvested culture medium may be clarified by common methods known in the art, such as low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45 µm. The harvested culture medium can be stored at +4°C prior to concentration.

The inventive processes of this invention can also be applied to the purification of infectious Zika virus particles grown on other cell substrates such as Chick embryo cell (CEF), Sf-9, high five, MRC-5, WI-38, MDCK, PER.C6, and avian cell lines, e.g. the duck cell line EB66 and many others.

To concentrate the titer of the Zika virus in the harvested culture medium, it may be subjected to concentration by any method known in the art. For example, the harvested culture medium may be concentrated by methods including, without limitation, ultrafiltration, ultracentrifugation, centrifugal concentrator, vacuum centrifugation, and lyophilization. In some embodiments, the harvested culture medium is concentrated by ultrafiltration and the retentate containing the Zika virus is collected. In some embodiments, the harvested culture medium is concentrated by precipitation in which polyethylene glycol (PEG) 8000 is dissolved in the culture medium (up to 10%) and the precipitate is dissolved in a buffer, for example phosphate-buffered saline (PBS, pH 7.0).

The harvested culture medium may be precipitated to produce a Zika virus supernatant. In some embodiments, the harvested culture medium is precipitated to remove host cell DNA such as Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. In some embodiments, the harvested culture medium is concentrated prior to precipitation. In some embodiments, the harvested culture medium is precipitated by adding protamine sulfate (e.g. SEQ ID NO: 1) to the harvested culture medium and incubating the mixture, for example at +4°C or on ice. In some embodiments, the harvested culture medium is treated with benzonase to remove host cell DNA e.g. Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. However, it was found that the treatment with protamine sulfate is preferred (see experimental part). In some embodiments, the precipitated culture medium is centrifuged to collect precipitated material and the supernatant containing the Zika virus, referred to as a “virus supernatant”, is collected.

The Zika virus supernatant may be further purified after precipitation, for example density gradient ultracentrifugation. In some embodiments, the Zika virus supernatant is further purified by sucrose gradient. Fractions may be collected from the sucrose gradients and assayed for presence of the Zika virus. Methods for assaying for Zika virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as Western blotting and ELISA. The fractions containing Zika virus may be pooled based on titer of the Zika virus and level of other impurities. The level or amount of impurities present in the Zika virus supernatant can be estimated by testing for host cell DNA e.g. Vero cell DNA, virus aggregates and/or host cell protein e.g. Vero cell protein (see experimental part). A particular embodiment of the invention is the improved sucrose gradient that allows for an efficient protamine separation as shown in the experimental part. It was surprisingly found that the addition of a Zika virus-containing fraction containing 10% (w/w) sucrose to a simple three layer sucrose density gradient (e.g. a gradient comprising a 15% (w/w) sucrose solution, a 35% (w/w) sucrose solution, and a 50% (w/w) sucrose solution) resulted in efficient separation of protamine sulphate without much loss of Zika virus. Thus a particularly preferred embodiment of the invention is the use of a sucrose density gradient that is able to efficiently separate protamine sulphate, wherein said sucrose density gradient is used in the purification of Zika virus.

To achieve a safe vaccine or composition for the administration to subjects, the Zika virus supernatant may be inactivated (see experimental part). According to the current invention, the inactivation step or steps may be performed at any point in the process such as e.g., directly

following harvest, before or after PS treatment or sucrose gradient centrifugation or any other permutation thereof. As used herein, the terms “inactivated” and “optimally inactivated” may be used interchangeably and refer to a process (or its result) by which the Zika virus is rendered unable to infect a host cell (non-infectious), but that does not affect or substantially affect the antigenicity of the Zika virus, for example, the immunogenic antigens exposed on the surface of the Zika virus are able to stimulate an immune response in a subject (*e.g.*, antigen-specific antibodies). By “does not affect or substantially affect the antigenicity of the virus” is meant that the inactivated Zika virus retains at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even essentially 100% of the antigenicity of a Zika virus that is not subjected to inactivation.

A variety of methods are known in the art for inactivating viruses. In some embodiments, the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

In some embodiments, the inactivating is by chemical inactivation and involves contacting the Zika virus with one or more chemical inactivation agents for a period of time under conditions such that the Zika virus is inactivated but the antigenic epitopes are substantially intact. In some embodiments, the Zika virus is inactivated for a period of time that is longer than is required to completely inactivate the Zika virus. In some embodiments, the Zika virus supernatant is inactivated for the number of days required to inactivate the Zika virus plus at least one additional day. Samples of the Zika virus supernatant may be taken at one or more times throughout the inactivation process and assessed for viral viability (infectivity) by any method known in the art, such as by infecting a monolayer of host cells (*i.e.*, plaque assay). Using such a procedure, the period of time that is required to completely inactivate the Zika virus can be determined, and a longer period of time is selected to ensure complete inactivation.

In some embodiments, the Zika virus is contacted with a chemical inactivation agent for between 1 day and 50 days, between 2 days and 40 days, between 2 days and 30 days, between 2 days and 20 days, between 2 days and 10 days, between 3 days and 9 days, between 4 days and 8 days, between 5 days and 7 days, between 2 days and 5 days, or between 5 and 10 days. In some embodiments, the virus is contacted with one or more chemical inactivation agents for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26

days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, or at least 50 days.

- 5 In some embodiments, the chemical inactivation is performed at about +5°C, +10°C, +15°C, +20°C, +25°C, +30°C, +35°C, +40°C, or about +45°C. In some embodiments, the chemical inactivation is performed at about +4°C. In some embodiments, the chemical inactivation is performed at about +22°C.
- 10 Any chemical inactivation agent known in the art may be suitable for inactivating the Zika virus in the methods described herein. It will be appreciated by one of skill in the art that factors such as the chemical inactivation agent and the temperature at which inactivation is performed may affect the length of time (number of days) required to completely inactivate the Zika virus. Examples of chemical inactivation agents include, without limitation, formaldehyde, enzymes, β -propiolactone,
- 15 ethanol, trifluoroacetic acid, acetonitrile, bleach, urea, guanidine hydrochloride, tri-n-butyl phosphate, ethylene-imine or a derivatives thereof, and organic solvents such as Tween, Triton, sodium deoxycholate, and sulfobetaine. A preferred inactivation is the inactivation with formaldehyde at 22°C +/- 2°C for about 10 days.
- 20 In some embodiments, the inactivating agent is neutralized after chemical inactivation of the Zika virus. In some embodiments, the inactivating agent is formaldehyde and is neutralized after chemical inactivation using sodium thiosulphate or sodium metabisulfite.

- In some embodiments, the Zika virus is inactivated by thermal inactivation. In some embodiments,
- 25 the thermal inactivation involves exposing the virus to heat, such as dry heat or vapor heat, for a period of time. In some embodiments, the thermal inactivation involves exposing the virus to temperatures of about +40°C, +45°C, +50°C, +55°C, +60°C, +65°C, +70°C, +75°C, +80°C, +85°C, +90°C, +95°C, or about +100°C. In some embodiments, the virus is exposed to heat for at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours,
- 30 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, about 96 hours, or longer. A preferred thermal inactivation involves exposing the virus to temperatures of about +56°C for 60 minutes.

- In some embodiments, the Zika virus is inactivated by exposing the Zika virus to acidic or alkaline
- 35 conditions for a period of time such that the Zika virus is completely inactivated. The pH of a Zika

virus preparation may be adjusted to a desired pH, for example by the addition of an acid, a base, or a buffer with a particular pH to the virus preparation. In some embodiments, the virus is inactivated at an acidic pH of about 2, 2.5, 3, 3.5, 4, 4.5, 5 or about 5.5. In other embodiments, the Zika virus is inactivated at an alkaline pH of about 8, 8.5, 9, 9.5, 10, or about 10.5.

5

In some embodiments, the Zika virus is inactivated using UV inactivation. UV inactivation involves exposing the Zika virus to energy-rich radiation, such as UV-A, UV-B, or UV-C light for a period of time.

10 It will be appreciated that any two or more methods of inactivation may be combined and performed concurrently or serially.

The inactivated Zika virus may be subsequently dialyzed to remove any undesired material, including the inactivating agent and any neutralizing agent, and/or to replace the buffer with a
15 buffer that is pharmaceutically acceptable for administration to subjects. In some embodiments, the inactivated Zika virus is dialyzed with PBS. In addition or alternatively, the inactivated Zika virus may be filtered, such as sterile filtered, through a 0.22 μm filter.

It is believed that the combination of the PS treatment with the optimized sucrose gradient
20 allowing for a complete (or almost complete) separation of PS provides a very efficient Zika virus purification in the very high range, e.g. above 70%, more preferably 75%, 80% or 90%, even more preferably 95%. It is believed that the complete reduction of PS in the Zika virus fraction through the process of the invention allows a very efficient inactivation with almost no or very low Zika viral loss e.g. below 30%, more preferably less than 25%, 20% or 10% loss, even more preferably
25 less than 15% loss.

Any of the methods or uses described herein may be for the prevention of a Zika virus infection in a subject. As used herein, the terms “prevent,” and “preventing”, include the administration of a Zika virus vaccine or composition to a subject to reduce, or delay the onset of the manifestation of
30 clinical or subclinical symptoms, complications, pathologies or biochemical indicia of a disease or infection, or to reduce or inhibit the spread/transmission of the Zika virus. As used herein, “prevent” may also be construed as “protecting from”. As used herein, antigen(s), such as an inactivated Zika virus, that is administered to a subject prophylactically (e.g., prior to infection) may be referred to as a vaccine.

35

Zika Vaccine

As described herein Zika virus may cause any of a variety of symptoms upon infection of a subject, and is generally characterized by mild fever; rash (exanthema) on face, neck trunk, upper arms; headache; sensitivity to light; non-inflammatory joint pain; conjunctivitis; lack of appetite; diarrhea; abdominal pain; and/or dizziness. Zika virus infection during pregnancy is likely associated with microcephaly in the fetus/neonate. There is also a probable association between the onset of Guillain-Barré syndrome or symptoms thereof. Diagnosis of Zika virus infection in subjects exposed to Zika virus or suspected of being exposed to Zika virus involves detecting the presence of virus-specific antibodies and/or molecular testing, such as PCR or real-time PCR detection of Zika virus.

Provided herein are methods for administering a dose of a therapeutically effective amount of a Zika virus vaccine to a subject in need thereof. In some embodiments, the subject is a mammalian subject, such as a human, non-human primate, rodent, rabbit, sheep, dog, cat, horse, or cow. In some embodiments, the subject is a mouse. In some embodiments, the subject is a human subject, such as a child, an adult, or an elderly adult. In some embodiments, the subject is a female subject. In some embodiments, the subject is pregnant or planning on becoming pregnant. In some embodiments, the subject is at risk of being exposed to Zika virus. In some embodiments, the subject is living in or traveling to an area where Zika virus is present or is thought to be present. In some embodiments, the subject is living in or traveling to an area that is experiencing a Zika virus infection outbreak. In some embodiments, the subject is living in or traveling to an area where an arthropod vector capable of transmitting the Zika virus vector is present or is thought to be present.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject in a therapeutically effective amount or a dose of a therapeutically effective amount. As used herein, a “therapeutically effective amount” of vaccine is any amount that results in a desired response or outcome in a subject, such as those described herein, including but not limited to prevention of infection, an immune response or an enhanced immune response to Zika virus, or prevention or reduction of symptoms associated with Zika disease.

In some embodiments, the therapeutically effective amount of a Zika virus vaccine or composition described herein is an amount sufficient to generate antigen-specific antibodies (*e.g.*, anti-Zika virus antibodies). In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 70% probability. In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 75%, 80%, 85% 90%, 95%,

96%, 97%, 98%, or at least 99% probability. Whether a subject has been seroconverted can be assessed by any method known in the art, such as obtaining a serum sample from the subject and performing an assay to detect anti-Zika virus antibodies. In some embodiments, a subject is seroconverted if a serum sample from the subject contains an amount of anti-Zika virus antibodies that surpasses a threshold or predetermined baseline. A subject is generally considered seroconverted if there is at least a 4-fold increase in anti-Zika virus antibodies (*i.e.*, anti-Zika E protein IgG antibodies) present in a serum sample from the subject as compared to a serum sample previously taken from the same subject.

In some embodiments, seroconversion of a subject is assessed by performing a plaque reduction neutralization test (PRNT). Briefly, PRNT is used to determine the serum titer required to reduce the number of Zika virus plaques by 50% (PRNT50) as compared to a control serum/antibody. The PRNT50 may be carried out using monolayers of Vero cells or any other cell type/line that can be infected with Zika virus. Sera from subjects are diluted and incubated with live, non-inactivated Zika virus. The serum/virus mixture may be applied to the Vero cells and incubated for a period of time. Plaques formed on the Vero cell monolayers are counted and compared to the number of plaques formed by the Zika virus in the absence of serum or a control antibody. A threshold of neutralizing antibodies of 1:10 dilution of serum in a PRNT50 is generally accepted as evidence of protection (Hombach *et. al.* Vaccine (2005) 23:5205-5211).

In some embodiments, the Zika virus may be formulated for administration in a composition, such as a pharmaceutical composition. The term “pharmaceutical composition” as used herein means a product that results from the mixing or combining of at least one active ingredient, such as an inactivated Zika virus, and one or more inactive ingredients, which may include one or more pharmaceutically acceptable excipient(s).

Pharmaceutical compositions of the invention, including vaccines, can be prepared in accordance with methods well known and routinely practiced in the art (see *e.g.*, Remington: The Science and Practice of Pharmacy, Mack Publishing Co. 20th ed. 2000; and Ingredients of Vaccines – Fact Sheet from the Centers for Disease Control and Prevention), *e.g.*, adjuvants and enhancers such as alum to help the vaccine improve its work, preservatives and stabilizers to help the vaccine remain unchanged (*e.g.*, albumin, phenols, glycine). Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically a therapeutically effective dose of the inactivated Zika virus preparation is employed in the pharmaceutical composition of the invention. The inactivated Zika virus is formulated into pharmaceutically acceptable dosage forms by

conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (*e.g.*, the prophylactic response).

Dosages of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired pharmaceutical response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors.

A physician, veterinarian or other trained practitioner, can start doses of the inactivated Zika virus vaccine employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect (*e.g.*, production of anti-Zika virus antibodies) is achieved. In general, effective doses of the compositions of the present invention, for the prophylactic treatment of groups of people as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and the titer of anti-Zika virus antibodies desired. Dosages need to be titrated to optimize safety and efficacy. In some embodiments, the dosing regimen entails subcutaneous or intramuscular administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 7. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 14. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 28. In some embodiments, the inactivated Zika virus is administered to the subject once.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject with, prior to, or after administration of one or more adjuvants. An adjuvant is a molecule that enhances a response in a subject, such as an immune response, to an antigen or other molecule. In some embodiments, an adjuvant may stabilize an antigen or other molecule. Determining whether a Zika virus vaccine or compositions thereof are administered with an adjuvant depends on various

factors (e.g., type and extent of response desired) and will be evident to one of skill in the art. In some embodiments, administering any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may enhance the production of virus neutralizing (anti-Zika virus) antibodies. In some embodiments, a subject that is administered any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may only require a single administration of the Zika virus vaccine or composition to be seroconverted (produce a level of anti-Zika virus antibodies). Examples of adjuvants may include, without limitation, aluminium salt (aluminium hydroxide or aluminium phosphate), calcium phosphate hydroxide, paraffin oil, killed bacteria, bacterial toxins, toxoids, subunits of bacteria, squalene, thimerosal, detergents, IL-1, IL-2, IL-12, 2-component adjuvants, such as 2-component adjuvants containing an antibacterial peptide and a TLR9 agonist (e.g., IC31®), and combinations such as Freund's complete adjuvant and Freund's incomplete adjuvant. In some embodiments, the Zika virus vaccines or compositions is administered with aluminium hydroxide. In some embodiments, the inactivated Zika virus vaccine or composition is administered with aluminium phosphate salt. A preferred aluminium salt is the aluminium hydroxide with reduced Cu content, e.g. lower than 1.25 ppb based on the weight of the Zika composition, an adjuvant described in detail in WO 2013/083726 or Schlegl et al., Vaccine 33 (2015) 5989-5996.

In some embodiments, the adjuvant is comprised of two components. In some embodiments, the 2-component adjuvant comprises an antibacterial peptide and a TLR9 agonist. In some embodiments, the antibacterial peptide is provided by the amino acid sequence KLKL₅KLK (SEQ ID NO: 71). In some embodiments, the TLR9 agonist is a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN). In some embodiments, the I-ODN comprises the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70). In some embodiments, the adjuvant is IC31®. In some embodiments, the adjuvant is in nanoparticle form (See, e.g., US Patent No. 8,765,148 B2, incorporated by reference in its entirety). In some embodiments, the adjuvant is IC31®, i.e. KLKL₅KLK (SEQ ID NO: 71) and the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70), in combination with an aluminium salt such as aluminium hydroxide.

The Zika virus vaccines or compositions described herein may be administered to a subject concomitantly with one or more vaccine to another infectious agent, such as another infectious agent is that present or thought to be present in the same geographic area as Zika virus. In some embodiments, the other infectious agent is one that the subject is also at risk of being in contact with. In some embodiments, the other infectious agent is transmitted by the same arthropod vector

as Zika virus. In some embodiments, the other infectious agent is Japanese Encephalitis virus, Yellow Fever virus, Dengue virus and/or Chikungunya virus.

Also within the scope of the present disclosure are kits for use in prophylactically administering to a subject, for example to prevent or reduce the severity of Zika virus infection. Such kits can include one or more containers comprising a composition containing inactivated Zika virus, such as an inactivated Zika virus vaccine. In some embodiments, the kit may further include one or more additional containers comprising a second composition, such as a second vaccine. In some embodiments, the second vaccine is a vaccine for another arbovirus. In some embodiments, the second vaccine is a Dengue virus vaccine and/or a Chikungunya virus vaccine.

In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise a description of administration of the composition containing inactivated Zika virus to prevent, delay the onset, or reduce the severity of Zika virus infection. The kit may further comprise a description of selecting a subject suitable for administration based on identifying whether that subject is at risk for exposure to Zika virus or contracting a Zika virus infection. In still other embodiments, the instructions comprise a description of administering a composition containing inactivated Zika virus to a subject at risk of exposure to Zika virus or contracting Zika virus infection.

The instructions relating to the use of the composition containing inactivated Zika virus generally include information as to the dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (*e.g.*, multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (*e.g.*, a paper sheet included in the kit), but machine readable instructions are also acceptable.

The kits of the present disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like. Also contemplated are packages for use in combination with a specific device, such as a syringe or an infusion device. The container may have a sterile access port, for example the container may be a vial having a stopper pierceable by a hypodermic injection needle. At least one active agent in the composition is an inactivated Zika virus, as described herein.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including”, “comprising”, or “having”, “containing”, “involving”, and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics and protein and nucleic chemistry described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

The present invention is further illustrated by the following examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference, in particular for the teaching that is referenced hereinabove. However, the citation of any reference is not intended to be an admission that the reference is prior art.

Table 1. Overview of process buffers and stock solutions.

Buffer	Composition	Final pH	Final conductivity [mS/cm]
A	0.5 M NaOH		n.a.
B	0.1 M NaOH		n.a.
C	25 mM Tris, 150 mM NaCl	7.4±0.2	16.5
D	1 M Tris	7.4±0.2	n.a.
E	4.5 M NaCl	n.a.	n.a.
F	1 M NaCl	n.a.	n.a.
G	1 % SDS	n.a.	n.a.
H	50 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.

I	35 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
J	15 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
K	10 x PBS	7.4±0.2	n.a.
L	50 mg/mL Protamine sulphate	7.4±0.2	n.a.
M	Drug substance formulation buffer (10mM Tris(hydroxymethyl)-aminomethan, 5 % Sucrose, 1% (10 mg/mL) rHSA)	7.4±0.2	1.3

Table 2. Abbreviations.

°Bx	Degrees Brix = sugar content (w/w) of an aqueous solution*
BSA	Bovine serum albumin
CC700	Capto™ Core 700
CPE	Cytopathic effect
EtOH	Ethanol
EU	Endotoxin units
DS	Drug Substance
DP	Drug Product
DSP	Downstream Process
HCP	Host cell protein
hcDNA	Host cell DNA
hpi	Hours post infection
HPLC	High Performance Liquid Chromatography
ID	Inner diameter
JEV	Japanese Encephalitis virus
LAL	Limulus amoebocyte lysate
LDS buffer	Lithium dodecyl sulfate sample loading buffer
LOD	Limit of detection
LOQ	Limit of quantitation
MALLS	Multiangle light scattering
mAU	Milli absorbance units
MS	Mass spectroscopy
NIV	Neutralized inactivated virus
PBS	Phosphate buffered saline
PD	Process development
PFU	Plaque forming units
p.i.	Post-infection
PS	Protamine sulphate or protamine sulfate
rcf	Relative centrifugal force
rHSA	Recombinant human serum albumin
Rms radius	Root mean square radius
rMSB	Research master seed bank
RSD	Relative standard deviation
SEC	Size exclusion chromatography
SGC	Sucrose gradient centrifugation
SGP	Sucrose gradient purified
SDS	Sodium dodecyl sulphate
TBS	Tris buffered saline
TFF	Tangential flow filtration
TCID50	Tissue culture infectious dose 50%
UF/DF	Ultrafiltration/diafiltration
WFI	Water for injection
ZikaV	Zika virus

*Degrees Brix (°Bx) is the sugar content of an aqueous solution. One degree Brix is 1 gram of sucrose in 100 grams of solution and represents the strength of the solution as percentage by mass.

°Bx corresponds to the sucrose content in percent (w/w), e.g., 45 °Bx equals 45 % (w/w) sucrose.

5

Table A. Primers for Zika virus sequencing: lower case letters indicate bases not included in ZIKA but containing restriction sites for later cloning when needed (therefore, two Tms provided).

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	T _m (gene-specific)	T _m (entire primer)	Amplicon size [bp]
1	9320_Zika_PF_1F	SEQ ID NO: 74 ttaggatccGTTGTTGATCTGTGTGAAT	69.9	74.6	707
	9321_Zika_PF_1R	SEQ ID NO: 75 taactcgagCGTACACAACCCAAGTT	69.3	75.6	
2	9322_Zika_PF_2F	SEQ ID NO: 76 ttaggatccTCACTAGACGTGGGAGTG	70	73.9	704
	9323_Zika_PF_2R	SEQ ID NO: 77 taactcgagAAGCCATGTCYGATATTGAT	69.8	73.7	
3	9324_Zika_PF_3F	SEQ ID NO: 78 ttaggatccGCATACAGCATCAGGTG	72.3	74.5	712
	9325_Zika_PF_3R	SEQ ID NO: 79 taactcgagTGTGGAGTTCCGGTGTCT	72	76.4	
4	9326_Zika_PF_4F	SEQ ID NO: 80 ttaggatccGAATAGAGCGAARGTTGAGATA	70.9	74	712
	9327_Zika_PF_4R	SEQ ID NO: 81 taactcgagTGGTGGGTGATCTTCTTCT	70.5	73.7	
5	9328_Zika_PF_5F	SEQ ID NO: 82 ttaggatccCAGTCACAGTGGAGGTACAGTAC	70.3	75	704
	9329_Zika_PF_5R	SEQ ID NO: 83 taactcgagCRCAGATACCATCTTCCC	71.5	77.3	
6	9330_Zika_PF_6F	SEQ ID NO: 84 ttaggatCCCTTATGTGCTTGGCCTTAG	70.7	72.7	698
	9331_Zika_PF_6R	SEQ ID NO: 85 taactcgagTCTTCAGCCTCCATGTG	70.4	76.9	
7	9332_Zika_PF_7F	SEQ ID NO: 86 ttaggatccAATGCCCACTCAAACATAGA	71.9	75	716
	9333_Zika_PF_7R	SEQ ID NO: 87 taactcgagTCATTCTTCTTCAGCCCTT	71	74	
8	9334_Zika_PF_8F	SEQ ID NO: 88 ttaggatccAAGGGTGATCGAGGAAT	70.9	75.2	703
	9335_Zika_PF_8R	SEQ ID NO: 89 taactcgagTTCCCTTCAGAGAGAGGAGC	71.9	73.4	
9	9336_Zika_PF_9F	SEQ ID NO: 90 ttaggatccTCTTTGCAAACCTGCGATC	71.9	75	699
	9337_Zika_PF_9R	SEQ ID NO: 91 taactcgagTCCAGCTGCAAAGGGTAT	71	74.9	
10	9338_Zika_PF_10F	SEQ ID NO: 92 ttaggatccGTGTGGACATGTACATTGA	71.4	75.8	706
	9339_Zika_PF_10R	SEQ ID NO: 93 taactcgagCCCATTGCCATAAAGTC	70.4	75.8	
11	9340_Zika_PF_11F	SEQ ID NO: 94 ttaggatccTCATACTGTGGTCCATGGA	71.6	78.1	692
	9341_Zika_PF_11R	SEQ ID NO: 95 taactcgagGCCCATCTCAACCCTTG	74	78	
12	9342_Zika_PF_12F	SEQ ID NO: 96 ttaggatccTAGAGGGCTTCCAGTGC	70.9	74	707
	9343_Zika_PF_12R	SEQ ID NO: 97 taactcgAGATACTCATCTCCAGGTTTGTG	70.2	72.2	

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	T _m (gene-specific)	T _m (entire primer)	Amplicon size [bp]
13	9344_Zika_PF_13F	SEQ ID NO: 98 ttaggatccGAAAACAAAACATCAAGAGTG	70.6	75.4	726
	9345_Zika_PF_13R	SEQ ID NO: 99 taactcgagGAATCTCTCTGTCATGTGTCCT	71.9	75.6	
14	9346_Zika_PF_14F	SEQ ID NO: 100 ttaggatccTTGATGGCAGACCAAC	73.1	75.6	715
	9347_Zika_PF_14R	SEQ ID NO: 101 ttaggatccGTTGTTGATCTGTGTGAAT	70.8	77.9	
15	9348_Zika_PF_15F	SEQ ID NO: 102 taactcgagCAGGTCAATGTCCATTG	71.9	75.4	719
	9349_Zika_PF_15R	SEQ ID NO: 103 ttaggatccTGTGTGTTCTATTGCTGGT	73.9	77.2	
16	9350_Zika_PF_16F	SEQ ID NO: 104 taactcgaGTGATCAGRGCCCCAGC	72.3	75.4	703
	9351_Zika_PF_16R	SEQ ID NO: 105 ttaggatccTGCTGCCCCAGAAGAGAA	72	76.3	
17	9352_Zika_PF_17F	SEQ ID NO: 106 taactcgaGCACCAACAYGGGTCTT	73.6	76	705
	9353_Zika_PF_17R	SEQ ID NO: 107 ttaggatccCTCAAGGACGGTGTGGC	72	75.5	
18	9354_Zika_PF_18F	SEQ ID NO: 108 taactcgagCAATGATCTTCATGTTGGG	71.7	75.8	699
	9355_Zika_PF_18R	SEQ ID NO: 109 ttaggatccTATGGGGGAGGACTGGT	71	74.1	
19	9356_Zika_PF_19F	SEQ ID NO: 110 taactGAGCCCAGAACCTTGGATC	73.3	75.5	711
	9357_Zika_PF_19R	SEQ ID NO: 111 ttaggatccCAGACCCCCAAGAAGGC	71.3	76.9	
20	9358_Zika_PF_20F	SEQ ID NO: 112 taactcgagCCCCTTTGGTCTTGCTCT	71.7	75	706
	9359_Zika_PF_20R	SEQ ID NO: 113 ttaggatccAGGAAGGATGTATGCAGATG	71.9	73.9	
21	9360_Zika_PF_21F	SEQ ID NO: 114 taactcgagACATTTGCGCATATGATTTTG	70.4	75.7	709
	9361_Zika_PF_21R	SEQ ID NO: 115 ttaggatccAGGAAGGACACACAAGAGT	71.8	75	
22	9362_Zika_PF_22F	SEQ ID NO: 116 taactcgagACAGGCTGCACAGCTTT	70	79.1	581
	9363_Zika_PF_22R	SEQ ID NO: 117 ttaggatccTCTCTCATAGGGCACAGAC	74.8	81.1	

SEQUENCES

- 5 SEQ ID NO: 1
A typical form of protamine
PRRRRSSRP VRRRRRPRVS RRRRRRGRR RR

10 Provided below are examples of nucleic acid sequences of the genomes of Zika viruses that may be used in the methods, compositions, and/or vaccines described herein.

SEQ ID NO: 2
KU321639.1 Zika virus strain ZikaSPH2015, Brazil, complete genome

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTAT
CAACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAAT
CCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGG
GCTTGAAGAGGCTGCCAGCCGGACTTCTGCTGGGTTCATGGGCCCATCAGGATGGTCTTGGCAAT
5 TCTAGCCTTTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
GTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGGGGCGCAGATACTAGTGTGCGAATTGTT
GGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATATGT
ACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGT
10 GTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
GCTGGATGAGGGGGTGGAAACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGT
TGTGTACGGAACCTGCCATCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCT
CCCCTCCCATTCCACTAGGAAGCTGCAAAACGCGGTCGCAAACTGGTTGGAATCAAGAGAATA
CACAAAGCACTTGATTAGAGTCGAAAATTGGATATTAGGAACCCTGGCTTCGCGTTAGCAGCA
15 GCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATAC
TGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
GTATGTCAGGTGGGACTTGGGTGATATTGTCTTGGAAACATGGAGGTTGTGTCACCGTAATGGC
ACAGGACAAACCGACTGTGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGT
AAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACA
20 AGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGA
CAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTT
TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
GCTGTCAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGAT
GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGT
25 TTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTT
GACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGG
CACGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAG
GACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGGCCAC
30 TTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCG
CAGCGTTACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTAC
AGTACGCAGGGACAGATGGACCTTGCAAGTTCCAGCTCAGATGGCGGTGGACATGCAAACTC
TGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCATTGTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
35 GAAGATCACCCACCCTGGCACAGGAGTGGCAGCACCATTTGGAAAAGCATTGAAAGCCACTGT
GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
CGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTG
GAGGAATGTCCTGGTTCTCACAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACAC
AAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAG
40 CCGTCTCTGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAG
GGGTGTTCTGCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCC
CCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTT
TCAAGAATGGAACACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
GAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA
45 GAGATTGCCCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTT
CGTCAGAGCAGCAAAGACAAATAACAGCTTTGTCTGTTGGATGGTGACACACTGAAGGAATGCCC
ACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCTGGGGTATTTACACT
AGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAG
CTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATG
50 ACACATGGAGGCTGAAGAGGGGCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCC
ACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGC
CACTCAGCCATCACAATAACAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTG
AAGAGCTTGAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTG
GAACAAGAGGACCATCTCTGAGATCAACCACCTGCAAGCGGAAGGGTGATCGAGGAATGGTGCT
55 GCAGGAGTGCACAATGCCCCACTGCTTCCGGCTAAAGATGGCTGTTGGTATGGAATGG
AGATAAGGCCCGAAGAAAGAACCAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCA
ACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGC

TGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGA
 TCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACC
 AGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCC
 5 TTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGATGGTTCTCATCAA
 TGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCT
 TGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAG
 GCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAA
 CTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGTGGTG
 10 GGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCT
 GTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAAGAGTGTGGACATGTACA
 TTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGC
 TCGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAG
 15 AGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCTTT
 GCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTG
 CCTGCTCCCAAGGAAGTAAAAAAGGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGT
 AGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGT
 GGCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAG
 20 ATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGC
 ACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGC
 CCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAA
 CTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTTCGT
 GATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGT
 25 TGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGA
 GCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGT
 ACTGTGATCTTAGCTCCAACCAGGGTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTC
 CAGTGCGTTATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAAT
 GTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTAT
 30 ATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACA
 AGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGAC
 GCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAAGTGGAAGTCCCAGAGAGACGCTGG
 AGCTCAGGCTTTGATTGGGTGACGATTATTCTGGAAAAACAGTTTGGTTTGTCCAAGCGTGA
 GGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCA
 35 GAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAA
 CTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTCTATAGATTCCAGGAGATGCCT
 AAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTACACATGCC
 AGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTG
 TATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTC
 40 CTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAG
 TAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCA
 TGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACAC
 AGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGC
 AGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAG
 45 TTTGTTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGG
 CTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAG
 CCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGG
 CGGCCCAATTGCCGAGACCCTAGAGACCATATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 GGAATCTTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAC
 50 TCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTC
 CTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCC
 AGGACAACCAAATGGCAATCATCATATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAA
 TGAACCTCGATGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGG
 AGGGGCCAACCATGGGATTCTCAATTGGACATTGACCTGCGGCCAGCCTCAGCTTGGCCATCTA
 55 TGCTGCCTTGACAACCTTCAATACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAAC
 TACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCAT
 TCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTACAATTAACGCCCCCT

GACCCTAATAGTGGCCATCATTTTGTCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAG
GCAGCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCCTGTTGTG
GATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATG
GGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGT
5 GGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACA
AGTACTGGAACCTCTACAGCCACTTCACTGTGTAACATTTTLAGGGGAAGTTACTTGGCTGG
AGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAAC
AGGAGAGACCCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGGCCCTGGAGTTCTA
CTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGA
10 CGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGA
GCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAG
TTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGG
TCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGT
GGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCA
15 TCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCCTCTCCATGGTGGGGGATTGGCTTG
AAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAA
CCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACT
CTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCA
CGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATG
20 TGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
TGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCA
CCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCT
CTAATAAACGGGGTGTGTCAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGA
ATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGACACT
25 AGGGTGCCAGACCCCCAAGAAGGTACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGA
AAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCT
GTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGA
GCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGA
GAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGG
30 AAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGA
AGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGA
AGGGTGCGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCGAGGAGGAAG
GATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGA
AGCTCTAATCACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTA
35 CACATACCAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGA
CATTATTTTCGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTT
ACCAACCTAGTGGTGCAACTCATTTCGAATATGGAGGCTGAGGAAGTCCTAGAGATGCAAGAC
TTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGG
CTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCAC
40 ATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCCCT
CAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTTGCTCCCACCACTCAACAAGCTCCATCT
CAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCCCCG
CGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCA
AATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTGTGTTCA
45 TCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAGGGAGAA
TGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCAC
ATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGAC
TTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAAAAAC
ACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACC
50 CAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGT
TGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAG
AAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGC
CTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGA
AAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATC
55 TCCAGAAGAGGGACTAGTGGTTAGAGGAGA

SEQ ID NO: 3

KU497555.1 Zika virus isolate Brazil-ZKV2015, Brazil, complete genome

CCAATCTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACA
 GGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGA
 GGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGA
 5 AGAGGCTGCCAGCCGGAAGTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGC
 CTTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGG
 AAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATA
 ATCAATGCCAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCCGAATCGTTGGCCTC
 CTGCTGACCACAGCTATGGCAGCGGAGGTCAGTAGACGTGGGAGTGCATACTATATGTACTTGG
 10 ACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTTATAT
 ACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGAT
 GAGGGGGTGAACACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTGGGGTGTGTAC
 GGAACCTGCCATCACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCC
 CATTCCACTAGGAAGCTGCAACGCGGTTCGCAACCTGGTTGGAATCAAGAGAATACACAAAG
 15 CACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCAGCTGCCA
 TCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGAT
 TGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTC
 AGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGGGGTTGTGTCACCGTAATGGCACAGGAC
 AAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCC
 20 TACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAA
 GCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGACAGAGGC
 TGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCT
 CCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAG
 TTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGATGAGAATA
 25 GAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCACCCTGGGGGGTTTTTGAA
 GCTTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTTGTATTACTTGACTATG
 AATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTCCATTACCTTGGCACGCTG
 GGGCAGACACCGGAAGTCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCA
 CATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGACTCAAGAAGGAGCAGTTCACACGGCCCTT
 30 GCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGGAAGGCTGTCTCTGGCCACTTGAAA
 TGTCGCCTGAAAATGGATAAACTTAGATTGAAGGCGGTGCATACTCCTTGTGTACCGCAGCGT
 TCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACG
 CAGGGACAGATGGACCTTGCAAGGTTCCAGTCTAGATGGCGGTGGACATGCAAACTCTGACCC
 CAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGATGA
 35 TGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAGAAGAT
 CACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAGGCACTTTGAAGCCACTGTGAGAGG
 TGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCT
 CAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGA
 ATGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGA
 40 ATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTC
 TCTGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGTGGTACAGGGGTG
 TTCGTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCTCCCCGTA
 GATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAG
 AATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTTAACGCAATCCTGGAAGAGAATG
 45 GAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGAT
 TGCCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAG
 AGCAGCAAAGACAAATAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCCACTCAA
 ACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTC
 TGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTA
 50 AGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACAT
 GGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACAT
 TGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCA
 GCCATCACAAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAG
 CTTGAAATTCGGTTTGAAGGAATGCCAGGCAAGTCCACGTGGAGGAACATGTGGAACA
 55 AGAGACCATCTCGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGG
 GAGTGCACAATGCCCCACTGTCTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATA
 AGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGAT

CACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGA
 AGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGATCCTGG
 GAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGAAAT
 5 GAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTT
 GCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCC
 TCGTGTTTTTTGCAAACCTGCGATCTCCGCCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTT
 TGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAACATCACCTTGGCA
 ATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCTTG
 10 CTACTTGCAGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACC
 ATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTG
 CTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGC
 CTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCATGGCC
 GCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAA
 15 GAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATG
 TGGCGCTAGATGAGAGTGGTGACTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGA
 TCATACTCAAGGTGGTCCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCTTTGCAGC
 TGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGC
 TCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGAC
 20 TGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCA
 CGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGT
 CAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAG
 CGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGG
 AATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTC
 25 AGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTTCGTGAT
 AAAAAATGGGAGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGA
 GTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCT
 GGGAAAACCAGGAGAGTTCTTCCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTACT
 GTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAG
 30 TCGGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTG
 CCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTA
 TGGATGAGGCCCCACTTCACAGATCCCTCAAGCATAGCAGCAAGAGGATACATTCAACAAGGG
 TTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGAACCCGTGACGCAT
 TTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCT
 35 CAGGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAA
 CGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCAGAAA
 GACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAACTGA
 CATTTTCAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTCTATAGATTCCAGGAGATGCCTAAAG
 CCGGTCATACTTGATGGCGAGAGAGTCACTTCTGGCTGGACCCATGCCTGTACACATGCCAGCG
 40 CTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTACCTGTATG
 GAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTG
 ACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTAGC
 AGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCATGAA
 AAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGAT
 45 AGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAG
 GTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGT
 TCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCTTTT
 GGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATT
 GACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCC
 50 CAATTGCCGGAGACCCTAGAGACCATATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAA
 TCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGG
 GGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATT
 GTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACA
 ACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACT
 55 CGGATGGTTGGAGAGAACAAGAGTAGCTTACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGG
 CAACCATAGGATTCTCAATTGACACTGCGGCCAGCCTCAGCTTGGGCCATGATGCTGC
 CTTGACAACCTTTTATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACCTACTCC
 TTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTGGTATGGGCAAAGGGATGCCATTCTACG

CATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCT
 AATAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCA
 GCTGCGCGTGTGCTGCCAGAGAAGACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGA
 5 ATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAG
 GTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGG
 GAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACT
 GGAATCCTCTACAGCCACTTCACTGTGTAAACATTTTAGGGGAAGTTACTTGGCTGGAGCTTCT
 CTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAG
 ACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTAC
 10 AAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGGCCCGCCGCGCCCTCAAGGACGGTGTG
 GCAACGGGAGGCCATGCTGTGTCCCAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGA
 TACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACG
 CCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGGCCCTGGTCATGAAG
 AACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTCTT
 15 TCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCCT
 GAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGAAAAAAGA
 CCAGGAGCCTTTTGCATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGC
 GACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATG
 AGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGTGTGTCCACCACGAGCCAGC
 20 TCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCG
 GCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACC
 GCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAAAACCAACCCATATA
 GGACATGGGCTTACCATGGAAGCTATGTGGCCCCACACAAGGGTCAGCGTCCCTCTAATAAA
 CGGGGTTGTGAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCAT
 25 GACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCC
 AGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTA
 GGCAAACACAAACGACCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGCAAT
 GCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGAA
 CGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 30 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGAAAGGCCA
 AGGGGACCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTGAAGCCCTTGG
 ATTCTTGAACGAGATCACTGGATGGGGAGAGAGAAGTCAAGGAGGTGGTGTGAAGGGCTGGG
 ATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGC
 AGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAAT
 35 CACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCA
 AAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGACATTATTTTC
 GAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCT
 AGTGGTGCAACTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCT
 GCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAAC
 40 GAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCT
 CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGG
 ATGGGACAACCTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGAC
 GGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGGCCGCTCTCTC
 CAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGC
 45 AGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCA
 GTTGAAGTGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACC
 ACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGAC
 AAGACCCCAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGT
 GGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTAAAAATACAGTCAAC
 50 ATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTTCGC
 TACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAGCACCAATCTTAATGTTGTGAGGCC
 TGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCTCCAGGAGAAGCTGGGT
 AACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCC
 CCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGG
 55 TGCGCACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAG
 AGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTGACGCTGGGAAA

GACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCG
GCCGGTGTGGGGAAATCCA

SEQ ID NO: 4

5 KU501215.1 Zika virus strain PRVABC59, Puerto Rico, complete genome
GTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTAT
CAACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAAT
CCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGG
GCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGAT
10 TCTAGCCTTTTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
GTGGGGAAAAAGAGGCTATGGAAACAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCT
GAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTG
TTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATAT
GTA CT TGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAA
15 GTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCT
ATGCTGGATGAGGGGGTGGAAACCAGATGACGTGCGATTGTTGGTGCAACACGACGTCAACTTGG
GTTGTGTACGGAACCTGCCATCACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACG
CTCCCCCTCCATTCCACCAGGAAGCTGCAAACGCGGTGCGAAACCTGGTTGGAATCAAGAGAA
TACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCCCTGGCTTCGCGTTAGCAG
20 CAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGAT
ACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGA
AGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAACATGGAGGTTGTGTCACCGTAATG
GCACAGGACAAACCGACTGTGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAG
GTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCTGACAGCCGCTGCCAACAC
25 AAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGG
ACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGT
TTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAA
TGCTGTCA GTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGA
TGAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCGAGAGCCGAAGCCACCCTGGGGGG
30 TTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACT
TGACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGTTCCACGACATTCCATTACCTTG
GCACGCTGGGGCAGACACCGGAACCTCCACTGGGAACAACAAGAAGCACTGGTAGAGTTCAA
GGACGCATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACAC
GGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCTCTGGCCA
35 CTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACT
GCAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTA
CAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACT
CTGACCCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
40 GAAGATCACCCACCCTGGCACAGGAGTGGCAGCACCATTTGGAAAAGCATTGAAAGCCACTGT
GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
CGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTG
GAGGAATGTCCTGGTTCTCACAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACAC
AAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAG
45 CCGTCTCTGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAG
GGGTGTTTCGTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCC
CCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTT
TCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
GAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA
50 GAGATTGCCCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTATTTCT
GTCAGAGCAGCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCA
CTCAAACATAGAGCATGGAACAGCTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTA
GTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGC
TGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGA
55 CACATTGGAGCTGAAGAGGGCCACTGTAGCTGAGATGAAAACATGTGAATGGCCAAAGTCCCA
CACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCC
ACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGA

AGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGG
 AACAAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTG
 CAGGGAGTGCACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGA
 5 GATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAA
 CTGATCACATGGACCACTTCTCCCTTGGAGTGCTTGTGATCCTGCTCATGGTGCAGGAAGGGCT
 GAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGAT
 CCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCG
 GAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCA
 GCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTT
 10 GGCCTCGTGCTTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGATGGTTCTCATCAAT
 GGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTT
 GGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGACACTGCTTGTGGCGTGGAGAGCAGG
 CCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAAC
 TTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGG
 15 GACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTG
 TTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCA
 TGGCCGCGGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCT
 CGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGA
 20 GAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTG
 CAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGC
 CTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTA
 GACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTG
 GCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGA
 25 TGTC AAGCAGGATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCCTGGGATGGGCAC
 AGCGAGGTGCAGCTCTTGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCC
 GGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACT
 TCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTG
 ATCAAAAACGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTT
 30 GAGTGCTTCGAGCCCTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAG
 CTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTA
 CTGTGATCTTAGCTCCAACCAAGGTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGGCTTCC
 AGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATG
 TGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATAT
 35 TATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAG
 GGTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGC
 ATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAG
 CTCAGGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTC AAGCGTGAGG
 AACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCAGA
 40 AAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTGCTGACAAC
 GACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAGGAGATGCCTAA
 AGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTACACATGCCAG
 CGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTA
 TGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCT
 45 TGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTA
 GCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACATCATG
 AAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAG
 ATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAG
 AGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTT
 50 TGTT CAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCT
 TTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCC
 ATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCG
 GCCCAATTGCCGAGACCCCTAGAGACCATAATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGG
 GAATCTTCTTCGTTCTGATGAGGAACAAGGGCAATGAGGAGATGGGCTTTGGAATGGTGACTCT
 55 TGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAAAGATGCTGTCTCTC
 ATTGTTGTTGCTTATTGCTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGG
 ACAACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGA

ACTCGGATGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGG
 GGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGC
 TGCCTTGACAACTTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACCTCATACAACAACCTAC
 5 TCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGCATGGGCAAAGGGATGCCATTCT
 ACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGAC
 CCTAATAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCA
 GCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGAT
 GGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGA
 CAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGCGACCCGCTGGGGGTGGG
 10 GGGAGGCTGGGGCTCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGT
 ACTGGAACCTCTACAGCCACTTCACTGTGTAACATTTTATAGGGGAAGTTACTTGGCTGGAGC
 TTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGG
 AGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTC
 CTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGACGG
 15 TGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCG
 GGGATACCTGCAGCCCTATGGAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTA
 CTACGTCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCA
 TGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGGA
 CGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCT
 20 AGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGAA
 AAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAACC
 CTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCT
 ACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACG
 AGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTG
 25 AATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTG
 GTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACC
 CATATAGGACATGGGCTTACCATGGAAGCTATGAGGGCCCCACACAAGGGTCAGCGTCTCTCT
 AATAAACGGGGTGTGTCAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGAAT
 AGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAG
 30 GGTGCCAGACCCCCAAGAAGGCACCTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAA
 GAGCTAGGCAAAACACAAACGGCCACGAGTCTGCACCAAAGAAGAGTTCATCAACAAGGTTTCGT
 AGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAACT
 TGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGA
 GTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAA
 35 AGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAG
 CCCTTGGAATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAG
 GGCTGGGATTACAAAGACTCGGATATGTCTTAGAAGAGATGAGTCGTATACCAGGAGGAAGGA
 TGTATGCAGATGACACTGCTGGCTGGGACACCCGCATTAGCAGGTTTGATCTGGAGAATGAAG
 CTCTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACA
 40 CATAACAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGACA
 TTATTTTCGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTAC
 CAACCTAGTGGTGCAACTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTT
 GTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCT
 CAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACA
 45 TGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCCTC
 AACTGGATGGGACAACTGGGAAGAAGTTCCGTTTTGCTCCCACCACTTCAACAAGCTCCATCTC
 AAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGGCCGC
 GTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCAA
 ATGTGGCAGTCTCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTAT
 50 CTGTGCCAGTTGACTGGGTTCCAACTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAT
 GGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACA
 TGGAAGACAAGACCCCAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGGAAGACT
 TGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTAAAAACA
 CAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCC
 55 AAGTTCGCTACTTGGGTGAAGAAGGCTTACACCTGGAGTGCTGTAAGCACCAATCTTAATGTT
 GTCAGGCCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGA
 AGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCC

TGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAA
AAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCT
CCAGAAGAGGGACTAGTGGTTAGAGGA

5 SEQ ID NO: 5

KU509998.1 Zika virus strain Haiti/1225/2014, Haiti, complete genome

5 GTTGTACTGTTGCTGACTCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTAT
CAACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAAT
10 CCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCTTTGGGG
GCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAAT
TCTAGCCTTTTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
GTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTT
15 GGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGT
ACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGT
GTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
GCTGGATGAGGGGGTGGAAACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGT
TGTGTACGGAACCTGCCATCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCT
20 CCCCTCCCATTCCACTAGGAAGCTGCAAAACGCGGTGCAAAACCTGGTTGGAATCAAGAGAATA
CACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCA
GCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATAC
TGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCGTAATGGC
ACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGT
25 AAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACA
AGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGA
CAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTT
TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
GCTGTCAAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGAT
30 GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCACCCTGGGGGGT
TTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTT
GACTATGAATAACAAGCACTGGTTGGTTTACAAAGGAGTGTTCCACGACATTCATTACCTTGG
CACGCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAG
GACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
35 GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAAGGGAAGGCTGTCCTCTGGCCAC
TTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCG
CAGCGTTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTAC
AGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTC
TGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
40 AGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
GAAGATCACCCACCCTGGCACAGGAGTGGCAGCACCATTTGGAAGCATTGGAAGCCACTGT
GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
CGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTTG
GAGGAATGTCCTGGTTCTCACAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACAC
45 AAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAG
CCGTCTCTGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAG
GGGTGTTCTGCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCC
CCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTT
TCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
50 GAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA
GAGATTGCCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTT
CGTCAGAGCAGCAAAGACAAATAACAGCTTTGTCTGTTGGATGGTGACACACTGAAGGAATGCC
ACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCGGGGTATTTACACT
AGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAG
55 CTGTTAAGGGAAGGAGGCTGTACACAGTGTACTAGGCTACTGGATTGAGATTGAGAAGAATG
ACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCC
ACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGC

CACTCAGCCATCACAATACCAGAGAGGGGCTACAGGACCCAAATGAAAGGGGCCATGGCACAGTG
 AAGAGCTTGAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTG
 GAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCT
 GCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGGCTAAAGATGGCTGTTGGTATGGAATGG
 5 AGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCA
 ACTGATCATATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGC
 TGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGA
 TCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACC
 10 AGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCC
 TTGGCCTCGTGCTTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGATGGTTCTCATCAA
 TGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCT
 TGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGCGACACTGCTTGTGGCGTGAGAGCAG
 GCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAA
 15 CTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTG
 GGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCT
 GTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTGCGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACA
 TTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGC
 20 TCGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAG
 AGAGATCATACTCAAGGTGGTCCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTT
 GCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTG
 CCTGCTCCCAAGGAAGTAAAAAAGGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGT
 AGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGT
 25 GGCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAG
 ATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGC
 ACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGC
 CCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAA
 CTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGT
 30 GATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGT
 TGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGA
 GCTGGGAAAACCAAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGT
 ACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTC
 CAGTGCGTTATATGACAACAGCAGTCAATGTACCCCACTCTGGAACAGAAATCGTCGACTTAAT
 35 GTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTAT
 ATTATGGATGAGGCCCCTTACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACA
 AGGGTTGAGATGGGCGAGGCGGTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGAC
 GCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCCAGAGAGAGCCTGG
 AGCTCAGGCTTTGATTGGGTGACGGATTATTCTGGAAAAACAGTTTGGTTTGTCCAAGCGTGA
 40 GGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCA
 GAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAA
 CTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTCTATAGATTCCAGGAGATGCCT
 AAAGCCGGTCATACTTGATGGCGAGAGAGTCAATTCTGGCTGGACCCATGCCTGTACACATGCC
 AGCGCTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTG
 45 TATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTC
 CTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAG
 TAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCA
 TGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACAC
 50 AGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGC
 AGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGACGCCAGAG
 TTTGTTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGG
 CTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAG
 CCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGG
 CGGCCCAATTTCGGGAGACCCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 55 GGAATCTTTTTCGCTTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGTGTGAC
 TCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTC
 CTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCC

AGGACAACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAA
 TGAAC TCGGATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGG
 AGGGGGCAACCATGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTA
 5 TGCTGCCTTGACAACTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAAC
 TACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCAT
 TCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCT
 GACCCTAATAGTGCCATCATTGCTCGTGCGCGACTACATGTACTTGATCCCAGGGCTGCAG
 GCAGCAGCTGCGCGTGCTGCCAGAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTG
 10 GATGGAATAGTGCTGACTGACATTGACACAATGACAATTGACCCCCAAGTGAGAGAAAAAGATG
 GGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGT
 GGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACA
 AGTACTGGAACCTCTACAGCCACTTCACTGTGTAAACATTTTTAGGGGAAGTTACTTGCTGG
 AGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAAC
 15 AGGAGAGACCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTA
 CTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGGCCCGCCGCGCCCTCAAGGA
 CGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGA
 GCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAG
 TTAACGCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGG
 20 TCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGT
 GGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCA
 TCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTG
 AAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGA
 CCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACT
 25 CTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCA
 CGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCTAGGAGGCCAGTGAAATATGAGGAGGATG
 TGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
 TGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCA
 CCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCCTCT
 30 CTAATAAACGGGGTGTGTCAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGA
 ATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGA
 AAGAGTCAAGCAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTTCATCAACAGGTTTC
 GTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGA
 35 GCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAGAGAGCACCACCTGAGAGGA
 GAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGG
 AAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCTGA
 AGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTA
 AGGGCTGGGATTACAAAGACTCGGATATGTCTAGAAGAGATGAGTCGCATACCAGGAGGAAG
 40 GATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGA
 AGCTCTAATCACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTA
 CACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGA
 CATTATTTGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTT
 ACCAACCTAGTGGTGCAACTCATTCCGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGAC
 45 TTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGG
 CTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCAC
 ATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCT
 CAACTGGATGGGACAACTGGGAAGAAGTTCCGTTTTGCTCCCACCACTTCAACAAGCTCCATCT
 CAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCCCCG
 50 CGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCA
 AATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCA
 TCTGTGCCAGTTGACTGGGTTCCAAC TGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAA
 TGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCAC
 ATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCTATTTGGGAAAAAGGGAAGAC
 55 TTGTGTTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAACAC
 ACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCAC
 CAAGTTCGCTACTTGGGTGAAGAAGGTTCTACACTGGAGTGCTGTAAGCACCAATCTTAATGT
 TGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAG

AAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGC
CTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGA
AAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATC
TCCAGAAGAGGGACTAGTGGTTAGAGGAGA

5

SEQ ID NO: 6

KU527068.1 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, complete genome

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTA
TCAACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAA
10 TCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTGGGG
GCTTGAAGAGGCTGCCAGCCGGAATTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGAAT
TCTAGCCTTTTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
GTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
15 AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTT
GGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGT
ACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGT
GTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
GCTGGATGAGGGGGTGAACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGT
20 TGTGTACGGAACCTGCCATCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCT
CCCCTCCCATTCCACTAGGAAGCTGCAACGCGGTCGCAACCTGGTTGGAATCAAGAGAATA
CACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAAGGAACCCTGGCTTCGCGTTAGCAGCA
GCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATAC
TGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
25 GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCGTAATGGC
ACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGT
AAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCAACACA
AGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGA
CAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTT
30 TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
GCTGTCACTTCAATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGAT
GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGT
TTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTGTATTACTT
GACTATGAATAACAAGCACTGGTTGGTCCACAAGGAGTGTTCCACGACATTCCATTACCTTGG
CACGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAG
35 GACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAAGGGAAGGCTGTCCTCTGGCCAC
TTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTACTCCTTGTGTACCG
CAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTAC
AGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTC
40 TGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
GAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAGCACTTTGAAGCCACTGT
GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
CGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTTG
45 GAGGAATGTCCTGGTTCTCAAAATCCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACAC
AAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAG
CCGTCTCTGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAG
GGGTGTTCTGCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCC
CCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTT
50 TCAAGAATGGAGAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCTTGAAGAG
AATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAG
AGATTGCCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTC
GTCAGAGCAGCAAAGACAAATAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCCA
CTCGAATCAGATAGCATGGAACAGCTTTCTGTGGAGGATCATGGGTTTCGGGGTATTTACACATA
55 GTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGC
TGTTAAGGGGAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGA
CACATGGAGGCTGAAGAGGGCCCATCTAATCGAGATGAAAACATGTGAATGGCCAAAGTCCCA

CACATTGTGGGCAGATGGAATAGAAGAGAGTGATCTGATCATTCCCAAGTCTTTAGCTGGGCCA
 CTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAA
 GAGCTTGAAATTCGGTTTGAGGAATGCCCCGGGCACTAAGGTCCACGTGGAGGAAACATGTGGA
 5 ACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGC
 AGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAG
 ATAAGGCCCAGGAAAGAACCAGAAAAGCAACTTAGTAAGGTCAGTGGTGAAGTGCAGGATCAACT
 GATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGA
 AGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCAGTGCTGGTAGCTATGATCC
 10 TGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGCGCCACCTTCGCGGA
 AATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGC
 GTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTG
 GCCTCGTGCTTTTGCAAACTGCGATCTCCGCTTGGAAGGCGACCTGATGGTTCTCATCAATG
 GTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTG
 GCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGCGACACTGCTTGTGGCGTGGAGAGCAGGC
 15 CTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACT
 TACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGG
 ACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGT
 TGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCAT
 20 GGCCGCGTCTGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCT
 CGATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGA
 GAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTG
 CAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGC
 CTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTA
 25 GACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTG
 GCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGA
 TGTCAGCAGGATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCA
 CAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCC
 CGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
 30 TTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTG
 ATCAAAAATGGGAGTTATGTTAGTGCCATACCCAAGGGAGGAGGAGGAAGAGACTCCTGTT
 GAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCTGGAG
 CTGGGAAAACAGGAGAGGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTA
 CTGTGATCTTAGCTCCAACCAGGGTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCC
 35 AGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATG
 TGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATAT
 TATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAG
 GGTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGC
 ATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAAGTCCCAGAGAGAGCCTGGAG
 40 CTCAGGCTTTGATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGG
 AACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCAGA
 AAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAACT
 GACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTCTATAGATTCCAGGAGATGCCTAA
 AGCCGGTCATACTTGATGGCGAGAGAGTCATTTTGGCTGGACCCATGCCTGTACACATGCCAG
 45 CGCTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTA
 TGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCT
 TGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTA
 GCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCATG
 AAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAG
 50 ATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAG
 AGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTT
 TGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCT
 TTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCC
 ATTGACAACCTCGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCG
 55 GCCCAATTTGCCGAGACCTAGAGACCATATTGCTTTTGGGGTTGCTGGGAACAGTCTCGTGG
 GAATCTTTTTCTGTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCT
 TGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTC

ATTGTTGTGTTTCCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGG
 ACAACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGA
 ACTCGGATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGG
 5 GAGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGC
 TGCCTTGACAACTTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACTAC
 TCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCT
 ACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGAC
 CCTAATAGTGGCCATCATTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCA
 GCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGAT
 10 GGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGA
 CAGGTGCTACTCATAGCAGTAGCAGTCTCCAGCGCCATACTGTGCGCGGACCGCCTGGGGGTGG
 GGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAG
 TACTGGAACCTCTTACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAG
 CTTCTCTAATCTACATAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAG
 15 GAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACT
 CCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGGCCCGCCGCGCCCTCAAGGATG
 GTGTGGCAACGGGAGGCCATGCTGTGTCCCAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGC
 GGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTT
 ACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTC
 20 ATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGG
 ACGTCTTTTCATATGGCGGTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
 TAGTCCTGAAGTGGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGA
 AAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAAC
 CCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTC
 25 TACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGTGTGTCCACCAC
 GAGCCAGTCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGT
 GAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATT
 GGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCAC
 CCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCTC
 30 TAATAAACGGGGTTGTTCAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGAA
 TAGCCATGACCACACACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACTA
 GGGTGCCAGCCCCAAGAAGGCATCGTCAGGATTATGAGCATGGTCTCTTCTGTTGTGGAA
 AGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTG
 TAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAG
 35 CTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAG
 AGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGA
 AAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTCGAA
 GCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAA
 GGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGG
 40 ATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTCGATCTGGAGAATGAA
 GCTCTAATCACCAACCAAATGGAGAAAGGGCATAGGGCCTTGGCATTGGCCATAATCAAGTAC
 ACATACCAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGAC
 ATTATTTTCGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTA
 CCAACCTAGTGGTGCAACTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACT
 45 TGTGGCTGCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGC
 TCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCAC
 ATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTT
 CAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTTGCTCCCACCACTTCAACAAGCTCCATCT
 CAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGGCCG
 50 CGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCA
 AATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCA
 TCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAA
 TGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCAC
 ATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGAC
 55 TTGTGTGTGGATCTCTCATAGGGCAGACCGCGCACCACCTGGGCTGAGAAACATTAATAAAC
 ACAGTCAACATGGTTCGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACC
 CAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGT

TGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAG
 AAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGC
 CTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCCATGCGCTTGGAGGCGCAGGATGGGA
 AAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATC
 5 TCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAACGCAAAACAGCATATTGACGC
 TGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAAT
 AGCGGCGGCCGGTGTGGGGAAATCCATGGGTCTT

SEQ ID NO: 7

10 KU681081.3 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, complete genome
 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTA
 TCAACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTTCATGAAAAACCCAAAAAAGAAA
 TCCGGAGGATTCCGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGG
 GCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGAT
 15 TCTAGCCTTTTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
 GTGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
 AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCACAGATACTAGTGTGCGAATTGTT
 GGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGT
 ACTTGGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCCAACCACACTGGGGATGAATAAGT
 20 GTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
 GCTGGATGAGGGGGTAGAACCAGATGACGTCCGATTGTTGGTGCAACACGACGTCAACTTGGGT
 TGTGTACGGAACCTGCCATCACAAAAAGGTGAAGCACGGAGATCCAGAAGAGCTGTGACGCT
 CCCCTCCCATTCCACTAGGAAGCTGCAACGCGGTCGCAGACCTGGTTGGAATCAAGAGAATA
 CACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCA
 25 GCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATAC
 TGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGTAATAGGGACTTTGTGGAAG
 GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCGTAATGGC
 ACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGT
 AAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCGCTGCCCAACACA
 30 AGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGGA
 CAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTT
 TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
 GCTGTCACTTCATGGCTCCCAGCAGTGGGATGATCGTTAATGACACAGGACATGAAACTGAT
 GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGT
 35 TTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTTGTATTACTT
 GACTATGAACAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGG
 CACTGTTGGGACAGACACCGGAACCTCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAG
 GACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
 GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGGCCAC
 40 TTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTACTCCTTGTGTACCG
 CAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTAC
 AGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACCTC
 TGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAGGCACTGAGAAGCTCTA
 AGATGATGCTGGAACCTTGATCCACCATTGGGGACTTTACATTGTCATAGGAGTCGGGGAGAA
 45 GAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAGCATTGGAAGCCACTGT
 GAGAGGTGCCAAGAGAATGGCAGTCTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
 CGTTCTTAACCTATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTG
 GAGGAATGTCTGGTTCTCAAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAATAC
 AAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAG
 50 CCGTCTCCGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAG
 GGGTGTTGCTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCC
 TCGTAGATTGGCAGCAGTAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTT
 TCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
 GAATGGAGTTCACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA
 55 GAGATTGCCCGTGCCTGTGAACAGCTGCCACGCTGGAAGGCTTGGGGGAAATCGTACTT
 CGTCAGAGCAGCAAAGACAAATAACAGCTTTGTGCTGGATGGGTGACACACTGAAGGAATGCCC
 ACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCCGGGTATTTCACT

AGTGTCTGGCTCAAGGTTAGAGAAGATTATTCAGTAGAGTGTGATCCAGCCGTCATTGGAACAG
 CTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAACG
 ACACATGGAGGCTGAGGAGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCC
 5 ACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGC
 CACTCAGCCATCACAAACACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTG
 AAGAGCTTGAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCACGTGGAGGAAACATGTG
 GAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCT
 GCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGG
 10 AGATAAGGCCCAGGAAAGAACCAGAAAGTAACTTAGTAAGGTCAATGGTGACTGCAGGATCA
 ACTGATCACATGGATCACTTTTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGC
 TGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGA
 TCCTGGGAGGATTTTCAATGAGTGATCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTTGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGGTAGCGGCATTCAAAGTCAGACC
 AGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCC
 15 TTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGATGGTTCTCATCAA
 TGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAATATCACCT
 TGGCAATCCTGGCTGCTCTGACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAGAGCAG
 GCCTTGCTACTTGCGGGGGGTTTCATGCTCCTCTCTCTGAAGGGGAAAGGCAGTGTGAAGAAGA
 ACTTACCATTGTGCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGTGGT
 20 GGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGC
 TGTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCC
 CATGGCCGCGGTGCGTCTGCTAATTGTCAAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTAC
 ATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTTACTGGAACAGTCCCCCG
 CTCGATGTGGCACTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGA
 25 GAGAGATCATACTCAAAGTGGTCCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCTT
 TGCAGCTGGAGCGTGGTACGTATACGTGAAAACCTGGAAAAAGGAGTGGTGCTCTATGGGATGT
 GCCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTC
 GTAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTAT
 GTGGCATGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGG
 30 AGATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGG
 GCACAGCAGGTGCAGCTCTGGCCGTGGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCT
 GCGCGGAATATTTAAGACAAAGGATGGGACATTGGAGCGGTTGCGCTGGACTATCCAGCAGG
 AACTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGCAATGGGGT
 CGTGATCAAGAATGGGAGTTATGTCAAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCC
 35 TGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCT
 GGAGCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAACGAGACTC
 CGTACTGTGATCTTAGCTCCAACCAGGGTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGC
 TTCCAGTGCGTTATATGACAACAGCAGTCAATGTACCCATTCTGGGACAGAAATCGTTGACTT
 AATGTGCCATGCCACCTTCACCTTACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTG
 40 TATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAA
 CAAGGGTTGAGATGGGCGAGGCAGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTG
 ACGCATTCCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAAGTCCAGAGAGAGCCT
 GGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGA AAAACAGTTTGGTTTGTCCCAAGCGT
 GAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTGCATACAGCTCAG
 45 CAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTCGTCTGTGAC
 AACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTGCATAGATTCCAGGAGATGC
 CTAAGCCCGTGCATCTTGTATGGCGAGAGAGTCAATTCTGGCTGGACCCATGCCTGTACACATG
 CCAGCGCTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATC
 TGTATGGAGGTGGGTGCGCAGAGACTGATGAAGACCATGCACACTGGCTTGAAGCAAGAATGC
 50 TCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAA
 AGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAAGT
 CATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTAC
 ACAGATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACAGTGTGCCG
 GCAGAGTTGTGGACACAGACCGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAGCCAG
 55 AGTTTGTTCAGATGATCGCGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGC
 GGCTTTTGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACGGAGAGATTCCAGGA
 AGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGC

GGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCG
CTGGGAATCTTTTTTCGTCTTGATGCGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGA
CTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGCGT
5 CCTCATTGTTGTGTTCCATTGCTGGTGGTGTCTACACCTGAGCCAGAAAAGCAAAGATCCCCC
CAGGACAACCAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCA
ATGAACTCGGATGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAG
GAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCGGCCTGGGCCATC
TATGCTGCCCTGACAACCTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACTTCATACAACA
10 ACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCC
ATTCTACGCATGGGACTTTGGAGTCCCCTGCTAATGATAGTTGCTACTCACAATTAACACCC
CTGACCCTAATAGTGGCTATCATTTTGTCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGC
AGGCAGCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTG
TGGATGGAATAGTGGTGACTGACATTGACACAATGACTATTGACCCCCAAGTGGAGAAAAAGA
TGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGG
15 GTGGGGGGAAGCTGGGGCCCTGATCACAGCTGCAACTTCCACTTTGTGGGAAGGCTCTCCGAA
CAAGTACTGGAACCTCTACAGCCACTTCACTGTGCAACATTTTTAGGGGAAGTTACTTGGCT
GGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGA
ACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTC
TACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGGCCCCGCGCCCTCAAG
20 GACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTG
GAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGG
AGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCT
GGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGG
GTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCAT
25 CATCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGC
TTGAAAAAAGACCAGGAGCCTTTTGTGTAAAAGTGTGTGCCCATACACCAGCACTATGATGGA
AACCTTGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAA
CTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGTGTGTCCAC
CACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATGAGGAGGA
30 TGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATC
ATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCAGCGGAAACGTGGTTCTTTGACGAGAAC
CACCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGTCC
TCTCTAATAAACGGGGTTGTGACGGCTCCTGTCAAACCCCTGGGATGTGGTGAAGGTCAGCAG
GAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACA
35 CCAGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCCCTGGTTGTG
GAAAGAGCTAGGCAAACACAACCGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGG
TTCGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACCGCAGTGG
AAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAGAGAGCACCACCTGAGAG
GAGAGTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTT
40 GGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTC
GAAGCCCTTGGATTCTTAAATGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGT
GAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGA
AGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGTATCTGGAGAAT
GAAGCTTTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTAGCATTGGCCATAATCAAG
45 TACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATG
GACATTATTTCAAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACA
TTTACCAACCTAGTGGTGCAACTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAA
GACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGAT
AGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTT
50 GCACATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAA
CCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTTGTCCCACTTCAACAAGCTCC
ATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGC
CCGTGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAGTCATATGC
GCAAATGTGGCAGTTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATCTGT
55 TCATCTGTGCCAGTTGACTGGGTTCCACTGGGAGAACTACCTGGTCAATCCATGGAAGGGAG
AATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACC
ACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTATCTGGGAAAAAGGGAAG

ACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTA
 ACACAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCA
 CCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTATAAGCACCATCTTAGT
 GTTGTCAAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGA
 5 GAGGCTGGGAAACCAAGCCCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCT
 GCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGG
 GAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGG
 ATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTGA
 CGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCG
 10 AATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCT

SEQ ID NO: 8

KU681082.3 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, complete genome
 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTA
 15 TCAACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAA
 TCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGG
 GCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGCCATGGGCCCATCAGGATGGTCTTGGCGAT
 ACTAGCCTTTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
 GTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
 20 AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGCGTCGGAATTGT
 TGGCCTCCTCCTGACCACAGCCATGGCAGTAGAGGTCACTAGACGTGGGAGTGCATACTATATG
 TACTTGGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCCAACCACACTGGGGATGAATAAG
 TGTTACATACAAATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTA
 TGTTGGATGAGGGGGTAGAACCAGATGACGTCGATTGCTGGTGCAACACGACATCAACTTGGG
 25 TTGTGTATGGAACCTGCCACCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGC
 TCCCCTCCCATTCCTAGGAAGCTGCAAACGCGGTGCGCAGACCTGGTTGGAATCAAGAGAAT
 ACACAAAGCACCTGATTAGAGTTGAAAATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGC
 AGCTGTCATCGCTTGGCTTTTGGGAAGTTCAACGAGCCAAAAAGTCATATATCTGGTCATGATA
 CTGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAA
 30 GGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGAACATGGAGGTTGTGTTACCGTAATTGG
 CACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCCGAGG
 TAAGATCCTACTGCTATGAGGCATCAATATCGGATATGGCTTCGGACAGCCGCTGCCAACACA
 AGGTGAGGCCTACCTTGACAAGCAGTCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGA
 CAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTT
 35 TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
 GCTGTCAAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAAACTGAT
 GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGT
 TTTGGGAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACC
 TGACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTG
 40 GCATGCTGGGGCAGACACTGGAATCCACATTGGAACAACAAGAAGCACTGGTAGAGTTCAA
 GGACGCACATGCAAAAAGGCCAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACAC
 GGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGAGCCAAGGGAAGGCTGTCCTCTGGCCA
 CTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGCACT
 GCAGCGTTCACATTACCAAGATCCCGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTA
 45 CAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGATATGCAAACT
 CTGACCCCAGTTGGGAGGTTGATAACCGCTAACCTGTAATCACTGAAAGCACCGAGAACTCTA
 AGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
 GAAGATCACCCATCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGT
 GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGGGG
 50 TGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTCG
 GAGGAATGTCCTGGTTCTCACAATTCTCATTGGAACGTTGCTGGTGTGGTTGGGTCTGAATAC
 AAAGAATGGATCTATTTCCCTTACGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAG
 CCGTTTCTGCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAG
 GGGTGTTCGTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCC
 55 TCGTAATTGGCAGCAGTCAAGCAAGCCTGGGAAGATGGGATCTGTGGGATCTCCTCTGTCTGTC
 TCAAGAATTGAAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
 GAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA

GAGATTGCCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTT
 CGTCAGAGCAGCAAAGACAAATAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCC
 ACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTTGGGGTATTTACACT
 AGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTCATTGGAACAG
 5 CTGCTAAGGGAAAGGAGGCTGTGCACAGCGATCTAGGCTACTGGATTGAGAGTGAGAAGAACG
 ACACATGGAGGCTGAAGAGGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCC
 ACACATTGTGGACAGATGGAGTAGAAGAAAGTGATCTGATCATACCCAAGTCTTTAGCTGGGC
 CACTCAGCCATCACAAACACCAGAGAGGGCTACAGGACTCAAATGAAAGGGCCATGGCACAGTG
 AAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTG
 10 GGACAAGAGGACCATCCCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCT
 GCAGGGAATGCACAATGCCCCACTGTCGTTCCGAGCTAAAGATGGCTGTTGGTATGGAATGG
 AGATAAGGCCCAGGAAAGAACCAGAAAGTAACTTAGTAAGGTCAATGGTGACTGCAGGATCA
 ACTGATCACATGGATCACTTCTCTCTTGGAGTGCTTGTGATTTTGCTCATGGTGACGGAAGGGCT
 GAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCCATGAT
 15 CCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCG
 GAAATGAACACTGGAGGAGATGTAGCTCATTTGGCGCTGATAGCGGCATTCAAAGTCAGACCT
 GCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAGAGCATGCTGCTGGCCTT
 GGCCTCGTGTCTTCTGCAAACCTGCGATCTCCGCTTGGAAGGCGACCTGATGGTTCTCATCAAT
 GGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAACATCACCT
 20 TGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAGAGCAG
 GCCTTGCTACTTGCGGGGGGTTTCATGCTCCTCTCTGAAAGGGGAAAGGCAGTGTGAAGAAGA
 ACCTACCATTGTGTCATGGCCTTGGGACTAACTGCTGTGAGGCTGGTCGACCCCATCAACGTGGT
 GGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTACTCACAGC
 TGTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCGGATATAGAGATGGCTGGGCC
 25 CATGGCCGCGGTTCGGTCTGCTAATTGTGCAATTACGTGGTCTCAGGAAAGAGTGTGGACATGTAC
 ATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAATCACTGGAAACAGTCCCCG
 GCTCGATGTGGCACTAGATGAGAGTGGTGATTTCTCCCTAGTGGAGGATGATGGTCCACCCATG
 AGAGAGATCATACTCAAAGTGGTCTCTGATGACCATCTGCGGCATGAACCCAATAGCCATACCCT
 TTGCAGCTGGAGCGTGGTACGTGTATGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATG
 30 TGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTCAATGACTC
 GTAGACTGCTTGGTTCAACACAAGTTGGAGTGGGAGTCATGCAAGAGGGGGTCTTCCACACTAT
 GTGGCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGAGACTTGATCCATACTGGGG
 AGATGTCAAGCAGGATCTGGTGTCACTGTGGTCCGTGGAAGCTAGACGCCGCTGGGACGG
 GCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCT
 35 GCCCCGAACATTTAAGACAAAGGATGGGGACATTGGAGCAGTTGCGCTGGACTACCCAGCAGG
 AACTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGTAATGGGGT
 CGTGATAAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCC
 TGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACCTGCATCCT
 GGAGCCGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTC
 40 CGTACTGTGATCTTAGCTCCAACCAGGGTCGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGC
 TTCCAGTTCGTTATATGACAACAGCAGTCAATGTCACCCATTCTGGGACAGAAATCGTTGACTT
 AATGTGCCATGCTACCTTCACGCTACTACAACCAATCAGAGTCCCCAACTATAATTTGT
 ATATTATGGATGAGGCCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAAC
 AAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGA
 45 CGCATTCCCGGACTCCAACCTACCAATTATGGACACCGAGGTGGAAGTCCCAGAGAGAGCCTG
 GAGCACAGGCTTTGATTGGGTGACGGATCATTCTGGGAAAACAGTCTGGTTTGTTCGAAGCGTG
 AGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTGCATACAGCTCAGC
 AGAAAGACTTTTGAGACAGAGTTCCAGAAAACGAAAAATCAAGAGTGGGACTTCGTCGTGACA
 ACCGACATTTTCAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTCATAGATTCCAGGAGATGCT
 50 TAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTTTGGCTGGACCCATGCCTGTCACACATGC
 CAGCGCTGCTCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCT
 GTATGGAGGTGGGTGCGCAGAGACTGATGAAGATCACGCACACTGGCTTGAAGCAAGAATGCT
 TCTTGACAACATTTACCTCCAAGATGGCCTCATAGCTTCGCTCTATCGACCTGAGGCCGACAAA
 GTAGCAGCTATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTC
 55 ATGAAAAGAGGAGATCTCCGGTTTGGTTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACA
 CAGATAGAAGATGGTGCTTTGATGGCATGACCAACACACATAATGGAAGACAGTGTGCCGG
 CAGAGGTGTGGACCAGATACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGA

GTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAAGAGTTTGCCGCTGGGAAAAGAGGAGCG
 GCCTTTGGAGTGATAGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAA
 GCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGC
 5 TGGGAATCTTTTCGTCTTGATGCGGAACAAGGGCATGGGGAAGATGGGCTTTGGAATGGTGAC
 TCTTGGGGCCAGCGCATGGCTTATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTC
 CTCATTGTCGTGTTCCATTATGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCTC
 AGGACAACCAAATGGCAATCATCATCATGGTAGCAGTGGGTCTTCTGGGCTTGATTACCGCCAA
 TGAACCTCGGATGGTTGGAGAGAAACAAAAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGG
 10 AGGGGGCAACCACAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCTATCTA
 TGCTGCTCTGACAACCTTTCATCACCCAGCCGTCCAACATGCGGTGACCACTTCATACAACAAC
 TACTCCTTAATGGCGATGGCCACGCAAGCTGGGGTGTTGTTTGGTATGGGCAAAGGGATGCCAT
 TCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATGGGTTGCTACTCACAATTAACACCTCT
 GACCCTAATAGTGGCCATCATTTTGTCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAG
 15 GCAGCAGCTGCGCGGGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTG
 GATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAAGGAAAGATG
 GGGCAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGT
 GGGGGGAGGCTGGGGCCCTGATCACAGCTGCAACTTCCACCTTGTTGGGAAGGCTCTCCGAACA
 AGTACTGGAACCTCCACAGCCACTTCACTGTGTAAACATTTTTAGGGGAAGTTACTTGGCTGG
 20 AGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAAC
 GGGAGAGACCTGGGAGAGAAATGGAAGGCCCGCCTGAACCAGATGTGCGGCCCTGGAGTTCTA
 CTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCCGCCGTGCCCTCAAGGA
 CGGTGTGGCAACAGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTTAGATGGCTGGTGGA
 GAGAGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAG
 25 TTAATATGCCGCCACCATCCGCAAAGTTTCAAGGAAGTGAAAGGATACACAAAAGGAGGCCCTGG
 TCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGT
 GGACGTCTTTCACATGGCGGCTGAGCCGTGTGACACTTTGCTGTGTGATATAGGTGAGTCATCA
 TCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTG
 AAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAA
 30 CCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGGGTGCCACTCTCCCGCAACT
 CTACACATGAGATGTACTGGGTCTCTGGAGCGAAAGCAACACCATAAAAGTGTGTGCCACCA
 CGAGCCAGTCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAAATATGAGGAGGATG
 TGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
 TGGTAACCGCATTGAGAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCA
 35 CCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGTCCTCT
 CTAATAAACGGGGTTGTGACGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGA
 ATAGCCATGACTGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGAGACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTATGGA
 AGGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTTATCAACAAGGTTT
 40 GTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGA
 GCTGTGAATGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCATCACCTGAGAGGA
 GAGTGTGAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGG
 AAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCTGA
 AGCCCTTGGATTCTTGAATGAGGATCATTGGATGGGGAGAGAGAATTCAGGAGGTGGTGTGA
 45 AGGACTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAG
 GATGTATGCAGATGATACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGA
 AGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTA
 CACATACCAAACAAAGTGGAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGA
 CATTATTTCAAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAATACATTC
 50 ACCAACCTGGTGGTGACGCTCATTCCGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGAC
 TTGTGGCTGCTGCGGAGGCCAGAGAAAGTGACCAACTGGTTGCAAAGCAACGGATGGGATAGG
 CTCAAAGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAACCAATTGATGATAGGTTTGCA
 CATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCC
 TCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTGTGCTCCCACTTCAACAACTCCATC
 55 TTAAGGACGGGAGGTCCATTGTGGTTCCCTGCCACCAAGATGAAGTGAAGGAGGAGCCCG
 CGTATACACAGGGGCGGGATGGAGCATCCGGAGAGACTGCTTGCTAGCAAAATCATATGCGCA
 AATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCA

TCTGTGCCAGTTGATTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAT
GGATGACCACTGAAGACATGCTTGTGGTATGGAACAGAGTGTGGATTGAGGAAAACGACCACA
TGGAAGACAAGACCCCAGTTACAAAATGGACAGACATTCCCTATTTGGGAAAAAGAGAAGACT
TGTGGTGTGGATCTCTCATAGGGCACAGACCGCTACTACCTGGGCTGAGAACATCAAAAATA
5 CAGTCAACATGATGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCC
AGGTTTCGCTACTTGGGTGAAGAAGGGTCCACACCTGGAGTGCTGTAAGCACCAATCTTAGTGTT
GTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGA
AGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCC
10 TGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAA
AAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCT
CCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCCGGAAAACGCAAAACAGCATATTGACGCT
GGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATA
GCGGCGGCCGCTGTGGGGAAATCCATGGGTCT

15 SEQ ID NO: 9

KU707826.1 Zika virus isolate SSABR1, Brazil, complete genome

GACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTGGAAC
GAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGC
TAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTC
20 TGCTGGGTTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTGGAGATTCACGGCAAT
CAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAAGAGGCTATGGAAAT
AATAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAA
GAAGAGACGAGGCGCAGATACTAGTGTCCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGC
AGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTAAGTGGACAGAAACGATGCTGGGGA
25 GGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGGATCTTGGA
CACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGAACCATGAT
GACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTGTGTACGGAACCTGCCATCACAAAA
AAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCATTCCACTAGGAAGCTGC
AAACGCGGTCGCAAACTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
30 ATTGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAG
CTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATC
AGGTGCATAGGAGTCAGCAATAGGACTTTGTGGAAGGTATGTCAGGTGGGACCTGGGTTGAT
GTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTTCGACATA
GAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCA
35 ATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAA
TCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGA
CTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGG
AAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTATGGCTCCCAGCAC
AGTGGGATGATTGTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAAGTTGAGATA
40 ACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGT
GAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGT
TGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
TCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAA
CTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTACACGCGCCCTTGCTGGAGCTCTGGAGG
45 CTGAGATGGATGGTGCAAAGGGAAGGCTGTCCCTCTGGCCACTTGAAATGTGCCTGAAAATGG
ATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACTGCAGCGTTACATTACCAAGAT
CCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACC
TTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCCAGTTGGGAGGTTGATA
ACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTGATCCAC
50 CATTTGGGGACTCTTACATTGTCTATAGGAGTCGGGGAGAAGAAGATCACCCACCACTGGCACA
GGAGTGGCAGCACCATTGGAAGAGCATTGTAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAG
TCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGG
CATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGTCTGGTTCTCACAAA
TTCTCATTGGAACGTTGCTGATGTGGTGGGTCTGAAACACAAAGAATGGATCTATTTCCCTTATG
55 TGCTTGGCCTTAGGGGAGTGTTGATCTTCTTATCCACAGCCGCTCTCTGCTATGTGGGGTGCTC
GGTGGACTTCTCAAAGAAGGAGACGAGATCGCGTACAGGGGTGTTTCGTCTATAACACGCTTGA
AGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAA

GCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAACATCATGTGG
 AGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTT
 GTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCGTGCTGTGAACGAG
 CTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAAATAAC
 5 AGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCCCACTCAACATAGAGCATGGAACAGC
 TTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACA
 CAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCA
 TCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGA
 10 AGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGA
 GGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAAGAGCTTGAAATTCGGTTTGAGGA
 ATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATC
 AACCCTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCACT
 GTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGA
 15 AAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGACCACTTCTCCCTT
 GGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATC
 ATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACC
 TGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGC
 TCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGA
 20 GCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACCTGCGA
 TCTCCGCTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTGGCCTGGTTGGCAATA
 CGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCAC
 TGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCCTTGCTACTTGCAGGGGGGTTTATGCT
 CCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTTGTCATGGCCCTGGGACTA
 25 ACCGCTGTGAGGCTGGTTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGG
 AAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGA
 GGGTTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGTGCGTCTGCTAATTGTC
 AGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCACATGG
 GAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGGT
 30 GATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTCTGA
 TGACCATCTGTGGCATGAACCCAATAGCCATAACCTTTGCAGCTGGAGCGTGGTACGTATACGT
 GAAGACTGGAAGGAGTGGTGTCTATGGGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGG
 GGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGG
 AGTGGGAGTTATGCAAGAGGGGGTCTTTACACTATGTGGCACGTCACAAAAGGATCCGCGCT
 35 GAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTATA
 CTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGT
 GCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGG
 GGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTAGACAA
 GTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTTCGTGATCAAAAATGGGAGTTATGTTAG
 40 TGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCT
 GAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCT
 TCCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCA
 GTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCAC
 45 GTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCAC
 AGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGC
 TGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCA
 ATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACG
 GATCATTCTGGAACAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTT
 50 GTCTGACAAAGGCTGGAACACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCC
 AGAAAAACAAACATCAAGAGTGGGACTTTGTCGTGACAACTGACATTTTCAAGATGGGCGCCA
 ACTTTAAAGCTGACCGTGTCTAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGA
 GAGAGTCATTCTGGCTGGACCCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCG
 CATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
 55 TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGAT
 GGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTT
 AAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACATGAAAAGAGGAGATCTTCCTGTT

TGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGGTGCTTTGATG
GCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGA
GAGAAAAGAGTGTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTG
AAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTG
5 GGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGCTGTGCTC
ATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCAATTGCCGGAGACCCTA
GAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTCTCGTCTTGATGA
GGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCA
TGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTTCTATTGCTG
10 GTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAATGGCAATCATC
ATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAA
CAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCA
ATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTA
CCCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTCCTTAATGGCGATGGCCAC
15 GCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGAGTC
CCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCATTTT
GCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAG
AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
GACACAATGACAATTGACCCCCAAGTGGAGAAAAGATGGGACAGGTGCTACTCATAGCAGTA
20 GCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATC
ACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCA
CTTCACTGTGTAACATTTTATAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACA
AGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATG
GAAGGCCCCGCTTGAACCAGATGTGCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACC
25 GAGGTGTGCAGAGAAGAGGCCCCGCGGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCT
GTGTCCCGAGGAAGTGAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGA
AAGGTCATTGATCTTGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAA
GTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAA
AGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGC
30 CGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAAGAAGCAG
GACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATA
AAGTGTTGTGCCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTAT
GGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTATTGGGTCTCTG
GAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGG
35 ACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTG
TGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGCA
GTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATG
GAAGCTATGAGGCCCCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTTGTCAGGCTCCT
GTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTA
40 TGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCCAAGAAGGCAC
TCGTGAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCACAAACACAAACGGCCA
CGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTTCGTAGCAATGCAGCATTAGGGGCAATA
TTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCT
CTAGTGGATAAGGAAAGAGAGACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATG
45 ATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAGGGCAGCCGCGCCATCTG
GTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTCAAGCCCTTGGATTCTTGAACGAGGATCAC
TGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACAAAGACTCGGATAT
GTCCTAGAAGAGATGAGTCGTATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGG
GACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAAAAA
50 GGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTC
CTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAAGACCAAAGGGG
AGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTCGGA
ATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAG
TGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATG
55 ATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTGAATGATATGGG
AAAAGTTAGGAAGGACACACAAGAGTGGAAACCCCTCAACTGGATGGGACAACTGGGAAGAAG
TTCCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCC

TGCCGCCACCAAGATGAACTGATTGGCCGGGCGCGTCTCTCCAGGGGCGGGATGGAGCATC
 CGGGAGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAA
 GGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCAACTGG
 5 GAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGT
 GTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAAT
 GGACAGACATCCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACA
 GACCGCGCACCACCTGGGCTGAGAACATTAACCAACAGTCAACATGGTGGCAGGATCATAG
 GTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGT
 10 CTACACCTGGAGTGTCTGTAAGCACCAGTCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTT
 GGGGAAAGCTGTGTCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGG
 CCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTC
 AAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCCTT
 CAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGG
 15 AG

SEQ ID NO: 10

KU744693.1 Zika virus isolate VE_Ganxian, China, complete genome

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTAT
 CAACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAAT
 20 CCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGG
 GCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAAT
 TCTAGCCTTTTTGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
 GTGGGGAAAAAAGATGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTG
 25 AGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCGGAATTGTT
 GGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATATGT
 ACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGT
 GTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
 GCTGGATGAGGGGGTGGAAACCAGATGACGTCGATTGTTGGTGAACACGACGTCAACTTGGGT
 30 TGTGTACGGAACCTGCCATCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCT
 CCCTTCCCATTCCACTAGGAAGCTGCAAACGCGGTGCGAAACCTGGTTGGAATCAAGAGAATA
 CACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCCCTGGCTTCGCGTTAGCAGCA
 GCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATAC
 TGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
 35 GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCGCAATGGC
 ACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGT
 AAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACA
 AGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTTTGCAAAAGAACGTTAGTGGA
 CAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTT
 40 TGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAAT
 GCTGTCAGTTCATGGCTCCCAGCACAGTGGGATGCTCGTTAATGACACAGGACATGAACTGAT
 GAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGT
 TTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTT
 GACTATGAATAACAAGCACTGGTTGGCTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGG
 45 CACGCTGGGGCAGCCACCGGAACCTCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAG
 GACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
 GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGGCCAC
 TTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTCCTTGTGTACCG
 CAGCGTTACATTACCAAGATCCCAGGCTGAAACAGTGGACGGGACAGTCACAGTGGAGGGAC
 50 AGTACGGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAGACTC
 TGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
 AGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAA
 GAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGTAAGCCACTGT
 GAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGG
 55 CGCTCTCAACTCATTGGGCAAGGGCAATCCATCAAATATTGGAGCAGCTTCAAATCATTGTTT
 GGAGGAATGTCCTGGTTCTCACAAATTCTATTGGGACGTTGCTGATGTGGTTGGGTCTGAACA
 CAAAGAATGGATCTATTTCCCTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTATCCACA
 GCCGTCTCAGGTGGTGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACA

GGGGTGTTCTCTATAACGATGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCC
 CCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGT
 TTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGA
 5 GAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACA
 GAGATTGCCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTT
 CGTCAGAGCAGCAAAGACAAATAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCC
 ACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCGGGGTATTTCACACT
 AGTGTCTGGCTCAAGGTTAGAGAAGACTATTGGTTAGAGTGTGATCCAGCCGTTATTGGAACAG
 CTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATG
 10 ACACATGGTGGCTGAAGAGGGGCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCC
 ACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGC
 CACTCAGCCATCACAATGCCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTG
 AAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCACGTGGAGGAAACATGTG
 GAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCT
 15 CCAGGGAGTGCACAATGCCCCACTGTCTTCCAGGCTAAAGATGGCTGTTGGTATGGAATGGA
 GATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAA
 CTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCT
 GAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGGTAGCTATGAT
 CCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCG
 20 GAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCA
 GCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGCGCTT
 GGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGATGGTTCTCATCAAT
 GGTTTGTCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTT
 AGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGG
 25 CCTTGCTACTTGCGGGGGGTTTATGTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAAC
 TTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGG
 GACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTG
 TTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCA
 TGGCCGCGGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 30 TGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCT
 CGATGTGGCGCTAGAGTGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGA
 GAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTG
 CAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGC
 CTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGC
 35 AGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGT
 GGCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAG
 ATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGC
 ACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGC
 CCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCACTGGATTACCCAGCAGGAA
 40 CTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGT
 GATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGT
 TGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGA
 GCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGT
 ACTGTGATCTTGGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTC
 45 CAGTGCGTTATATGACAACAGCAGTCAATGTACCCCACTCTGGAACAGAAATCGTCGACTTAAT
 GTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATTAGAGTCCCCAACTATAATCTGTATA
 TTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAA
 GGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACG
 50 CATTTCCGGA CTCAACTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGA
 GCTCAGGCTTTGATTGGGTGACGGAGTATTCTGGAAAAACAGTTTGGTTTGTTCACGCGTGAG
 GAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTGCATACAGCTCAGCAG
 AAAGACTTTTGAGACAGAGTTCAGAAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAAC
 TGACATTTAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGTGCATAGATTCCAGGAGATGCCTA
 AAGCCGGTCATACTTGGTGGCGAGAGAGTCACTTGGCTGGACCCATGCCTGTACACATGCCA
 55 GCGCTGCCAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGT
 ATGGAGTGGGTGCGCAGAGTACGCAAGACCATGCACACTGGCTTGAAGCAAGAATGTCTCC
 TTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGT

AGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACATCAT
 GAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACA
 GATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCA
 GAGGTGTGGACCAGACACGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGT
 5 TTTTGGAGTGATGGAAGCCCTGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGC
 CATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAAGCCGCGGC
 GGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTC
 10 TTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTT
 CATTGTTGTGTTCTTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAG
 GACAACCAAATGGCCATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATG
 AACTCGGATGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAG
 GGGGCAACCATGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATC
 15 CTGCCTTGACATCTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAATA
 CTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTC
 TACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGA
 CCCTAATAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGC
 AGCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGA
 20 GGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGG
 ACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTCTGAGGACCGCTGGGGGTG
 GGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAA
 GTACTGGAACCTCTACAGCCACCTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGA
 GCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACA
 25 GGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTAC
 TCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGAC
 GGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAG
 CGGGGATACCTGCAGCCCTATGGAAGGTTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGT
 TACTACGCCGCCACCATCCGCAAAGTTCAGAAGTGAAAGGATACACAAAAGGAGGGCCCTGGT
 30 CATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTG
 GACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTGTGCTGTGTGACATAGGTGAGTCATC
 CTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGATTGGCTTG
 AAAAAAGACCAGGAGCCCTTTTGTATAAAAAGTGTGTGCCCATACACCAGCACTATGATGGA
 CCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACT
 35 CTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCA
 CGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCTAGGAGGCCAGTGAAATATGAGGAGGATG
 TGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
 TGGTAACCGCATTGAAAGGATCCGCGCTGAGAAAGCGGAAACGTGGTTCTTTGACGAGAACCA
 CCCATATAGGACATGGGCTTACCATGGAAGCTATGATGCCGCCACACAAGGGTCAGCGTCCTCT
 40 CTAATAAACGGGGTGTGACGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGGA
 ATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGA
 AAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTT
 GTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAA
 45 GCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGA
 GAGTGCCAGAGTTGTGTGTACATCACAATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGG
 AAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCTGA
 AGCCCTTGGAATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGA
 AGGGCTGGGATTACAAAGACTCGGATATGTCTAGAAGAGATGAGTCGCATACCAGGAGGAAG
 50 GATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGA
 AGCTCTAATCACCACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTA
 CACATACCAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGA
 CATTATTTGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTCAACACATTT
 ACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGAG
 55 TTGTGGCTGCTGCGGAGGTGAGAGAAAGTACCAACTGGTTGCAGAGCAACGGATGGGATAGG
 TCAAACGAATGGCGGTGAGTGAGATGATTGCGTTGTGAAACCAATTGATGATAGGTTTGAC
 ATGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAGTGGAAACCT

CAACTGGATGGGACAACCTGGGAAGAAGTTCCCTTCTGCTCCCACCACTTCAACAAGCTCCATCT
 CAAGGACGGGAGGTCCATTGTGGTTCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCCCCG
 CGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCA
 AATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCA
 5 TCTGTGCCAGTTGACTGGGTTCCTTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAA
 TGGATGACCACTGAAGACATGCTTGTGGCGTGGAACAGAGTGTGGATTGAGGAGAACGACCAC
 ATGGAAGACAAGACCCAGTCACGAAATGGACAGACATTCCCTATTGGGAAAAAGGGGAAGAC
 TTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAAAAAC
 ACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACC
 10 CAAGTTCGCTACTTGGGTGAAGAAGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGT
 TGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAG
 AAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGC
 CTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGA
 AAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATC
 15 TCCAGAAGAGGGACTAGTGGTTAGAGGAGA

SEQ ID NO: 11

LC002520.1 Zika virus genomic RNA, strain: MR766-NIID, Uganda, complete genome

AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTTCGAGTCTGAAGCGAGAGCTAACAACAGT
 20 ATCAACAGGTTTAATTTGGATTTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAGAAGAA
 ATCCGGAGGATTCCGGATTGTCAATATGCTAAACGCGGAGTAGCCCGTGTAACCCCTTGGG
 AGGTTTGAAGAGGTTGCCAGCCGACTTCTGCTGGGTCTATGGACCCATCAGAATGGTTTTGGCG
 ATACTAGCCTTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTT
 CCGTGGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGT
 25 TGAGAATAATCAATGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATC
 ATTGGCCTCCTGCTGACTACAGCCATGGCAGCAGAGATCACTAGACGCGGGAGTGCATACTAC
 ATGTACTTGGATAGGAGCGATGCCGGGAAGGCCATTTCTGTTGCTACCACATTGGGAGTGAACA
 AGTGCCACGTACAGATCATGGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGGCC
 TATGCTGGATGAGGGAGTGAACCAAGATGATGTGCGATTGCTGGTGCAACACGACATCAACTTG
 30 GGTGTGTACGGAACCTGTCATCAGAAAAAGGTGAGGCACGCGATCTAGAAGAGCCGTGAC
 GCTCCCTTCTCACTCTACAAGGAAGTTGCAAAACGCGGTTCGACAGACCTGGTTAGAATAAGAGA
 ATACAGGAAGCACTGATCAAGGTTGAAAACCTGATATTTCAGGAACCCCGGTTTTCGCTAGT
 GGCCGTTGCCATTGCCTGGCTTTTGGGAAGCTCGACGACCAAAAAGTCATATACTTGGTCATG
 ATACTGCTGATTGCCCCGGCATAACAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTTCGTGG
 35 AGGGCATGTGAGGTGGGACCTGGGTTGATGTTGTCTTGGAAACATGGAGGCTGCGTTACCGTGAT
 GGCACAGGACAAGCCAACAGTTGACATAGAGTTGGTCACGACGACGGTTAGTAACATGGCCGA
 GGTAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTCGTTGCCCAACA
 CAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTG
 GACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAAGGGAGCTTGGTGACATGTGCCAAG
 40 TTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACCGGAAAATCTGGAGTATCGGATA
 ATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGACTGTCAATGATATAGGATATGAAACTG
 ACGAAAATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGAGCGGAAGCAACCTTGGGAG
 GCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGAATTTTTCAGATCTGTATTA
 CCTGACCATGAACAATAAGCATTGGTTGGTGACAAAGAGTGGTTTCATGACATCCCATTGCCT
 45 TGGCATGCTGGGGCAGACACTGGAACCTCCACACTGGAACAACAAAGAGGCATTGGTAGAATTC
 AAGGATGCCCACGCCAAGAGGCAACCGTCGTCGTTCTGGGGAGCCAGGAAGGAGCCGTTTAC
 ACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAAGCTGTTCTCTGGC
 CATTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCATATTCCTTGTGCA
 CTGCGGCATTACATTCACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGG
 50 TGCAGTATGCAGGGACAGATGGACCCTGCAAGATCCCAGTCCAGATGGCGGTGGACATGCAGA
 CCCTGACCCCAGTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAACT
 CAAAGATGATGTTGGAGCTTGACCCACCATTGGGGATTCTTACATTGTATAGGAGTTGGGGA
 CAAGAAAATCACCCACCCTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCAC
 TGTGAGAGGCGCCAAGAGAATGGCAGTCTTGGGGGATACAGCCTGGGACTTCGGATCAGTCGG
 55 GGTGTGTTCACTCACTGGGTAAAGGCATTACCAAGATTTTTGGAGCAGCTTCAAATCACTG
 TTTGGAGGAATGCTCTGTTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGTTAGGTTTGA
 ACACAAAGAATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCCTCTC

CACGGCTGTTTCTGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGG
CACGGGGGTATTATCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCTGAC
TCCCCCGCAGATTGGCAGCAGCAGTCAAGCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCA
TCCGTTTCAAGAATGGAAAACATCATGTGGAATCAGTAGAAGGGGAGCTCAATGCTATCCTA
5 GAGGAGAATGGAGTTCAACTGACAGTTGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGGT
CCACAAAGATTGCCAGTGCCTGTGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCG
TATTTTGTAGGGCGGCAAAGACCAACAACAGTTTTTGTGTGCGACGGTGACACACTGAAGGAAT
GTCCGCTTGAGCACAGAGCATGGAATAGTTTTCTGTGGAGGATCACGGGTTTGGAGTCTTCCA
CACCAGTGTCTGGCTTAAGGTCAGAGAAGATTACTATTAGAATGTGACCCAGCCGTCATAGGA
10 ACAGCTGTAAAGGGAAGGGAGGCCGCGCACAGTGATCTGGGCTATTGGATTGAAAGTGAAAAG
AATGACACATGGAGGCTGAAGAGGGGCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAG
TCTCACACATTGTGGACAGATGGAGTAGAAGAAAGTGATCTTATCATACCCAAGTCTTTAGCTG
GTCCACTCAGCCACCACAACACCAGAGAGGGTTACAGAACCCAAGTGAAAGGGCCATGGCACA
GTGAAGAGCTTGAAATCCGTTTGGAGGAATGTCCAGGCACCAAGGTTTACGTGGAGGAGACAT
15 GCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGT
GCTGTAGGGAATGCACAATGCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAA
TGGAGATAAGGCCCAGGAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGTGACAGCGGGG
TCAACCGATCATATGGACCACTTCTCTCTTGGAGTGCTTGTGATTCTACTCATGGTGCAGGAGG
GGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAATGGCAGTGCTGGTAGTCA
20 TGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCTACTTT
CGCAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTCAG
ACCAGCCTTGCTGGTCTCCTTCATTTTCAGAGCCAATTGGACACCCCGTGAGAGCATGCTGCTA
GCCCTGGCTTCGTGTCTTCTGCAAACTGCGATCTCTGCTCTTGAAGGTGACTTGATGGTCTCAT
TAATGGATTTGCTTTGGCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACATC
25 GCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAG
CGGGCCTGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGA
AGAACCTGCCATTTGTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCTATTAATGT
GGTAGGACTACTGTTACTACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCAC
AGCCGTTGGCCTGATATGTGCACTGGCCGGAGGGTTTGCCAAGGCAGACATTGAGATGGCTGG
30 ACCCATGGCTGCAGTAGGCTTGCTAATTGTCAGCTATGTGGTCTCGGGAAGAGTGTGGACATG
TACATTGAAAGAGCAGGTGACATCAGTGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCCT
CGCCTTGACGTGGCATGGATGAGAGTGGTGATTCTCCTTGGTAGAGGAAGATGGTCCACCCA
TGAGAGAGATCATACTTAAGGTGGTCTGATGGCCATCTGTGGCATGAACCCAATGACTATACC
TTTTGCTGCAGGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGA
35 CGTGCCTGCTCCCAAAGAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGA
CTCGCAGACTGCTAGGTTCAACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACA
CCATGTGGCACGTTACAAAAGGAGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACT
GGGGGGATGTCAAGCAGGACTTGGTGTCTACTGTGGGCCTTGGAAGTTGGATGCAGCTTGGG
ATGGACTCAGCGAGGTACAGCTTTTGGCCGTACCTCCCGGAGAGAGGGCCAGAAACATTGAGA
40 CCCTGCCTGGAATATTCAAGACAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCCTG
CAGGGACCTCAGGATCTCCGATCCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATG
GGGTTGTGATCAAGAATGGAAGCTATGTTAGTGCTATAACCCAGGGAAAGAGGGAGGAGGAG
ACTCCGGTTGAATGTTTCGAACCTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTGATCTGC
ATCCAGGAGCCGGAAAAACCAGGAGAGTTCTTCCTGAAATAGTCCGTGAAGCCATAAAAAAGA
45 GACTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTGCTGCTGAGATGGAGGAGGCCTTGA
GAGGACTTCCGGTGCGTTACATGACAACAGCAGTCAACGTCACCCATTCTGGGACAGAAATCG
TTGATTTGATGTGCCATGCCACTTTCACCTTACGCTTACTACAACCCATCAGAGTCCCTAATTAC
AATCTCTACATCATGGATGAAGCCCACTTCACAGACCCCTCAAGTATAGCTGCAAGAGGATATA
TATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTATGACTGCCACACCACCAGGAA
50 CCCGTGATGCGTTTCTGACTCTAACTACCAATCATGGACACAGAAGTGGAAGTCCCAGAGAG
AGCCTGGAGCTCAGGCTTTGATTGGGTGACAGACCATTCTGGGAAAACAGTTTGGTTCTTCCA
AGCGTGAGAAACGGAAATGAAATCGCAGCCTGTCTGACAAAGGCTGGAAAGCGGGTCATACA
GCTCAGCAGGAAGACTTTTGGAGACAGAATTTAGAAAACAAAAAATCAAGAGTGGGACTTTGT
CATAACAACCTAGACATCTCAGAGATGGGCGCCAACCTCAAGGCTGACCGGGTCATAGACTAG
55 GAGATGCCTAAAACCACTACTTGTAGGTGAGAGAGTCATCTTGGCTGGGCCCATGCCTGTC
ACGCATGCTAGTGCTCAGAGGAGAGGACGTATAGGCAGGAACCCCTAACAAACCTGGAGAT
GAGTACATGTATGGAGGTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGCTTGAAGCA

AGAATGCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGCCTGAGG
 CCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAAGCTGAGGACAGAGCAAAGGAAGACCTTCG
 TGGAACTCATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAAT
 AACTTACACAGACAGAAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACAG
 5 CGTACCAGCAGAGGTGTGGACAAAGTATGGAGAGAAGAGAGTGTCTCAAACCGAGATGGATGG
 ATGCTAGGGTCTGTTCAGACCATGCGGCCCTGAAGTCGTTCAAAGAATTTCGCCGCTGGAAAAA
 GAGGAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGG
 TTTCAGGAAGCCATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTAT
 AAGGCAGCGGCAGCCCAACTGCCGAGACCCTAGAGACCATTATGCTCTTAGGTTTGCTGGGA
 10 ACAGTTTCACTGGGGATCTTCTTCGCTTGATGCGGAATAAGGGCATCGGGAAGATGGGCTTTG
 GAATGGTAACCCTTGGGGGCCAGTGCATGGCTCATGTGGCTTTTCGGAAATTGAACCAGCCAGAAT
 TGCATGTGTCTCATTGTTGTGTTTTTATTACTGGTGGTGTCTCATACCCGAGCCAGAGAAGCAAA
 GATCTCCCCAAGATAACCAGATGGCAATTATCATCATGGTGGCAGTGGGCCTTCTAGGTTTGAT
 AACTGCAAACGAACTTGGATGGCTGGAAAGAACAAAAAATGACATAGCTCATCTAATGGGAAG
 15 GAGAGAAGAAGGAGCAACCATGGGATTCTCAATGGACATTGATCTGCGGCCAGCCTCCGCCTG
 GGCTATCTATGCCGCATTGACAACCTCTCATCACCCAGCTGTCCAACATGCGGTAACCACTTCA
 TACAACAATACTCCTTAATGGCGATGGCCACACAAGCTGGAGTGTGTTTGGCATGGGCAAA
 GGGATGCCATTTTATGCATGGGACCTTGGAGTCCCGCTGCTAATGATGGGTTGCTATTACAAAT
 TAACACCCCTGACTCTGATAGTAGCTATCATTCTGCTTGTGGCGCACTACATGTACTTGATCCCA
 20 GGCCTACAAGCGGCAGCAGCGCTGCTGCCAGAAAAGGACAGCAGCTGGCATCATGAAGAAT
 CCCGTTGTGGATGGAATAGTGGTAACTGACATTGACACAATGACAATAGACCCCAAGGTGGAG
 AAGAAGATGGGACAAGTGTTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCGGACC
 GCCTGGGGATGGGGGGAGGCTGGAGCTCTGATCACAGCAGCGACCTCCACCTTGTGGGAAGGC
 TCTCCAAACAAATACTGGAACCTCCTCTACAGCCACCTCACTGTGCAACATCTTCAGAGGAAGCT
 25 ATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAAACGCTGGCCTGGTTAAGAGACGTGG
 AGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGATGTGCGCCCT
 GGAGTTCTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCC
 CTCAAGGATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAGCTCAGATGG
 TTGGTGGAGAGAGGATATCTGCAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGAGGG
 30 GGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGCAGGAGGTGAGAGGATACACAAAGGGA
 GGTCCCGGTCAATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATAGTTTCGTCTCAAG
 AGTGGAGTGGAGCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTG
 AGTCATCATCTAGTCCTGAAGTGGAAGAGACAGCAACACTCAGAGTGCTCTCTATGGTGGGG
 ACTGGCTTGAAAAAAGACCAGGGGCCTTCTGTATAAAGGTGCTGTGCCCATACACCAGCACTAT
 35 GATGGAAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCATTGTC
 TCGCAACTCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAGTGT
 GTCCACCACAAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACAT
 GAAAATCATCGGCAGGCGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTTCTTGA
 40 TGAAAACCAACCCATACAGGACATGGGCCTACCATGGGAGCTACGAAGCCCCACGCAAGGATC
 AGCGTCTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGA
 GTTACAGGAATAGCCATGACTGACACCACACCATAACGCCAACAAAGAGTCTTCAAAGAAAAA
 GTGGACACCAGGGTGCCAGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCC
 TGGCTGTGGAAGGAGCTGGGGAAACGCAAGCGGCCACGCGTCTGCACCAAAGAAGAGTTTATC
 45 AACAAGGTGCGCAGCAATGCAGCACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGAC
 GGCTGTGGAAGCTGTGAATGATCCAAGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCA
 CCTGAGAGGAGAGTGTACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAGCAAG
 GAGAGTTTCGGGAAAGCAAAAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCT
 TGGAGTTTGAAGCCCTTGGATTCTTGAACGAGGACCATTGGATGGGAAGAGAAAACTCAGGAG
 50 GTGGAGTCGAAGGGTTAGGATTGCAAAGACTTGGATACATTCTAGAAGAAATGAATCGGGCAC
 CAGGAGGAAAGATGTACGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATC
 TGGAGAATGAAGCTCTGATTACCAACCAAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCG
 TGATTAAATACACATACCAAAACAAAGTGGTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAA
 CAGTTATGGACATCATTTCAAGACAAGACCAGAGGGAGTGGACAAGTTGTCACTTATGTCTCT
 55 CAACACATTACCAACTTGGTGGTGCAGCTTATCCGGAACATGGAAGCTGAGGAAGTGTAGTA
 GATGCAAGACTTATGGTTGGAGGAAGCCAGAGAAAGTGACCAGATGGTTGCAAGCAATGG
 ATGGGATAGACTCAAACGAATGGCGGTCACTGGAGATGACTGCGTTGTGAAGCCAATCGATGA

TAGGTTTGCACATGCCCTCAGGTTCTTGAATGACATGGGAAAAGTTAGGAAAGACACACAGGA
 GTGGA AACCTCGACTGGATGGAGCAATTGGGAAGAAGTCCC GTTCTGCTCCCACCACTTCAAC
 AAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCCGCCACCAAGATGAACTGATTG
 5 GCCGAGCTCGCGTCTCACCAGGGG CAGGATGGAGCATCCGGGAGACTGCCTGTCTTGCAAAAT
 CATATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGC
 CATTTGCTCGGCTGTGCCAGTTGACTGGGTACCAACTGGGAGAACCACCTGGTCAATCCATGGA
 AAGGGAGAATGGATGACCACTGAGGACATGCTCATGGTGTGGAATAGAGTGTGGATTGAGGAG
 AACGACCATATGGAGGACAAGACTCCTGTAAACAAAATGGACAGACATTCCCTATCTAGGAAAA
 AGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCACCTTGGGCTGAAAA
 10 ATCAAAGACACAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTAT
 CTATCCACCCAAGTCCGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTTGTAAGCACCA
 ATTTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAAGCTGTGCAGCCTGTAACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAA
 GCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAGCG
 15 CAGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGACT
 AGCTGTGAATCTCCAGCAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAG
 CATATTGACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACA
 GATCGCCGAACAGCGGCGGCCGGTGTGGGGAAATCCATGGTTTCT

SEQ ID NO: 12

AY632535.2 NC_012532.1 Zika virus strain MR 766, Uganda, complete genome

AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTTCGAGTCTGAAGCGAGAGCTAACAACAGT
 ATCAACAGGTTTAATTTGGATTTGGA AACGAGAGTTTCTGGTCATGAAAAACCCCAAAGAAGA
 AATCCGGAGGATCCGGATTGTCAATATGCTAAACGCGGAGTAGCCCGTGTAACCCCTTGGG
 25 AGGTTTGAAGAGGTTGCCAGCCG GACTTCTGCTGGGT CATGGACCCATCAGAATGGTTTTGGCG
 ATACTAGCCTTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTT
 CCGTGGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGT
 TGAGAATAATCAATGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATC
 ATTGGCCTCCTGCTGACTACAGCCATGGCAGCAGAGATCACTAGACGCGGGAGTGCATACTAC
 30 ATGTACTTGGATAGGAGCGATGCCGGGAAGGCCATTTCTGTTGCTACCACATTGGGAGTGAACA
 AGTGCCACGTACAGATCATGGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGCCC
 TATGCTGGATGAGGGAGTGGAACCATGATGTGATTGCTGGTGCAACACGACATCAACTTG
 GTTGTGTACGGAACCTGTCATCACAAAAAAGGTGAGGCACGCGCATCTAGAAGAGCCGTGAC
 GCTCCCTTCTCACTCTACAAGGAAGTTGCAAACGCGGTTCGACAGACCTGGTTAGAATCAAGAGA
 35 ATACACGAAGCACTTGATCAAGGTTGAAA ACTGGATATTCAGGAACCCCGGGTTTGCCTAGT
 GGCCGTTGCCATTGCCTGGCTTTTGGGAAGCTCGACGAGCCAAAAAGTCATATACTTGGTCATG
 ATACTGCTGATTGCCCCGGCATA CAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTCGTGG
 AGGGCATGTCAGGTGGGACCTGGGTTGATGTTGTCTTGGAACATGGAGGCTGCGTTACCGTGAT
 GGCACAGGACAAGCCAACAGTCGACATAGAGTTGGTCACGACGACGGTTAGTAACATGGCCGA
 40 GGTAAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTCGTTGCCCAACA
 CAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTG
 GACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAAGGGAGCTTGGTGACATGTGCCAAG
 TTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACCGGAAAATCTGGAGTATCGGATA
 ATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGATTGGATATGAAACTGACGAAGATAGA
 45 GCGAAAGTTCGAGGTTACGCCTAATTCACCAAGAGCGGAAGCAACCTTGGGAGGCTTTGGAAGC
 TTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCTGTATTACCTGACCATGA
 ACAATAAGCATTGGTTGGTGCACAAAGAGTGGTTTCATGACATCCCATTGCCTTGGCATGCTGG
 GGCAGACACCGGAACTCCCACTGGAACAACAAAGAGGCATTGGTAGAATTCAAGGATGCCCA
 CGCCAAGAGGCAAACCGTCGTCGTTCTGGGGAGCCAGGAAGGAGCCGTTACACGCGCTCTCGC
 50 TGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTTCTCTGGCCATTTGAAATG
 CCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGT CATATTCCTTGTGCACTGCGGCATTC
 ACATTACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCAAGTGGAGGTGCAGTATGCA
 GGGACAGATGGACCCTGCAAGATCCCAGTCCAGATGGCGGTGGACATGCAGACCCTGACCCCA
 GTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAAGCTCAAAGATGATG
 55 TTGGAGCTTGACCAACCATTTGGGGATTCTTACATTGTCTAGGAGTTGGGGGACAAGAAATCA
 CCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGTGAGAGGCG
 CCAAGAGAATGGCAGTCTTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCA

ACTCACTGGGTAAGGGCATTACACAGATTTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAAT
 GTCCTGGTTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGGTTAGGTTTGAACACAAAGAAT
 GGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCCTCTCCACGGCTGTTTC
 5 TGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGGCACGGGGGTATT
 CATCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGA
 TTGGCAGCAGCAGTCAAGCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGA
 ATGGAACACATCATGTGGAAATCAGTAGAAGGGGAGCTCAATGCTATCCTAGAGGAGAATGGA
 GTTCAACTGACAGTTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAGATTGC
 CAGTGCCTGTGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGC
 10 GGCAAAGACCAACAACAGTTTTGTTGTCGACGGTGACACACTGAAGGAATGTCCGCTTGAGCA
 CAGAGCATGGAATAGTTTTCTTGTGGAGGATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGG
 CTTAAGGTCAGAGAAGATTACTCATTAGAATGTGACCCAGCCGTCATAGGAACAGCTGTTAAG
 GGAAGGGAGGCCGCGCACAGTGATCTGGGCTATTGGATTGAAAGTGAAAAGAATGACACATGG
 AGGCTGAAGAGGGCCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTG
 15 TGGACAGATGGAGTAGAAGAAAGTGATCTTATCATACCCAAGTCTTTAGCTGGTCCACTCAGCC
 ACCACAACACCAGAGAGGGTTACAGAACCCAAGTGAAAGGGCCATGGCACAGTGAAGAGCTT
 GAAATCCGGTTTGAAGGAATGTCCAGGCACCAAGGTTTACGTGGAGGAGACATGCGGAACTAGA
 GGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGTGCTGTAGGGAA
 TGCACAATGCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAATGGAGATAAGG
 20 CCCAGGAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGTGACAGCGGGGTCAACCGATCAT
 ATGGACCACTTCTCTCTTGGAGTGCTTGTGATTCTACTCATGGTGCAGGAGGGGTGAAGAAGA
 GAATGACCACAAAGATCATCATGAGCACATCAATGGCAGTGCTGGTAGTCATGATCTTGGGAG
 GATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCTACTTTCGCAGAAATGAA
 CACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTCAGACCAGCCTTGCTG
 25 GTCTCCTTCATTTTCAGAGCCAATTGGACACCCCGTGAGAGCATGCTGCTAGCCCTGGCTTCGT
 GTCTTCTGCAAACTGCGATCTCTGCTCTTGAAGGTGACTTGATGGTCCTCATTAATGGATTTGCT
 TTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACATCGCTCTACCAATCT
 TGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGGCCTGGCTAC
 TTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGAAGAACCTGCCATTT
 30 GTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATGTGGTAGGACTACTGT
 TACTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCACAGCCGTTGGCCTGA
 TATGTGCACTGGCCGAGGGTTTGCCAAGGCAGACATTGAGATGGCTGGACCCATGGCTGCAG
 TAGGCTTGCTAATTGTCAGCTATGTGGTCTCGGGAAGAGTGTGGACATGTACATTGAAAGAGC
 AGGTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCCTCGGCTTGACGTGGC
 35 ACTGGATGAGAGTGGTGACTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCAT
 ACTCAAGGTGGTCCTGATGGCCATCTGTGGCATGAACCCAATAGCTATACCTTTTGCTGCAGGA
 GCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGACGTGCCTGCTCCC
 AAAGAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGACTCGCAGACTGCT
 AGGTTCAACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGT
 40 TACAAAAGGAGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAA
 GCAGGACTTGGTGTCTACTGTGGGCCTTGGAAGTTGGATGCAGCTTGGGATGGACTCAGCGA
 GGTACAGCTTTTGGCCGTACCTCCCGGAGAGAGGGGCCAGAAACATTCAGACCCTGCCTGGAAT
 ATTCAAGACAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGG
 ATCTCCGATCCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAA
 45 GAATGGAAGCTATGTTAGTGCTATAACCCAGGGAAAGAGGGAGGAGGAGACTCCGGTTGAATG
 TTTCGAACCCTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTGATCTGCATCCAGGAGCCGGA
 AAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAAGAGACTCCGGACAGTG
 ATCTTGGCACCAACTAGGGTTGTCGCTGCTGAGATGGAGGAGGCCTTGAGAGGACTTCCGGTGC
 GTTACATGACAACAGCAGTCAACGTCACCCATTCTGGGACAGAAATCGTTGATTTGATGTGCCA
 50 TGCCACTTTCACGCTTACTACAACCCATCAGAGTCCCTAATTACAATCTCAACATCATGG
 ATGAAGCCCACTTCACAGACCCCTCAAGTATAGCTGCAAGAGGATACATATCAACAAGGGTTG
 AAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCACACCACCAGGAACCCGTGATGCGTTTCC
 TGACTCTAACTACCAATCATGGACACAGAAGTGGAAGTCCAGAGAGAGCCTGGAGCTCAGG
 CTTTGATTGGGTGACAGACCATCTGGGAAAACAGTTTGGTTTCGTTCCAAGCGTGAGAAACGGA
 55 ATTGAAATCGCAGCCTGTCTGACAAAGGCTGAAAGCGGGTCATACAGCTCAGCAGGAAGACT
 TTTGAGACGAATTTTCAGAAAAACAAAGATCAAGAGTGGGACTTTGTTCATAACAACATGACATC
 TCAGAGATGGGCGCCAACCTCAAGGCTGACCGGGTCATAGACTCTAGGAGATGCCTAAAACCA

GTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGGCCCATGCCTGTACGCATGCTAGTGCTG
 CTCAGAGGAGAGGACGTATAGGCAGGAACCCTAACAAACCTGGAGATGAGTACATGTATGGAG
 GTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGCTTGAAGCAAGAATGCTTCTTGACA
 ACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGCCTGAGGCCGATAAGGTAGCCGC
 5 CATTGAGGGAGAGTTTAAGCTGAGGACAGAGCAAAGGAAGACCTTCGTGGAACATCATGAAGAG
 AGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAATAACTTACACAGACAGA
 AGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACAGTGTACCAGCAGAGGTT
 TGGACAAAGTATGGAGAGAAGAGAGTGTCTAAACCGAGATGGATGGATGCTAGGGTCTGTTCA
 GACCATGCGGCCCTGAAGTCGTTCAAAGAATTGCGCCGCTGGAAAAAGAGGAGCGGCTTTGGGA
 10 GTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAGGAAGCCATTGAC
 AACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCAA
 CTGCCGGAGACCCTAGAGACCATTATGCTCTTAGGTTTGCTGGGAACAGTTTCACTGGGGATCT
 TCTTCGTCTTGATGCGGAATAAGGGCATCGGGAAGATGGGCTTTGGAATGGTAACCCTTGGGGC
 CAGTGCATGGCTCATGTGGCTTTTCGGAATTGAACCAGCCAGAATTGCATGTGTCTCATTGTT
 15 GTGTTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGATCTCCCCAAGATAACC
 AGATGGCAATTATCATCATGGTGGCAGTGGGCCTTCTAGGTTTGATAACTGCAAACGAACTTGG
 ATGGCTGGAAAGAACAAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAAGAAGGAGCAA
 CCATGGGATTCTCAATGGACATTGATCTGCGGCCAGCCTCCGCCTGGGCTATCTATGCCGCATT
 GACAACCTCTCATACCCCAGCTGTCCAACATGCGGTAACCACTTCATACAACAACACTACTCCTTA
 20 ATGGCGATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAGGGATGCCATTTATGCAT
 GGGGACCTTGGAGTCCCGCTGCTAATGATGGGTTGCTATTACAAATTAACACCCCTGACTCTGA
 TAGTAGCTATCATTCTGCTTGTGGCGCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGC
 AGCGCGTGCTGCCCAGAAAAGGACAGCAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAAT
 AGTGGTAACCTGACATTGACACAATGACAATAGACCCCCAGGTGGAGAAGAAGATGGGACAAGT
 25 GTTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCGGACCGCCTGGGGATGGGGGGAG
 GCTGGAGCTCTGATCACAGCAGCGACCTCCACCTTGTGGGAAGGCTCTCCAAACAAATACTGG
 AACTCCTCTACAGCCACCTCACTGTGCAACATCTTCAGAGGAAGCTATCTGGCAGGAGCTTCCC
 TTATCTATACAGTGACGAGAAACGCTGGCCTGGTTAAGAGACGTGGAGGTGGGACGGGAGAGA
 CTCTGGGAGAGAAAGTGGAAAGCTCGTCTGAATCAGATGTCGGCCCTGGAGTTCTACTCTTATAA
 30 AAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCCCTCAAGGATGGAGTGGC
 CACAGGAGGCATGCCGTATCCCGGGGAAGTGCAAAGATCAGATGGTTGGAGGAGAGAGGAT
 ATCTGCAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGAGGGGGCTGGAGCTATTATGC
 CGCCACCATCCGCAAAGTGCAGGAGGTGAGAGGATACACAAAGGGAGGTCCCGTCTATGAAG
 AACCCATGCTGGTGCAAAGCTATGGGTGGAACATAGTTTCGTCTCAAGAGTGGAGTGGACGTCTT
 35 CCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAGTCATCATCTAGTCCT
 GAAGTGGAAGAGACACGAACACTCAGAGTGCTCTCTATGGTGGGGGACTGGCTTGAAAAAAGA
 CCAGGGGCCCTTCTGTATAAAGGTGCTGTGCCCATACACCAGCACTATGATGGAAACCATGGAG
 CGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCATTGTGTGCAACTCCACACAT
 GAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAGTGTGTCCACCACAAGTCAG
 40 CTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGAACCTC
 GGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAAATCATCGGCAGG
 CGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACCAACCCATAC
 AGGACATGGGCCTACCATGGGAGCTACGAAGCCCCACGCAAGGATCAGCGTCTTCCCTCGTG
 AACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAGTTACAGGAATAGCC
 45 ATGACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACCAGGGTG
 CCAGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCTGGCTGTGGAAGGAG
 CTGGGGAAACGCAAGCGGCCACGCGTCTGCACCAAAGAAGAGTTTATCAACAAGGTGCGCAGC
 AATGCAGCACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTGT
 GAATGATCCAAGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAAACACCACCTGAGAGGAGAGTG
 50 TCACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAGCAAGGAGAGTTTCGGGAAAG
 CAAAAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCT
 TGGATTCTTGAACGAGGACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCGAAGGGTT
 AGGATTGCAAAGACTTGGATACATTCTAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTA
 CGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATCTGGAGAATGAAGCTCTG
 55 ATTACCAACCAATGAGGAAGGGACAGAACTCTGGCGTTGGCCGTGATTAAATACACATAC
 CAAAACAAAGTGTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATT
 TCAAGACAAGACCAGAGAGGGAGTGGACAAGTTGTCACTTATGCTCTCAACACATTCACCAAC

TTGGTGGTGCAGCTTATCCGGAACATGGAAGCTGAGGAAGTGTTAGAGATGCAAGACTTATGG
 TTGTTGAGGAAGCCAGAGAAAGTGACCAGATGGTTGCAGAGCAATGGATGGGATAGACTCAAA
 CGAATGGCGGTCACTGGAGATGACTGCGTTGTGAAGCCAATCGATGATAGGTTTGCACATGCC
 CTCAGGTTCTTGAATGACATGGGAAAAGTTAGGAAAAGACACACAGGAGTGGAACCCTCGACT
 5 GGATGGAGCAATTGGGAAGAAGTCCCCTTCTGCTCCCACCACTTCAACAAGCTGTACCTCAAGG
 ATGGGAGATCCATTGTGGTCCCTTGGCGCCACCAAGATGAACTGATTGGCCGAGCTCGCGTCTC
 ACCAGGGGCAGGATGGAGCATCCGGGAGACTGCCTGTCTTGCAAAATCATATGCGCAGATGTG
 GCAGTCCCTTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGCCATTTGCTCGGCTGTG
 CCAGTTGACTGGGTACCAACTGGGAGAACCACCTGGTCAATCCATGGAAAGGGAGAATGGATG
 10 ACCACTGAGGACATGCTCATGGTGTGGAATAGAGTGTGGATTGAGGAGAACGACCATATGGAG
 GACAAGACTCCTGTAAACAAAATGGACAGACATTCCCTATCTAGGAAAAAGGGAGGACTTATGG
 TGTGGATCCCTTATAGGGCACAGACCCCGCACCACTTGGGCTGAAAACATCAAAGACACAGTC
 AACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCTATCCACCCAAGTC
 CGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTTGTAAGCACCAATTTTAGTGTTGTCAG
 15 GCCTGCTAGTCAGCCACAGTTTGGGGAAAAGCTGTGCAGCCTGTAACCCCCCAGGAGAAGCTG
 GGAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGTGA
 GCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAAGCGCAGGATGGGAAAAGA
 AGGTGGCGACCTTCCCCACCCTCAATCTGGGGCCTGAACTGGAGACTAGCTGTGAATCTCCAG
 CAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAACGCAAAACAGCATATTGACGTGGGA
 20 AAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAACCTCGG
 CGGCCGGTGTGGGGAAATCCATGGTTTCT

SEQ ID NO: 13

KJ776791.1, Zika virus strain H/PF/2013 polyprotein gene, complete cds

25 AGTATCAACAGGTTTTATTTTGGATTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAA
 GAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTT
 GGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCAATGGGCCATCAGGATGGTCTTG
 GCGATTCTAGCCTTTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGG
 GTTCAGTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCA
 30 TGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGA
 ATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACCTAGACGTGGGAGTGCATAC
 ATATGTACTGGACAGAAACGACGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGA
 ATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATG
 CCCTATGCTGGATGAGGGGTGGAACACAGATGACGTCGATTGTTGGTGCAACACGACGTC AAC
 35 TTGGGTTGTGTACGGAACCTGCCATCAGAAAAGGTGAAGCACGAGATCTAGAAGAGCTGT
 GACGCTCCCCCTCCATTCCACTAGGAAGCTGCAACGCGGTCGCAACCTGGTTGGAATCAAG
 AGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTCGCGTTA
 GCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCA
 TGATACTGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGT
 40 GGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCGTA
 ATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCG
 GAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCGCTGCCCA
 ACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTA
 GTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTTGGCAAAGGGAGCCTGGTGACATGCGCT
 45 AAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGG
 ATAATGCTGTGCTCAGTTTATGGCTCCAGCACAGTGGGATGATCGTTAATGACACAGGACATGAA
 ACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTG
 GGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGT
 50 ATTACTTGACTATGAATAACAAGCACTGGTTGGTTTCAAGGAGTGGTTCCACGACATTCCATT
 ACCTTGGCACGCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAAGAAGCACTGGTAGA
 GTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGT
 TCACACGGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTC
 TGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTG
 55 TGATCCGCAGCGTTACATTACCAAGATCCCGCTGAAACACTGCACGGGACAGTCACAGATG
 GAGGTACGATACGACAGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGACATG
 CAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAG
 AACTCTAAGATGATGCTGGAACCTTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCG

GGGAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGAA
 GCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCA
 GTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAAT
 CATTGTTTGGAGGAATGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGT
 5 CTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTT
 ATCCACAGCTGTCTCTGCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGC
 GGTACAGGGGTGTTCTGTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCT
 GACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATC
 TCCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATC
 10 CTGGAAGAGAATGGAGTTCAACTGACGGTCTGTGGGATCTGTAAAAAACCCCATGTGGAGA
 GGTCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAA
 TCGTACTTCGTCAGAGCAGCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAG
 GAATGCCCACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCTGGGGTAT
 TTCACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTAT
 15 TGAACAGCTGTAAAGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGA
 GAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCC
 AAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATAACCAAGTCTTT
 AGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATG
 GCACAGTGAAGAGCTTGAAATTTCGTTTGAAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGA
 20 AACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGA
 ATGGTGCTGCAGGGAGTGCACAATGCCCCACTGTCTGTTCCGGGCTAAAGATGGCTGTTGGTAT
 GGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGTAACCTTAGTAAGGTCAATGGTGACTGC
 AGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAG
 GAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCGATGGCAGTGCTGGTA
 25 GCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGAATTTTGATGGGTGCCA
 CCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAG
 TCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCT
 GCTGGCCTTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGAAGGCGACCTGATGGTTC
 TCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAA
 30 CATCACCTTGGCAATCCTGGCTGCTCTGACACCCTGGCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCAGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTA
 AGAAGAACTTACCATTGTCTATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCCGACCCCATCAA
 CGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACT
 CACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTTCGCCAAGGCAGATATAGAGATGGC
 35 TGGGCCCATGGCCGCGTCTGCTAATTGTGCTAGTTACGTGGTCTCAGGAAAGAGTGTGGAC
 ATGTACATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGT
 CCCCCGCTCGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCC
 CCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCAT
 ACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATG
 40 GGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAA
 TGAATCGTAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCA
 CACTATGTGGCACGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATA
 CTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCCTG
 GGACGGGCACAGCGAGGTGCAGCTCTTGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCA
 45 GACTCTGCCCCGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCC
 AGCAGGAACTTCAGGATCTCCAATCCTAGACAAAGTGTGGGAGAGTGATAGGACTTTATGGCAA
 TGGGGTCGTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGA
 GACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTG
 CATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCCTGAAATAGTCCGTGAAGCCATAAAAAACA
 50 AGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTGCTGCTGAAATGGAGGAAGCCCTTA
 GAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGAAATCGT
 CGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTAT
 AATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACA
 TTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACAGGAA
 55 CCCGTGACGCAATTTCCGGACTCCAAGTACCAATTATGAGACACCGAAGTGAAGTCCCGAGGA
 GAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTC
 AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACA

GCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGT
CGTGACAACCTGACATTTTCAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTCATAGATTCCAGG
AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCA
CACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGAT
5 GAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCA
AGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGG
CCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTG
TGAACTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAAT
AACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
10 TGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGG
ACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAG
AGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
CCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAA
AGCCGCGGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAAC
15 AGTCTCGCTGGGAATCTTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGA
ATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTG
CATGTGTCCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAG
ATCTCCCCAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATT
ACCGCCAATGAACTCGGATGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGG
20 AGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGG
GCCATCTATGCTGCCTTGACAACCTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATA
CAACAACCTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGG
GATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTA
ACACCCCTGACCCTAATAGTGGCCATCATTTTGCTCGTGGCGCACTACATGTACTTGATCCCAG
25 GGCTGCAGGCAGCAGCTGCGCGTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACC
CTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGA
AAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCG
CCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCGGCAACTTCCACTTTGTGGGAAGGCT
CTCCGAACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAACATTTTtaggggaagTTA
30 CTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGG
GGTGGAAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCT
GGAGTTCTACTCTACAAAAGTCAAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGC
CCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATG
GTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGG
35 GGGCTGGAGTTACTACGCCGCCACCATCCGCAAAAGTTCAAGAAGTGAAAGGATACACAAAAGG
AGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAA
GAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGT
GAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGG
GATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAGCACTA
40 TGATGGAAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCT
CCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAGTG
TGTCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATG
AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACA
TGAAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTG
45 ACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCCACACAAGGGT
CAGCGTCCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGG
AGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAA
AGTGGACACTAGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCC
50 TGGTTGTGGAAAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATC
AACAAGGTTTCGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACT
GCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCAC
CTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGG
GGAATTTGGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCT
AGAGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAAGTCAAGGAGG
55 TGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCTTAGAAGAGATGAGTCGCATACC
AGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCT
GGAGAATGAAGCTCTAATCACCACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCAT

AATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGA
 CAGTTATGGACATTATTTTCGAGACAAGACCAAGGGGGAGCGGACAAGTTGTCACTTACGCTC
 TTAACACATTTACCAACCTAGTGGTGCAACTCATTCCGAATATGGAGGCTGAGGAAGTTCTAGA
 5 GATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGG
 ATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGA
 TAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGA
 GTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTGTCTCCCACTTCAAC
 AAGTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAAGTATTG
 10 GCCGGGCCCCGCTCTCTCCAGGGGCGGATGGAGCATCCGGGAGACTGCTTGCCCTAGCAAAAT
 CATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGC
 CATTGTTCATCTGTGCCAGTTGACTGGGTTCACACTGGGAGAACTACCTGGTCAATCCATGGA
 AAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAG
 AACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAA
 AGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAAC
 15 ATTA AAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTAC
 CTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTGAAGCACCAA
 TCTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCC
 CCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
 CCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGC
 20 AGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCA
 GCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAG

In some embodiments, the Zika virus has a RNA genome corresponding to the DNA
 25 sequence provided by the nucleic acid sequence of any one of SEQ ID NOs: 2-13 or 72. In
 some embodiments, the Zika virus has a variant genome that is at least 80%, 81%, 82%,
 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-
 13 or 72.

30

Provided below are amino acid sequences of the E-proteins of Zika strains that may be
 used in the methods, compositions, and/or vaccines described herein.

35 SEQ ID NO: 14
 isol-ARB15076.AHF49784.1.Central_African_Republic/291-788 Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 40 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAV
 HTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRKGVSYSLCTAAFTFTKVPAETLHGTVTVEV
 QYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKIT
 HHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKGIHQIFGA AFKSLFGGMS
 WFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

45 SEQ ID NO: 15
 isol-IbH_30656.AEN75265.1.Nigeria/291-788 Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 50 YLTMNNKHWLVHKEWFHDIPLPWHSGADTETPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAV

HTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEV
 QYAGRDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKI
 THHWHRSGSIIGKAFAEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKSLFGGMS
 WFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

5

SEQ ID NO: 16

ArB1362.AHL43500.1.-/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRLGWNGCGLFGKGSVLTCAKFTCSKKMTGKSI
 10 QPENLEYRIMLSVHGSQHSGMIVNDXXXXXXNRAEVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
 DFDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLG
 SQEGAVHTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 TVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIG
 VGDKKITHHWHRSGSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKS
 15 LFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 17

ArD128000.AHL43502.1.-/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 20 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRLGWNGCGLFGKGSVLTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMXXXXXGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
 DFDLYYLTMMNNKHRLVRKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 25 GDKKITHHWLKKGSSIGKAFAEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGVHQIFGAAFKSL
 FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 18

ArD158095.AHL43505.1.-/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 30 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRLGWNGCGLFGKGSVLTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 35 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GDKKITHHWHRSGSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKSL
 FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 19

ArD158084.AHL43504.1.-/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 40 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRLGWNGCGLFGKGSVLTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGS
 45 QEGAVHTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GDKKITHHWHRSGSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGGVFNSLKGKGIHQIFGAAFKSL
 FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

50 SEQ ID NO: 20

isol-ARB13565.AHF49783.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRLGWNGCGLFGKGSVLTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD
 55 FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLFSGHLKCRLLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV

GDKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGA AFKSL
FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 21

5 isol-ARB7701.AHF49785.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I
QPENLEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD
10 FSDLYYLT M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K R Q T V V V L G S
QEGAVHTALAGALEAEMDGAKGRLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVP A E T L H G T
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GDKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGA AFKSL
FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

15 SEQ ID NO: 22

isol-ArD_41519.AEN75266.1.Senegal/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
20 D F S D L Y Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K R Q T V V V L G
SQEGAVHTALAGALEAEMDGAKGRLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVP A E T L H G
TVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIG
VGDKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFK S
L F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V M I F L S T A V S A

25 SEQ ID NO: 23

MR766-NIID.BAP47441.1.Uganda/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I
30 QPENLEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
D F S D L Y Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K R Q T V V V L G
SQEGAVHTALAGALEAEMDGAKGKLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVP A E T L H G
TVTVEVQYAGTDGPCKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GDKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFK S L
35 F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V M I F L S T A V S A

SEQ ID NO: 24

LC002520.1/326-829 Zika virus genomic RNA, strain: MR766-NIID, Uganda, Flavivirus envelope
glycoprotein E.
40 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I
QPENLEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
D F S D L Y Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K R Q T V V V L G
SQEGAVHTALAGALEAEMDGAKGKLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVP A E T L H G
45 T V T V E V Q Y A G T D G P C K I P V Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V
GDKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFK S L
F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V M I F L S T A V S A

SEQ ID NO: 25

50 isol-MR_766.AEN75263.1.Uganda/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I
QPENLEYRIMLSVHGSQHSGMIVNDTGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGL
D F S D L Y Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K R Q T V V V L G
55 S Q E G A V H T A L A G A L E A E M D G A K G K L F S G H L K R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G
T V T V E V Q Y A G T D G P C K I P V Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V

GDKKITHHWHRSSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFKSL
FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 26

5 ArD7117.AHL43501.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFTCSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD
10 FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKLR LKGVSYSLCTAVCTAAKVPAETLHG
TVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIG
VGDKKITHHWHRSSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFKSL
LFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

15 SEQ ID NO: 27

AY632535.2/326-825 NC_012532.1 Zika virus strain MR 766, Uganda, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFTCSKKMTGKSI
20 QPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD FSDL
YYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGSQEGA
VHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKVPAETLHGTVTVE
VQYAGTDGPCKIPVQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKI
THHWHRSSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFKSLFGGMS
WFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

25 SEQ ID NO: 28

MR_766.AAV34151.1.Uganda/291-790 Flavivirus envelope glycoprotein E. |Q32ZE1|Q32ZE1_9FL
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFTCSKKMTGKSI
30 QPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD FSDL
YYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGSQEGA
VHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKVPAETLHGTVTVE
VQYAGTDGPCKIPVQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKI
THHWHRSSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFKSLFGGMS
35 WFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 29

MR_766.YP_009227198.1.Uganda/1-500 envelope protein E [Zika virus]
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
40 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFTCSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLD FSDL
YYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGSQEGA
VHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKVPAETLHGTVTVE
VQYAGTDGPCKIPVQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKI
45 THHWHRSSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGA AFKSLFGGMS
WFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 30

50 KU681081.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand,
Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
55 QEGAVHTALAGALEAEMDGAKGR LSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITEGTENSKMMLELDPPFGDSYIVIGV

GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVLNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 31

5 isol-Zika_virus%H.sapiens-tc%THA%2014%SV0127-_14.AMD61710.1.Thailand/291-794 Flavivirus
envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTGKSI
10 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWH T GADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITEGTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGVLNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 32

CK-ISL_2014.AIC06934.1.Cook_Islands/1-504 Flavivirus envelope glycoprotein E. (Fragment) OS=Zika
virus GN=E PE=4 SV=1

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
20 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGV
25 GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 33

Natal_RGN.AMB18850.1.Brazil:_Rio_Grande_do_Norte,_Natal/291-794 Flavivirus envelope glycoprotein
E.]

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTGKSI
30 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
35 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 34

isol-Si323.AMC37200.1.Colombia/1-504 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTGKSI
40 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
45 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 35

KU707826.1/317-820 Zika virus isolate SSABR1, Brazil, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTGKSI
55 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAE TLHGT

VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

5 SEQ ID NO: 36

KU509998.1/326-829 Zika virus strain Haiti/1225/2014, Haiti, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
10 FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

15

SEQ ID NO: 37

isol-GDZ16001.AML82110.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
20 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
25 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 38

BeH819015.AMA12085.1.Brazil/291-794 Flavivirus envelope glycoprotein E.]

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
30 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
35 GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 39

MRS_OPY_Martinique_PaRi_2015.AMC33116.1.Martinique/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
40 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT
45 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 40

KU501215.1/308-811 Zika virus strain PRVABC59, Puerto Rico, Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASIS
50 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLT MN NKHWLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
55 QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV

GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 41

5 Haiti%1225%2014.AMB37295.1.Haiti/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
10 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 42

15 KU527068.1/308-811 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, Flavivirus envelope
glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSI
20 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
25 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 43

isol-Z1106027.ALX35662.1.Suriname/5-508 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
30 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
35 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 44

isol-FLR.AMM39804.1.Colombia: Barranquilla/291-794 Flavivirus envelope glycoprotein E.
40 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGT
45 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 45

50 PLCal_ZV_isol-From_Vero_E6_cells.AHL37808.1.Canada/254-757 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
55 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRRLITANPVITESTENSKMMLELDPPFGDSYIVIGV

GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 46

5 BeH818995.AMA12084.1.Brazil/291-794 Flavivirus envelope glycoprotein E. [Zika virus].
IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGVGNGCGLFGKGSVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
10 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

15 SEQ ID NO: 47

H/PF/2013.AHZ13508.1.French_Polynesia/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGVGNGCGLFGKGSVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
20 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

25 SEQ ID NO: 48

PRVABC59.AMC13911.1.Puerto_Rico/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGVGNGCGLFGKGSVTCAKFACSKKMTGKSI
30 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
35 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 49

KU321639.1/326-829 Zika virus strain ZikaSPH2015, Brazil, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
40 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGVGNGCGLFGKGSVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
45 GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 50

ZikaSPH2015.ALU33341.1.Brazil/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
50 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGVGNGCGLFGKGSVTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGT PHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYSLCTAAFTFTKIP AETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGV
55 GEKKITHHWHRSRGSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLF
GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 51

103344.AMC13912.1.Guatemala/291-794 polyprotein [Zika virus]. 103344.AMC13912.1.Guatemala
Flavivirus envelope glycoprotein E.

5 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEIRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 10 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 52

isol-Brazil-ZKV2015.AMD16557.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

15 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGT
 20 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 53

KU497555.1/308-811 Zika virus isolate Brazil-ZKV2015, Flavivirus envelope glycoprotein E.

25 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGT
 30 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 54

isol-ZJ03.AMM39806.1.China/291-794 Flavivirus envelope glycoprotein E.

35 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 40 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 45 GEKKITHHWHRSRGSTIGKAFEATVRGARRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 55

isol-FSS13025.AFD30972.1.Cambodia/291-794 Flavivirus envelope glycoprotein E.

50 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 55 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKIHQIFGAAFKSLF
 GGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 56

isol-Z1106032.ALX35660.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 5 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 10 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 57

isol-Z1106033.ALX35659.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 15 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 20 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 58

isol-BeH828305.AMK49165.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 25 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGT
 30 VTVEVQYAGTDGPCKVPAQMAVDTQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 EKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
 GMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 59

isol-GD01.AMK79468.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 35 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNGTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 40 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGT
 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 60

isol-Z1106031.ALX35661.1.Suriname/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 45 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
 50 FSDLYYLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
 QEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGT
 VTVEVQYAGTDGPCKVLAQMAVDMQTLTPVGRLLITANPVITESTENSKMMLELDPPFGDSYIVIGV
 GEKKITHHWHRSRGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
 55 GGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

SEQ ID NO: 61

ACD75819.1.Micronesia/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPAVDIELVTTTTSNMAEVRSYCYEASI
SDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKS
IQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGL
DFSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLG
5 SQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRRLKGVSYSLCTAAFTFTKIPAETLHG
TVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIG
VGEKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKS
LFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

10 SEQ ID NO: 62

KU681082.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
15 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRRLKGVSYSLCTAAFTFTKIPAETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
GEKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
20 GGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

SEQ ID NO: 63

isol-Zika_virus% H.sapiens-tc% PHL% 2012% CPC-0740.AMD61711.1.Philippines/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
25 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRRLKGVSYSLCTAAFTFTKIPAETLHGT
30 VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
GEKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

SEQ ID NO: 64

35 isol-BeH823339.AMK49164.2.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVSTTTSNMAEVRSYCYEATIS
DIASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQ
PENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDF
SDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTAVVLGSQ
40 EGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRRLKGVSYSLCTAAFTFTKIPAETLHGT
TVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
EKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLF
GMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

45 SEQ ID NO: 65

isol-P6-740.AEN75264.1.Malaysia/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASIS
DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
QPENLEYRIMLSVHGSQHSGMIVNDXGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLD
50 FSDLYYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGS
QEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRRLKGVSYSLCTAAFTFTKIPAETLHGT
VTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
GDKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSL
FGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

55 SEQ ID NO: 66

KU744693.1/326-829 Zika virus isolate VE_Ganxian, China, Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMLVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGL
 DFDLYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNEALVEFKDAHAKRQTVVVLG
 5 SQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETVDG
 TTVTEGQYGGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIG
 VGEKKITHHWRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIIGAAFKSL
 FGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG

10 SEQ ID NO: 67

isol_VE_Ganxian.AMK79469.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMLVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGL
 15 DFDLYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNEALVEFKDAHAKRQTVVVLG
 SQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETVDG
 TTVTEGQYGGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIG
 VGEKKITHHWRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIIGAAFKSL
 FGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG

20 SEQ ID NO: 68

ArD157995.AHL43503.1.-/291-794 Flavivirus envelope glycoprotein E.

ISCIGVSNRDLVEGMSGGTWVDVVEHGGCVTEMAQDKPTVDIELVTMTVSNMAEVRSYCYEASL
 SDMASASRCPTQGEPSLDKQSDTQSVCKRTLGDGRWGNGCGIFGKGS�VTCCKFTCKKMPGKSIQ
 25 PENLEYRIMLPVHGSQHSGMIVNDIGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDF
 SDLYLTMNNKHWLVHKEWFHDIPLPWHAGADTTPHWNNEALVEFKDAHAKRQTVVVLGSQ
 EGAVHTALAGALEAEMDGAKGRLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 TVEVQSAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
 DKKITHHWRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLF
 30 GGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 69

MR_766.ABI54475.1.Uganda/291-788 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASIS
 35 DMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSI
 QPENLEYRIMLSVHGSQHSGMIVNDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTTPHWNNEALVEFKDAHAKRQTVVVLGSQEGAV
 HTALAGALEAEMDGAKGRLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGT
 TVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGV
 40 DKKITHHWRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLF
 GGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

SEQ ID NO: 70

5'-(dIdC)₁₃-3'

45 dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC

SEQ ID NO: 71

KLK peptide

KLKLLLLLKLK

50 SEQ ID NO: 72

ZIKV Sequence H/PF/2013 as sequenced

CAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTTGGGA
 TTTGGAAACGAGAGTCTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGATTCCGGATTG
 55 TCAATATGCTAAACGCGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAG
 CCGGACTTCTGCTGGGTCATGGGCCCATCGGATGGTCTTGGCGATTCTAGCCTTTTGGAGATT
 ACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAGAGGCT

ATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGG
AAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACA
GCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGAC
GCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
5 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGA
ACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCAT
CACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACTAGG
AAGCTGCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGA
10 GTCGAAAATTGGATATTACAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTT
TGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATA
CAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTG
GGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTC
GACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAG
GCATCAATATCGGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGAC
15 AAGCAATCAGACACTCAATATGTCTGCAAAGAAGCTTAGTGGACAGAGGCTGGGGAAATGGA
TGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGA
CCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCCC
AGCACAGTGGGATGATCGTTAATGACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTG
AGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTG
20 ATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATGAATAACAAGCA
CTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACC
GGAAGTCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAG
GCAAAGTGTGCTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACGGCCCTTGCTGGAGCTCT
GGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCTCTGGCCACTTGAAATGTGCCTGAA
25 AATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCGCAGCGTTCACATTCACC
AAGATCCCGGCTGAAACACTGCACGGGACAGTCAAGTGGAGGTACAGTACGCAGGGACAGAT
GGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAAGTCTGACCCCACTTGGGAGG
TTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAAGTCTAAGATGATGCTGGAAGTGT
ATCCACCATTTGGGGACTCTTACATTGTCTAGGAGTCCGGGAGAAGAAGATCACCCACCACTG
30 GCACAGGAGTGGCAGCACCATTGGAAAAGCAATTTGAAGCCACTGTGAGAGGTGCCAAGAGAAT
GGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGC
AAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAAATCATTGTTTGGAGGAATGTCTGTTTCT
CACAAATTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCT
CCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCTGTCTCTGCTGATGTGG
35 GGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCTATAACG
ACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAG
CAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAATGGAAAACAT
CATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGAC
GGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
40 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACA
AATAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGG
AACAGCTTTCTTGTGGAGGATCATGGGTTCTGGGGTATTTCACACTAGTGTCTGGCTCAAGGTTA
GAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTAAAGGGAAAGGAGG
CTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGA
45 GGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATG
GAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATAC
CAGAGAGGGGTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTT
TGAGGAATGCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCT
GAGATCAACCACTGCAAGCGGAAGGTTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCC
50 CCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGA
ACCAGAAAGTAACTTAGTAAGGTCAATGGTGAAGTGCAGGATCAACTGATCATGGATCACTT
CTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCAC
AAAGATCATCATAAGCACATCGATGGCAGTGTGGTAGCTATGATCCTGGGAGGATTTTCAATG
AGTGACCTGGCTAAGCTTGCAATTTTGTGAGTGGCGCCACCTTCGCGGAAATGAACACTGGAGGA
55 GATGTAGCTCATCTGGCGCTGATAGCGGCAATTCAAAGTCAGACCAAGCGTGTCTGGTATCTTTCA
TCTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCA
AACTGCGATCTCCGCCTTGAAGGCGACCTGATGGTCTCATCAATGGTTTTGCTTGGCCTGGT

TGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTGGCTGCTCT
 GACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCTTGCTACTTGGCGGGG
 GTTTATGCTCCTCTCTCTGAAGGGAAGGCAGTGTGAAGAAGAACTTACCATTTGTCATGGCC
 CTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAA
 5 GGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCAT
 TGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGTGCGTCTGC
 TAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACA
 TCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
 AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGT
 10 GGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTAC
 GTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCCCAAGGAAGTA
 AAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACA
 CAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGA
 TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTG
 15 GTGTCATACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTC
 TTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAGACA
 AAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGT
 TATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCT
 20 TCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGG
 AGAGTTCTTCCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTACTGTGATCTTAGCTC
 CAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGAC
 AACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTC
 ACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCC
 25 ACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCG
 AGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAA
 CTCACCAATTATGGACACCGAAGTGGAAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTG
 GGTGACGGATCATTCTGGA AAAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGAT
 CGCAGCTTGTCTGACAAAGGCTGGAAAACGGGTGATACAGCTCAGCAGAAAGACTTTTGAGAC
 30 AGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAACTGACATTTAGAGAT
 GGGCGCCAACCTTTAAAGCTGACCGTGTATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTT
 GATGGCGAGAGAGTCAATTCTGGCTGGACCCATGCTGTGTCACACATGCCAGCGCTGCCAGAGG
 AGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGC
 GCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTAC
 35 CTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCGGACAAAGTAGCAGCCATTGAGG
 GAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCATGAAAAGAGGAGATC
 TTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGGTG
 CTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAG
 ACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGC
 40 GGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGA
 AGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGC
 TGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGGA
 GACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCT
 TGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCAT
 45 GGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCTCATTGTTGTGTTCTTA
 TTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAATGGCA
 ATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGG
 AGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGA
 TTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTT
 50 CATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAATACTCCTTAATGGCGATG
 GCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCAT
 CATTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCT
 GCCCAGAAGAAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACT
 55 GACATTGACACAATGACAATTGACCCCAAGTGGAGAGAAAAGATGGGACAGGTGCTACTCATA
 GCAGTAGCCGTCTCCAGCGCCATACTGTCTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCC
 CTGATCACAGCGGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTTA

CAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACA
GTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGA
GAAATGGAAGGCCCGCTTGAACCAGATGTGCGCCCTGGAGTTCTACTCCTACAAAAAGTCAGG
CATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAG
5 GCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGC
CCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCAT
CCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCATGTT
GGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGCTCTTTCATATGGCG
GCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAG
10 AAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCCT
TTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCAGCG
TAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTACTG
GGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGG
GCGCATGGACGGGCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGGCTCTGGCAC
15 GCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAG
GATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGC
TTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCCTCTCTAATAAACGGGGTTGTC
AGGCTCCTGTCAAAACCCTGGGATGTGGTGAAGTGCAGGAATAGCCATGACCGACACC
ACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGAAGACTAGGGTGCCAGACCCCCAA
20 GAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAGCTAGGCAAACAC
AAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTCGTAGCAATGCAGCATTG
GGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAG
GTTCTGGGCTCTAGTGGAACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGAGTTGTGT
GTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAGGGCAGCC
25 GCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAA
CGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAA
GACTCGGATATGTCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCA
AATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGT
30 GGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTGAGACAAGA
CCAAAGGGGGAGCGGACAAGTTGTCACCTACGCTCTTAACACATTTACCAACCTAGTGGTGCAA
CTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGG
TCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGATGGGATAGGCTCAAACGAATGGCAGTC
AGTGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGA
35 ATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAAC
TGGAAGAAGTTCCGTTTTGCTCCCACCCTCAACAAGCTCCATCTCAAGGACGGGAGGTCCA
TTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCGCGCTCTCTCAGGGGCGGG
ATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTAT
TTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGG
40 TTCCAACTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACA
TGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAG
TTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCAT
AGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAACACACAGTCAACATGGTGCGCAG
GATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTCGCTACTTGGGTGA
45 AGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAGTGTTGTCAGGCCTGCTAGTCAGC
CACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTA
TAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCCTGTGAGCCCCTCAGAGGAC
ACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACCTTCC
CCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGTG
50 GTTAGAGGAGACCCCCCGGAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACT
CCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCGGCTGTGGG
G

SEQ ID NO: 73

55 AHZ13508.1, Zika virus polyprotein from Polynesian outbreak (H/PF/2013)
MKNPKKSGGFRIVNMLKRGVARVSPFGGLKRLPAGLLLGHGPIRMVLAFLAFLRFTAIPSLGLIN
RWGSVGKKEAMEIHKFKDLAAMLRIINARKEKKRRGADTSVGIVGLLLTTAMAAEVTRRGSAYY

MYLDRNDAGEAISFPTTLGMNKCYYIQIMDLGHMCDATMSYECPMLDEGVEPDDVDCWCNTTSTW
VVGTCCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTWLESREYTKHLIRVENWIFRNPGFALAAAA
IAWLLGSSTSQKVIYLVILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDVVLHGGCVTVMAQDKPT
VDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGC
5 GLFGKGS�VTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPN
SPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWN
NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRK
GVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITES
TENSMMLELDPPFGDSYIVIGVGEKKITHHWHRSSTIGKAFEATVRGAKRMAVLGDTAWDFGSV
10 GGALNSLKGIIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAV
SADVGCSDVFSKKEKTRCGTGTVFYNDVEAWRDYKYHPDSPRRLAAAVKQAWEDGICGISSVSRM
ENIMWRSVEGELNAILEENGVLTVVVGSVKNPMWRGPQRLPVPVNLPHGWKAWGKSYFVRAA
KTNSFVVDGDTLKECPLKHRAWSFLVEDHGFVGFHTSVWLKVREDYSLECDPAVIGTAVKGKE
AVHSDLGYWIESEKNDTWRLKRAHLIEMKTCEWPKSHTLWTDGIEESDLIPKSLAGPLSHNTREG
15 YRTQMKGPWHSEELIRFECECPGTVHVEETCGTRGPSLRSTTASGRVIEEWCCRECTMPPLSFRAK
DGCWYGMEIRPRKEPESNLVRSMVTAGSTDHMDHFSGLVLVILLMVQEGKKRMTTKIIISTMAV
LVAMILGGFSMSDLAKLAILMGATFAEMNTGGDVAHLALIAAFKVRPALLVSFIFRANWTPRESML
LALASCLLQTAISALEGDLMLVINGFALAWLAIRAMVVPRTDNITLAILAALTPLARGTLLVAWRAG
LATCGGFMLLSLKGKGSVKKNLPFVMALGLTAVRLVDPINVVGLLLLTRSGKRSWPPSEVLTAVGL
20 ICALAGGFAKADIEMAGPMAAVGLLIVSYVVSQSVDMYIERAGDITWEKDAEVTGNSPRLDVALD
ESGDFSLVEDDGPMPREIILKVVLMTICGMNPIAIPFAAGAWYVYVKTGKRSGALWDVPAPKEVKK
GETTDGVYRVMTRRLGSTQVGVGMQEGVFHTMWHTKGSALRSGEGRDPYWGVDVKQDLVS
YCGPWKLDAAWDGHSEVQLLAVPPGERARNIQTLPGIFKTKDGDIGAVALDYPAGTSGSPILDKCG
RVIGLYGNGVVIKNGSYVSAITQGRREEETPVECFEPSMLKKKQLTVLDLHPGAGKTRRVLPEIVRE
25 AIKTRLRTVILAPTRVVAEMEEALRGLPVRVMTTAVNVTHSGTEIVDLMCHATFTSRLLQPIRVN
YNLYIMDEAHFTDPSSIAARGYISTRVEMGEAAAFMTATPPGTRDAFPDSNSPIMDTEVEVPERAWS
SGFDWVTDHSGKTVWFVPSVRNGNEIAACLTAKAGKRVQLSRKTFETEFQKTKHQEWDVFTTDIS
EMGANFKADRVIDSRRLKPVILDGERVILAGPMPVTHASAAQRRGRIGRNPKNPGDEYLYGGGCA
ETDEDHAHWLEARMLLDNIYLQDGLIASLYRPEADKVAIEGEFKLRTQKTFVELMKRGDLPVW
30 LAYQVASAGITYTDRRCWCFDGTNTTIMEDSVPAEVWTRHGEKRVLKPRWMDARVCSHAALKS
FKEFAAGKRGAAFGVMEALGTLPGHMTERFQEAIDNLAVLMRAETGSRPYKAAAALPETLETIML
LGLLTVSLGIFVLMRNKGIGKMGFGMVTLGASAWLMLWSEIEPARIACVLIVVFLLLVVLPEPEK
QRSPQDNQMAIIMVAVGLLGLITANELGWLERTKSDLSHLMGRREEGATIGFSMDIDLRPASAWAI
YAALTTFITPAVQHAVTTSYNNYSMLMAMATQAGVLFMGKGMFPFYAWDFGVPLLMIGCYSQLTPL
35 TLIVAIILLVAHYMYLIPGLQAAAAARAAQKRTAAGIMKNPVVDGIVVTDIDTMTIDPQVEKKMGQV
LLIAVAVSSAILSRTAWGWGEAGALITAATSTLWEGSPNKYWNSSTATSLCNIFRGSYLAGASLIYT
VTRNAGLVKRRGGGTGETLGEKWKARLNQMSALEFYSSYKSGITEVCREEARRALKDGVATGGH
AVSRGSAKLRWLVERGYLQPYGKVIDLGCGRGGWSYAAATIRKVQEVKGYTKGGPGHEEPMVLVQ
SYGWNIVRLKSGVDVFHMAAEPDCTLLCDIGESSSSPEVEEARTLRVLSMVGDWLEKRPAGFCIKV
40 LCPYTSTMMETLERLQRRYGGGLVRVPLSRNSTHEMYWVSGAKSNTIKSVSTTSQLLLGRMDGPRR
PVKYEEDVNLGSGTRAVVSCAEAPNMKIIGNRIERIRSEHAETWFFDENHPYRTWAYHGSYEAPTQ
GSASSLINGVVRLLSKPWDVVTGVTGIAMTDTTPYGGQQRVFKEKVDTRVPDPQEGTRQVMSMVSS
WLWKELGKHKRPRVCTKEEFINKVRSNAALGAIFEEKEWKTAVEAVNDPRFWALVDKEREHLR
GECQSCVYNMMGKREKKQGEFGKAKGSRAIWMWLGARFLEFEALGFLNEDHWMGRENSGGV
45 EGLGLQRLGYVLEEMSRIPGGRMYADDTAGWDTRISRFLENEALITNQMEKGHRALALAIKYTY
QNKVVVKVLRPAEKGKTVMDIISRDQQRSGQVVTYALNTFTNLVVQLIRNMEAEEVLEMQDLWLL
RRSEKVTNWLQSNGWDRLKRMASVGGDCVVKPIDDRFAHALRFLNDMGKVRKDTQEWKPTSGW
DNWEEVPFCSHHFNKLHLKDGSRIVVPCRHQDELIGRARVSPGAGWSIRETACLAKSQAQMWQLL
YFHRRDLRLMANAICSSVPVDWVPTGRTTWSIHGKGEWMTTEDMLVVWNRVWIEENDHMEDKTP
50 VTKWTDIPYLGKREDLWCGSLIGHRPRTTWAENIKNTVNMVRRRIIGDEEKYMDYLSTQVRYLGEEG
STPGVL

SEQ ID NO: 74

9320_Zika_PF_1F

55 ttaggatccGTTGTTGATCTGTGTGAAT

SEQ ID NO: 75

9321_Zika_PF_1R
taactcgagCGTACACAACCCAAGTT

5 SEQ ID NO: 76
9322_Zika_PF_2F
ttaggatccTCACTAGACGTGGGAGTG

10 SEQ ID NO: 77
9323_Zika_PF_2R
taactcgagAAGCCATGTCYGATATTGAT

15 SEQ ID NO: 78
9324_Zika_PF_3F
ttaggatccGCATACAGCATCAGGTG

SEQ ID NO: 79
9325_Zika_PF_3R
taactcgagTGTGGAGTTCCGGTGTCT

20 SEQ ID NO: 80
9326_Zika_PF_4F
ttaggatccGAATAGAGCGAARGTTGAGATA

25 SEQ ID NO: 81
9327_Zika_PF_4R
taactcgAGTGGTGGGTGATCTTCTTCT

30 SEQ ID NO: 82
9328_Zika_PF_5F
ttaggatccCAGTCACAGTGGAGGTACAGTAC

35 SEQ ID NO: 83
9329_Zika_PF_5R
taactcgagCRCAGATACCATCTTCCC

SEQ ID NO: 84
9330_Zika_PF_6F
ttaggatCCCTTATGTGCTTGGCCTTAG

40 SEQ ID NO: 85
9331_Zika_PF_6R
taactcgagTCTTCAGCCTCCATGTG

45 SEQ ID NO: 86
9332_Zika_PF_7F
ttaggatccAATGCCCACTCAAACATAGA

50 SEQ ID NO: 87
9333_Zika_PF_7R
taactcgagTCATTCTCTTCTTCAGCCCTT

55 SEQ ID NO: 88
9334_Zika_PF_8F
ttaggatccAAGGGTGATCGAGGAAT

SEQ ID NO: 89
9335_Zika_PF_8R

taactcgagTTCCTTCAGAGAGAGGAGC

SEQ ID NO: 90

9336_Zika_PF_9F

5 ttaggatccTCTTTTGCAAAGTGGATC

SEQ ID NO: 91

9337_Zika_PF_9R

10 taactcgagTCCAGCTGCAAAGGGTAT

SEQ ID NO: 92

9338_Zika_PF_10F

ttaggatccGTGTGGACATGTACATTGA

SEQ ID NO: 93

9339_Zika_PF_10R

15 taactcgagCCCATTGCCATAAAGTC

SEQ ID NO: 94

9340_Zika_PF_11F

20 ttaggatccTCATACTGTGGTCCATGGA

SEQ ID NO: 95

9341_Zika_PF_11R

25 taactcgagGCCATCTCAACCCTTG

SEQ ID NO: 96

9342_Zika_PF_12F

30 ttaggatccTAGAGGGCTTCCAGTGC

SEQ ID NO: 97

9343_Zika_PF_12R

taactcgAGATACTCATCTCCAGGTTTGTGTTG

SEQ ID NO: 98

9344_Zika_PF_13F

35 ttaggatccGAAAACAAAACATCAAGAGTG

SEQ ID NO: 99

9345_Zika_PF_13R

40 taactcgagGAATCTCTCTGTCATGTGTCCT

SEQ ID NO: 100

9346_Zika_PF_14F

45 ttaggatccTTGATGGCACGACCAAC

SEQ ID NO: 101

9347_Zika_PF_14R

50 ttaggatccGTTGTTGATCTGTGTGAAT

SEQ ID NO: 102

9348_Zika_PF_15F

taactcgagCAGGTCAATGTCCATTG

SEQ ID NO: 103

9349_Zika_PF_15R

55 ttaggatccTGTTGTGTTCCCTATTGCTGGT

5 SEQ ID NO: 104
9350_Zika_PF_16F
taactcgaGTGATCAGRGCCCCAGC

10 SEQ ID NO: 105
9351_Zika_PF_16R
ttaggatccTGCTGCCCAGAAGAGAA

15 SEQ ID NO: 106
9352_Zika_PF_17F
taactcgaGCACCAACAYGGGTTCTT

20 SEQ ID NO: 107
9353_Zika_PF_17R
ttaggateCTCAAGGACGGTGTGGC

25 SEQ ID NO: 108
9354_Zika_PF_18F
taactcgagCAATGATCTTCATGTTGGG

30 SEQ ID NO: 109
9355_Zika_PF_18R
ttaggatccTATGGGGGAGGACTGGT

35 SEQ ID NO: 110
9356_Zika_PF_19F
taactcGAGCCCAGAACCTTGATC

40 SEQ ID NO: 111
9357_Zika_PF_19R
ttaggatccCAGACCCCCAAGAAGGC

45 SEQ ID NO: 112
9358_Zika_PF_20F
taactcgagCCCCTTTGGTCTTGTCT

50 SEQ ID NO: 113
9359_Zika_PF_20R
ttaggatccAGGAAGGATGTATGCAGATG

55 SEQ ID NO: 114
9360_Zika_PF_21F
taactcgagACATTTGCGCATATGATTTTG

SEQ ID NO: 115
9361_Zika_PF_21R
ttaggatccAGGAAGGACACACAAGAGT

SEQ ID NO: 116
9362_Zika_PF_22F
taactcgagACAGGCTGCACAGCTTT

SEQ ID NO: 117
9363_Zika_PF_22R
ttaggatccTCTCTCATAGGGCACAGAC

In some embodiments, the Zika virus has a polyprotein including an envelope (E) protein with an amino acid sequence provided by any one of SEQ ID NOs: 14-69. In some embodiments, the polyprotein or E protein sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-69 or 72.

The terms "identical" or "percent identity" in the context of two or more nucleic acids or amino acid sequences refer to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*e.g.*, at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity) over a specified region or over the entire sequence, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. In some embodiments, the identity exists over the length of a protein, such as the E protein.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. Methods of alignment of sequences for comparison are well known in the art. See, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) *Adv. Appl. Math.* 2:482c, by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48:443, 1970, by the search for similarity method of Pearson and Lipman. *Proc. Natl. Acad. Sci. USA* 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, Jalview and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), by multi sequence alignment implementation using *e.g.* CLUSTALW (Larkin et al., (2007). *Bioinformatics*, 23, 2947-2948.) or MAFFT (Katoh & Toh, 2008, *Briefings in Bioinformatics* 9:286-298), or by manual alignment and visual inspection (see, *e.g.*, Brent et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (Ringbou ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., *Nuc. Acids Res.* 25:3389-3402, 1997 and Altschul et al., *J. Mol. Biol.* 215:403-410, 1990, respectively.

EXAMPLES

Example 1: Production of a Zika drug substance suitable for application as a vaccine in humans and animals

5

Materials and Methods:

For the production of ZikaV the JEV process platform (Srivastava et al., Vaccine 19 (2001) 4557-4565; US 6,309,650B1) was used as a basis. Small changes of certain process steps were adapted to ZikaV properties and to improve purity. A short summary of the process steps is outlined below (see also Figure 9A and B). Briefly, the unexpected and novel purification properties of protamine sulphate (PS) were evaluated in purification processes for Zika Virus. As shown in Figure 10, non-infectious virus particle aggregates, HCP and other LMW impurities were removed by PS precipitation as shown by removal of aggregate shoulder in SEC-HPLC and no loss of infectious virus titer by PS treatment. Further optimization of the Zika purification protocol is provided below.

Upstream:

- Roller Bottle based Vero cell expansion (25x850cm² CellBind):
- 5% CO₂, 35°C, MEM+2mM L-Glutamine + 10% FBS
- 20 • Infection with ZikaV research Master Seed Bank (rMSB) at MOI 0.01
- Virus Production without serum
- 5% CO₂, 35°C, MEM+2mM L-Glutamine
- Multiple harvests (days 2, 3, 5 and 7) with re-feed
- Sterile filtration of harvests and storage at 2-8°C until further processing

25 Downstream:

- Pooling of harvests and concentration by ultrafiltration (100kDa)
- Stabilization of concentrated harvest (Tris/10% sucrose) for storage if required (-80°C)
- Removal of hcDNA by Protamine Sulphate (2 mg/mL)
- Sucrose Gradient Purification (optimized three layered gradient)
- 30 • Formaldehyde Inactivation (0.02%, 22°C, 10 days), neutralization with Na-metabisulfite
- Dilution to DS antigen target content and formulation with Aluminium hydroxide (0.5mg Al/mL)

Zika Virus Strain H/PF/2013 was originally isolated from a 51-year-old woman (accession number KJ776791.1, also SEQ ID NO: 13 herein) from French Polynesia. A sample was obtained from the

European Virus Archive (EVAg; Ref-SKU: 001v-EVA1545). Based on this material, a research master seed bank (rMSB) was prepared on Vero cells as the cell substrate and the genomic sequence was checked by sequencing. Because the genomic sequence at the 5' and 3' flanking sequences of Zika virus strain H/PF/2013 was unknown, primers for sequencing were designed in those regions based on other Zika virus strains whereas the internal primers were designed from the published sequence (SEQ ID NOs: 74 to 117, see also Table A). The sequence obtained from the rMSB by use of these primers is provided by SEQ ID NO: 72. There was 100% overlap of the sequence with the published sequence of Zika Virus Strain H/PF/2013 (SEQ ID NO: 13). However, we sequenced additional regions 5' (an additional 40 bp) and 3' (an additional 160 bp) represented in SEQ ID NO: 72. In a preferred embodiment, the Zika virus of the invention comprises SEQ ID NO: 72. The genomic RNA is somewhat longer than the sequence according to SEQ ID NO: 72 (perhaps an additional 200 bp). Additionally, a Zika virus adapted to a host cell such as e.g. Vero cells may be expected to contain one or more mutations. For these reasons, the Zika virus of the current invention comprises the sequence of SEQ ID NO: 72 or, preferably, a sequence with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 72. Furthermore, because the viral genome is likely to contain even further flanking regions to SEQ ID NO: 72; in one embodiment, the Zika virus of the invention contains the sequence of SEQ ID NO: 72 and optionally further comprises extensions at the 5' and/or 3' ends of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120 or at least 130 nucleotides. In a preferred embodiment, the Zika virus comprises at least the coding sequence for the entire polyprotein of Zika Virus Strain H/PF/2013 of the invention i.e. the amino acid sequence of SEQ ID NO: 73 or a polyprotein with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 73. Furthermore, the Zika virus comprises at least the coding sequence for the E-protein of Zika Virus Strain H/PF/2013 of the invention SEQ ID NO: 47 or an E-protein thereof with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 47.

Virus growth on Vero Cells

Vero cells were grown in Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS). Roller bottle cultures of Vero cell monolayers were infected with Zika Virus Strain H/PF/2013 at a multiplicity of infection (moi) of 0.01 plaque forming units (pfu) per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM without FBS and incubated at +35°C with 5% CO₂. Infected Vero cell cultures were incubated until the virus titer reaches a desired level.

The culture medium was harvested at days 2, 3, 5 and 7 and were pooled from those harvest days and then centrifuged in a standard centrifuge. The supernatants were then filtered. Virus culture supernatants were concentrated by TFF ultrafiltration to remove cell culture media components and to reduce batch volume.

Evaluation of harvest Procedure

The current JEV harvest process has scheduled harvests on days 3, 5, 7 and 9 post infection. To mimic the JEV process roller bottles were infected with ZIKV bank P4-FBS at an MOI of 0.01 in infection medium (MEM with 2% FBS + 2mM L-glutamine) for 2 hours. After removing the inoculum the cells were washed twice with PBS and 200 mL production medium (MEM+ 2mM L-glutamine) was added.

After taking a sample on day 2 the first virus harvest was conducted on day 3 after infection. At this point significantly higher CPE could be observed compared to cells where virus was removed on day 2. Plaque assay analysis showed that the viral titers on day 2 were in the same range as for the standard harvesting schedule. However, starting with the day 3 harvest, the observed titers were significantly lower correlating with the increased CPE observed compared to the standard harvest schedule. On day 5 post infection no more living cells could be observed at all and the experiment was terminated with a final day 5 harvest.

Table 3: The calculated titers per plaque assay are summarized in the list below.

	Log 10 PFU/mL
sample day2	7.02
harvest day 3	6.66
harvest day 5	6.26

This finding led to an optimized harvest schedule to better control of CPE and allow additional harvest day 5 and 7, see Figure 15. For both harvest days the optimized ZikaV protocol yield significant higher virus titers compared to the modified protocol showing that the time of the first harvest is crucial for production yields. Additionally first harvesting at day 3 results in maximum 2 harvest points whereas first harvesting at day 2 allows for 4 harvest points further increasing the yield gain.

Downstream Purification of Zika virus

The purification process was carried out at room temperature (18-22°C) unless stated otherwise. Virus purification started with concentration of filtered combined harvest using 100 kDa cut-off TFF ultrafiltration modules to remove cell culture media components and reduce batch volume. After concentration, the pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris pH 7.5 and 10% sucrose (w/w) using stock solution of both components (see Figure 11 for SEC-HPLC of different harvests prior to PS treatment). This allowed for freezing the concentrated harvest at <-65°C if required.

Host cell DNA and protein reduction as well reduction of non-infectious virus aggregates in the concentrated material was achieved by precipitation with protamine sulphate (2 mg/mL) followed by sucrose density centrifugation (2-8°C) as final polishing step (see Figure 20 for SEC-HPLC of different harvests post PS treatment). The purification process was designed to be completed within 2 working days with SGC starting on end of day 1 followed by fractionation and SDS-PAGE analysis on day 2. The sucrose gradient fractions were stored at 2-8 °C during the SDS-PAGE analysis (Silver staining) to identify the pure fractions containing ZikaV (see Figure 21). After pooling the relevant fractions, the pool was diluted and inactivated by Formalin. After pooling the relevant fractions of sucrose gradient centrifugation, the pool was diluted 1:3 in PBS and inactivated by Formalin (0.02% v/v, 200ppm). Fractions were subjected to analysis by SDS-PAGE.

Effect of PS treatment on virus recovery

Samples of individual 30x concentrated harvests days 2, 3, 5 and 7 were analysed before (Figure 11) and after PS (Figure 12) treatment by SEC-HPLC and plaque assay. SEC-HPLC was used for determination of relative total ZikaV content (active + inactive) expressed as peak area, whereas the rel. ZikaV peak purity is given as relative content of virus monomer population to total virus peak. Plaque assay states the content of total active virus particles in each sample. Experimental results are summarized in Table 4. The virus peak recovery by SEC-HPLC was only between 12 to 36% with peak purity after PS treatment in the range of >90% (no virus aggregates detected). The recovery of active virus particles by plaque assay was all > 100% (130-700%, range within the variability of the assay) showing that no active virus particles were lost during PS treatment. These results show that during PS treatment only non-infective (immature and/or aggregated virus) particles were removed.

Table 4: ZikaV recovery by SEC-HPLC and plaque assay before and after PS treatment.

SEC-HPLC

	Peak area mAU*min			
Harvest day	30x conc	30x + PS	SEC Recovery (%)	rel. virus monomer content after PS (%)
Day 2	101.36	18.63	18	89%
Day 3	144.51	17.48	12	90%
Day 5	19.97	5.92	30	96%
Day 7	68.80	24.43	36	99%

Plaque Assay

	PFU/mL		
Harvest day	30x conc	30x + PS	Plaque Recovery (%)
Day 2	3E+08	5E+08	179
Day 3	2E+08	4E+08	193
Day 5	1E+08	9E+08	700
Day 7	3E+08	4E+08	132

Sucrose gradient centrifugation

The PS treated harvest was split in two parts and loaded on two centrifuge bottles. Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ZikaV material. The ZikaV PS treated concentrated harvest was loaded on top of a solution consisting of three layers of sucrose with different densities. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and complete separation of the virus particles from residual contaminants as demonstrated for ChikV (Fig. 15D). The optimal volumes of the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation in 100 mL bottle scale are shown in Table 5.

Table 5: Individual layers/volumes for a centrifugation in bottle.

Solution	Volume (mL)
PS treated harvest in 10% sucrose (L)	40
15% sucrose (J)	15
35% sucrose (I)	15
50% sucrose (H)	20
Total volume	90

The sucrose gradient bottles were prepared by stratifying the individual sucrose layers. A plastic tube was attached to peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle. Using a peristaltic pump the ZikaV material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as feed vessel. The first solution pumped was the ZikaV material as it represented the solution of lowest density (10 % sucrose (w/w)). After the ZikaV material the sucrose solutions were pumped in ascending order starting with the 15 % (w/w) solution J, followed by 35 % sucrose solution I and finishing with the highest density sucrose solution H (50 % (w/w)). The described setup is shown in Figure 14. After all sucrose solutions were transferred the plastic tubing was carefully removed in order not to disturb the layers.

Prior to centrifugation the centrifuge was pre-cooled to 4°C. The prepared SG bottles were carefully transferred into the pre-cooled rotor. (Note: Sudden movement of the bottles during transfer to the rotor must be avoided in order not to disturb the sucrose layers.) The bottles were centrifuged at ~11.000 RCF max at 4 °C for at least 20 hours, no brake/deceleration activated. In case a different centrifuge system with a different rotor is used the necessary speed and centrifugation times need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A plastic tube attached to peristaltic pump tubing was used for harvesting the sucrose gradient. The bottle containing the gradient was mounted onto a laboratory stand in a tilted position (~12°) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle (see Figure 14).

Using a peristaltic pump set to a flow rate of 30 mL per minute the gradient was harvested and manually split into 2 mL fractions. A total number of 32 fractions per bottle were harvested (~ 64 mL) and the remaining volume was discarded. The fractions were immediately tested by SDS-PAGE / silver stain to identify the virus containing fractions with sufficient high purity. Representative SDS-PAGE is shown in Figure 14. Fraction 10-14 were pooled and further processed.

The purified viral solution was inactivated by incubation with 0.02% formaldehyde over a period of ten days in a 22°C controlled-temperature incubator. The formaldehyde is neutralized by addition of sodium metabisulphite on the tenth day.

5 The sucrose gradient pool (~17mL after sampling) was further diluted 3-fold with PBS to a final volume of 51 mL in a PETG container. A volume of 1% formaldehyde (10,000 ppm) solution equivalent to 1/50 of the final volume of the pre-formaldehyde pool was added to this pool resulting in an effective concentration of 200 ppm. The formaldehyde-treated solution was mixed on a magnetic stirrer for 10 minutes. After sampling, the formaldehyde-treated viral solution was
10 placed within a cooled incubator at 22°C ± 2°C. On Day 5 post addition of formaldehyde, the formaldehyde-treated viral solution was filtered through a 0.2 µm filter and then placed in the incubator at 22°C ± 2°C again. On Day 10, after removing the 10-Day inactivation final sample, a volume of 1 % (of the weight of the final formaldehyde-treated viral solution) of 200 mM-sodium metabisulphite solution (2mM final concentration) was aseptically transferred into the PETG
15 container containing the formaldehyde-treated viral solution. After mixing for 5 minutes on a magnetic stirrer, the neutralized inactivated viral solution is held at room temperature (20 to 25°C) for a minimum of 30 minutes. After sampling, the neutralized inactivated viral solution is stored at 5°C ± 3°C until further processing.

20 *Inactivation by formaldehyde*

Critical parameters for this step are final formalin concentration, temperature, mixing and transfer into a new container. A preliminary acceptance criterion for maximum pfu/mL (determined by plaque assay) has been set on the diluted pool pre formaldehyde treatment.

The quality of the neutralized inactivated viral solution was monitored by the following
25 parameters: Plaque assay on Day 10, SEC-HPLC, SDS-PAGE/Western Blot.

Interestingly, SEC-HPLC analysis of samples taken during the inactivation period followed by neutralization with bisulfite showed more or less constant peak area throughout the inactivation period. This is in contrast to JEV where losses of viral particles up to 60% are observed using the
30 process disclosed by Srivastava et al. Vaccine 19 (2001) 4557-4565. In a scale-down model the viral losses were even much higher due to surface/area ratio at smaller scale and high losses due to unspecific adsorption. Differences of the ZikaV inactivation experiment and JEV inactivation were noticed as follows:

A) Much higher purity of ZikaV SGP pool with regard to residual PS (<2µg/mL) compared
35 to JEV. The 3-fold ZikaV inactivated sample contained therefore <<1µg/mL of residual PS.

Commercial JEV SGP pool contains on average ~120µg/mL (up to 152 µg/mL possible). The average dilution to inactivation solution of ~14-fold results in a residual PS content up to ~11 µg/mL. It may be that higher amount of residual PS could cause virus precipitation due to cross-linking / reaction with formalin.

- 5 B) ZikaV inactivation sample contained ~10% sucrose (3-fold dilution of SGP pool containing ~30-35% sucrose). Sucrose might have stabilizing effect of viral ZikaV particles during treatment with formalin.

Dilution to DS and Formulation with Aluminium hydroxide (DP)

- 10 For preparation of ZikaV drug substance used in mouse potency assay an antigen content (expressed as total viral particles or SEC peak area) of 5 times higher compared to Ixiaro was targeted. The basis for determination of antigen content was SEC-HPLC. Briefly, a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25°C, was used to detect ZikaV at 214 nm detection wavelength in harvest samples
- 15 and throughout the downstream process. In the current JEV process the antigen content in NIV is determined by a specific ELISA. A good correlation was observed between antigen content determined by ELISA and SEC-HPLC. On average, the antigen content in commercial NIV samples is in the range of 33 AU/mL corresponding to ~5.2mAU JEV peak area, see Figure 21.
- 20 ZikaV NIV day10 (Zika peak ~36 mAU, analysed on Waters HPLC/Superose6 Increase column) was diluted with PBS to a target of 6.3 (~5.7x dilution). Aluminium hydroxide was added to a final concentration of 0.5 mg/mL Aluminium (1/20 v/v Alum 2% stock solution added) to prepare ZikaV Drug Product (DP). The DP was gently mixed for 5 min. An aliquot of the DP was removed, Alum sedimented by centrifugation and the clear supernatant analysed by SEC-HPLC.
- 25 No ZikaV peak was detected in the supernatant indicating complete adsorption (estimated as >95%) of viral particles on the mineral adjuvant. Formulated ZikaV DP was stored at 2-8°C.

The impurity profile of the inactivated Zika virus DS is comparable to the profile of JEV DS with the exception of a lower PS content (Table 6).

30

Table 6: Determination of impurity profile in Zika and JEV DS samples:

	Specification (JEV DS)	JEV	Zika
HCP (ng/mL)	<100 LOQ 12 ng/mL	<LOQ	<LOQ
DNA (pg/mL)	<200 LOQ 40 pg/mL	<40	<40

Aggregates by SEC-MALLS (%)	Not specified, part of characterization LOQ 5%	<LOQ	<LOQ
PS (µg/mL)	Specification only at SGP pool to demonstrate consistent process performance (19-152 µg/mL), *PS content in DS calculated based on PS content in SGP pool (~100 µg/mL) and average dilution factor (~28x) to DS; LOQ 2 µg/mL	~4*	<<LOQ

*Typical PS impurity in a JEV sample produced in accordance with protocol disclosed in Srivastava et al. Vaccine 19 (2001) 4557-4565.

SEC-MALLS Results

- 5 A representative SEC-HPLC elution profile of ZikaV NIV at 214 nm detection wave length is shown in Figure 16. Note that BSA (50 µg/mL) was added to the sample to minimize losses in HPLC glass vial due to unspecific surface adsorption. ZikaV monomer content was estimated as ~98% with a multimer content of ~2%.
- 10 SEC-MALLS analysis (Figure 17) of the sample confirmed the radius R_z of the monomer ZikaV population peak 1 as 21.6 nm and ~49 nm for the multimer peak 2. Cumulative particle size distribution showed that 89% of all viral particles are within a radius range between 18 to 25 nm (Figure 18).
- 15 Results confirm purity and homogeneity of ZikaV NIV.

Viral titer by plaque assay

Table 7: Active ZikaV pfus were quantified by plaque assay throughout the process.

Sample	Pfu/mL
Harvest day 2 (filtered)	6.4×10^7
Harvest day 3 (filtered)	1.0×10^8
Harvest day 5 (filtered)	1.5×10^8
Harvest day 7 (filtered)	1.1×10^8
PS treated harvest 300x concentrate (=SGP load)	9.0×10^8
SGP pool	8.9×10^8
Inactivation start (SGP pool 1:3 diluted)	3.4×10^8
Inactivation day 5	<LOD
Inactivation day 10	<LOD

- 20 *Comparison of PS and Benzonase on process performance*

A direct comparison of DNA removal method of concentrated ZikaV harvest pool was done. One aliquot was treated with PS (2 mg/mL, 15min at room temperature), the other aliquot was treated with Benzonase (50 U/mL, 2 mM MgCl₂, 4h RT, 48h 2-8°C). Both samples were further purified by sucrose gradient as described in this report. Interestingly, the Benzonase treated samples did not yield any pure fractions after sucrose gradient centrifugation of the treated ZikaV harvest. In those fractions where the specific virus bands were detected, a high amount of host cell protein was detected throughout the collected fractions. The PS treated material resulted in pure ZikaV containing fractions as expected. This finding may suggest that PS is not only effective for DNA removal by precipitation; in addition it improves the recovery of virus particles in the gradient by disrupting interaction of DNA (fragments) and virus particles. Benzonase treatment does not remove DNA, it only results in its fragmentation. Residual DNA fragments might still interact with virus particles and residual HCPs resulting in cross-contamination and co-purification in the sucrose gradient. Pooled SGP fractions were also analysed by SEC-HPLC. Although a large peak was detected, SDS-PAGE confirmed that this sample was highly contaminated with HCPs. A large peak might be detected at UV214 and 280nm after SEC-HPLC analysis due to possible interaction of HCPs with large virus particles, changing the UV absorbance.

Immunogenicity of Vero grown Zika virus

Immunization of mice

Prior to immunization, groups of ten 6-week-old female CD1 mice were bled via vena facialis and pre-immune sera were prepared. One intraperitoneal immunizations of 200 µL were administered. A dose titration (12 µg, 3 µg, 1 µg, 0.33 µg, 0.11 µg, 0.037 µg and 0.012 µg, equivalent to the protein amount in IXIARO) of inactivated Zika virus formulated with aluminium hydroxide (Al(OH)₃) at a final concentration of 0.7%. Three weeks after immunization, blood was collected and immune sera were prepared. All animal experiments were conducted in accordance with Austrian law (BGB1 Nr. 501/1989) and approved by "Magistratsabteilung 58".

Plaque reduction neutralization test (PRNT)

Twelve well plates were used for PRNT. Each well was seeded with 1 mL medium containing 4x10⁵ Vero cells and incubated 35°C with 5% CO₂ overnight. Pools of heat inactivated sera from each dose group were tested in triplicate. The target viruses (H/PF/2013 (SEQ ID NO: 13) or MR766 (SEQ ID NO: 11)) were diluted to 100 pfu/165 µL. Equal volumes of target virus and serum dilution were incubated at 35°C with 5% CO₂ for 1 hour. The cell culture medium was aspirated from the Vero cells and 330 µL of the mixture target virus/serum dilution were added to each well and the plates were rocked back and forth 5 times before incubating for 2 hours at 35°C

with 5% CO₂. To each well 1 mL of a 2% methylcellulose solution containing EMEM and nutrients was added, the plates were then incubated for 5 days at 35°C with 5% CO₂ before staining the cells for 1 hour with crystal violet/5% formaldehyde and subsequently washed 3 times with deionized water. The plates were air dried and the numbers of plaques in each well were manually counted.

Results

Neutralization was observed with serum pools from mice immunized with inactivated Zika virus vaccine (H/PF/2013) down to 37 ng (dosing equivalent to the amount protein in IXIARO®) against Zika viruses of both the Asian (H/PF/2013) and African (MR766) lineages (Figures 19 and 20, respectively). Complete inhibition was seen at the 1:20 serum dilution with an immunization dose down to 110 ng (dosing equivalent to the amount protein in IXIARO®). The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

Another neutralization assay was performed using the microneutralization assay as described by Larocca, et al. (2016, Nature doi:10.1038/nature18952). It was found that the inactivated Zika virus of the current invention had an MN50 (microneutralization) titer of 90 at 1 µg of inactivated purified virus.

Further methods: The immunogenicity of inactivated Zika virus preparations is assessed using a mouse model of Zika infection. Groups of adult mice are immunized subcutaneously (s.c.) with 500, 50, or 5 ng of inactivated Zika virus with adjuvant (*e.g.* aluminium hydroxide with or without IC31®), or without adjuvant. An additional group of mice receive PBS as a negative control. Each group is administered the indicated inoculum at t=0 and in some cases also at three to four weeks later (t=3/4). Beginning approximately three weeks after administration of the last immunization, serum samples are obtained from each of the mice at regular intervals. The serum samples are tested for the presence of neutralizing antibodies using PRNT.

The *in vivo* protective efficacy of the inactivated Zika virus preparations is also assessed using a mouse model of Zika infection, *i.e.* IFN-alpha/beta receptor knock-out mice (A129) (see *e.g.* Dowall et al., 4. March 2016, <http://dx.doi.org/10.1101/042358>) or blocking of the IFN-alpha/beta receptor by administration of anti-IFN-alpha/beta receptor monoclonal antibodies to C57BL/6 or BALB/c mice (see *e.g.* Pinto et al., 7. December 2011, DOI: 10.1371/journal.ppat.1002407). For

protection assays, groups of 10 three- to eight-weeks-old A129, C57BL/6 or BALB/c mice are inoculated subcutaneously in the hindquarters with inactivated Zika virus with adjuvant (aluminium hydroxide) or without adjuvant at t=0. Age-matched controls are inoculated with PBS or non-specific antigens in alum. Mice are optionally boosted with a second administration of the indicated inoculation three to four weeks later. The mice are then challenged subcutaneously at three to eight weeks post immunization by inoculation with a deadly dose of live Zika virus. One day prior to challenge of C57BL/6 and BALB/c mice, they are passively administered (intraperitoneally) anti-IFN-alpha/beta receptor monoclonal antibodies. Challenged mice are monitored daily for morbidity and mortality for up to twenty-one days. Another alternative is to challenge intracranially adult vaccinated/non-vaccinated adult mice and observe protection.

It is expected that the Zika virus produced by the process of the invention will provide very similar functional read-outs in *in vitro*, *in vivo* and finally human trials as the currently licensed JEV vaccine in the EU and US and elsewhere, IXIARO®. The dosage may alter but due to the very similar impurity profile and almost identical manufacture, a very similar efficacy and safety result will be expected as was determined for the currently licensed JEV vaccine (licensed in the EU and US and elsewhere).

Discussion & Conclusion

The existing manufacturing platform for production of inactivated JEV vaccine IXIARO® was used as a basis for a manufacturing feasibility study of inactivated ZikaV vaccine candidate (Asian strain H/PF/2013). The virus was produced on Vero cells cultivated in roller bottles. The virus was purified by PS treatment followed by an optimized sucrose gradient. Inactivation was done by formalin treat (0.02 %, 10 days at 22 °C). For exploratory immunization studies in mice, a DP formulated with Alum was prepared with an estimated 5-fold higher virus particle content compared to IXIARO®, the commercial JEV Vaccine. The impurity profile of the DS met all criteria as defined in the specification for IXIARO®, the commercial JEV vaccine. The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

The *in vivo* data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was higher than the recently reported inactivated Zika virus vaccine candidate

(Larocca, et. al, 2016, supra.). Inactivated viruses are among the safest vaccines and especially preferred for deliver to populations where safety is especially concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge
5 in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

Further more detailed aspects of the invention:

A1. A Zika virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with
5 at least a 70% probability.

A2. The Zika virus vaccine of A1, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability.
10

A3. The vaccine of A1 or A2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.
15

A4. The vaccine of any one of A1-A3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.
20

A5. The vaccine of any one of A1-A4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

A6. The vaccine of A5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent to completely inactivate the Zika virus as measured by plaque assay.
25

A7. The vaccine of A6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.
30

A8. The vaccine of A7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

A9. The vaccine of any one of A5-A8, wherein the chemical activation is performed at about +4°C or about +22°C.
35

A10. The vaccine of any one of A1-A9, further comprising an adjuvant.

A11. The vaccine of A10, wherein the adjuvant is an aluminum salt adjuvant.

5

A12. The vaccine of A11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

A13. The vaccine of any one of A10-A12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

10

A14. The vaccine of A13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).

15

A15. The vaccine of any one of A1-A14, further comprising one or more pharmaceutically acceptable excipient.

B1. A kit comprising a Zika virus vaccine of any one of A1-A15.

20

B2. The kit of B1, further comprising a second vaccine.

B3. The kit of B2, wherein the second vaccine is a West Nile virus vaccine, a Japanese Encephalitis virus vaccine, a yellow fever virus vaccine, a Dengue virus vaccine or a Chikungunya virus vaccine.

25

C1. A method, comprising administering a first dose of a therapeutically effective amount of the Zika virus vaccine of any one of A1-A15 to a subject in need thereof.

30

C2. The method of C1, further comprising administering a second dose of a therapeutically effective amount of the Zika virus vaccine.

C3. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

C4. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

C5. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

C6. The method of any one of C1-C5, wherein the administering results in production of Zika virus neutralizing antibodies.

D1. A method of producing a Zika virus vaccine, comprising

(i) passaging a Zika virus on Vero cells, thereby producing a culture supernatant comprising the Zika virus;

(ii) harvesting the culture medium of (i);

(iii) precipitating the harvested culture medium of (ii), thereby producing a Zika virus supernatant; and

(iv) optimally inactivating the Zika virus in the Zika virus supernatant of (iii) thereby producing an inactivated Zika virus.

D2. The method of D1, further comprising concentrating the culture medium of (ii) prior to step (iii).

D3. The method of D1 or D2, wherein the precipitating of (iii) comprises contacting the culture medium of (ii) with protamine sulfate or benzonase.

D4. The method of any one of D1-D3, further comprising (v) dialyzing the inactivated Zika virus of (iv), thereby producing a dialyzed Zika virus.

D5. The method of D4, further comprising (vi) filtering the dialyzed Zika virus of (v).

D6. The method of any one of D1-D5, wherein the inactivating is by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

D7. The method of D6, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for at least 4 days.

5 D8. The method of D6 or D7, wherein the chemical inactivation agent comprises formaldehyde.

D9. The method of any one of D6-D8, wherein the chemical activation is performed at about +4°C or about +22°C.

10

D10. The method of D8 or D9, further comprising neutralizing the formaldehyde.

D11. The method of D10, wherein the neutralizing is performed with sodium metabisulfite.

15

E1. The use of the optimally inactivated Zika virus vaccine of any one of A1-A15 for the treatment and prevention of a Zika virus infection.

20 E2. The use of E1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

E3. The use of E2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

25 E4. The use of E3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

E5. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

30

E6. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

35 E7. The use of any one of E1-E6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

F1. A pharmaceutical composition for use in the treatment and prevention of a Zika virus infection, wherein said pharmaceutical composition comprises the optimally inactivated Zika virus vaccine of any one of A1-A15.

F2. The pharmaceutical composition of F1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

F3. The use of F2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

F4. The use of F3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

F5. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

F6. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

F7. The use of any one of F1-F6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

G1. A Zika virus vaccine comprising an inactivated Zika virus particle, wherein the Zika virus vaccine is able to confer seroprotection on at least 70% of subjects that are administered the Zika virus vaccine.

G2. The Zika virus vaccine of G1, wherein the Zika virus particle is able to confer seroprotection on at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of vaccinated subjects that are administered the Zika virus vaccine, preferably on at least 80% of subjects.

G3. The vaccine of G1 or G2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-

13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.

5 G4. The vaccine of any one of G1 to G3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

10 G5. The vaccine of any one of G1 to G4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

G6. The vaccine of G5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

15 G7. The vaccine of G6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

20 G8. The vaccine of G7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

G9. The vaccine of any one of G5 to G8, wherein the chemical activation is performed at about +4°C or about +22°C.

25 G10. The vaccine of any one of G1 to G9, further comprising an adjuvant.

G11. The vaccine of G10, wherein the adjuvant is an aluminum salt adjuvant.

30 G12. The vaccine of G11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

G13. The vaccine of any one of G10 to G12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

G14. The vaccine of G13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).

G15. The vaccine of any one of G1 to G14, further comprising one or more pharmaceutically acceptable excipients.

G16. The vaccine of any one of G1 to G15, wherein the vaccine contains protamine sulphate or fragments or break-down products of PS at amounts too low to detect by HPLC, i.e., below 1 µg/mL, especially below 100 ng/mL.

G17. The vaccine of G16, wherein said protamine sulphate or fragments or break-down products of PS can be detected by mass spectroscopy or another sensitive method.

Q1. A process of purification of infectious Zika virus particles, comprising the steps of:

(a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;

(b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);

(c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05µg/mL.

Q2. The process of Q2, wherein the virus particles are from Zika virus.

Q3. The process of Q1 or Q2, additionally comprising the step of:

(d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.

Q4. The process of any of Q1 to 3, wherein the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.

5 Q5. The process of any of Q1 to 4, wherein the crude harvest (a) comprising Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

Q6. The process of Q5, wherein the one or more pre-purification step(s) comprises

- (a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
- 10 (b) digestion of host cell genomic DNA by enzymatic treatment; and/or
- (c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

Q7. The process of any one of Q1 to 6, wherein the concentration of protamine sulphate is 0.5
15 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.

Q8. The process of any one of Q1 to 7, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude
20 harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

Q9. The process of any one of Q5 to 8, wherein the one or more pre-purification step(s) prior to step (b) of any of Q5 to 8 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

25

Q10. The process of any one of Q1 to 9, wherein the residual impurity of the virus preparation (c) is less than 10%.

Q11. The process of any one of Q1 to 10, wherein the Zika virus is propagated in a cell line
30 selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

35 Q12. The process of Q11, wherein said cell line is a Vero cell line.

Q13. The process of any one of Q1 to 12, wherein the infectious virus particles is an infectious Zika virus particle that is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

5

Q14. The process of any one of Q1 to 13, wherein the Zika virus is a strain of the Asian lineage or an immunogenic variant thereof.

Q15. The process of any one of Q1 to 14, wherein said process resulting in final Zika virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

10

Q16. Use of the process according to any one of Q1 to 15 for manufacturing a composition for immunization against a virus infection.

15

Q17. The use according to Q16, wherein the composition for immunization against a virus infection is an infection caused by Zika virus.

Q18. A composition comprising the virus particles obtainable or obtained by the process of any one of Q1 to 17 for treating and/or preventing an infection, such as e.g. a Zika virus infection.

20

Q19. A Zika virus vaccine comprising an inactivated Zika virus particle grown on vero cells, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability and comprises minor amounts of protamine sulphate, preferably below the detection limit.

25

Q20. The Zika virus vaccine of Q19, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability, preferably a 80% probability.

30

Q21. The vaccine of Q19 or 20, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.

35

Q22. The vaccine of any one of Q19, 20 and 21, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

5

Q23. The vaccine of any one of Q19, 20 to 22, wherein the Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.

Q24. The vaccine of Q23, wherein the sucrose gradient centrifugation is an optimized sucrose gradient centrifugation.

10

Q25. The vaccine of Q24, wherein the optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose solution, a second sucrose solution with 35% (w/w) sucrose solution, and a third sucrose solution with a 50% (w/w) sucrose solution.

15

Q26. The vaccine of any one of Q19, 20 to 25, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

Q27. The vaccine of Q26, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

20

Q28. The vaccine of Q27, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

25

Q29. The vaccine of Q28, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

Q30. The vaccine of any one of Q27-29, wherein the chemical activation is performed at about +4°C or about +22°C.

30

Q31. The vaccine of any one of Q19 to 30, further comprising an adjuvant.

Q32. The vaccine of Q31, wherein the adjuvant is an aluminum salt adjuvant.

35

Q33. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

5 Q34. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide with less than 1.25ppb Cu based on the final pharmaceutical composition comprising the Zika virus, preferably the inactivated Zika virus.

10 Q35. The vaccine of any one of Q19 to 34, further comprising one or more pharmaceutically acceptable excipient.

R1. Use of protamine, preferably a protamine salt, to separate infectious and non-infectious Zika virus particles, host cell proteins and/or undefined low molecular weight materials.

R2. A process of purification of infectious Zika virus particles, comprising the steps of:

- 15 (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b), wherein the enrichment of infectious virus particles in the virus preparation (b) relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.
- 20

R3. The use of R1 or the process of R2, wherein the virus particles are from Zika virus.

R4. A process of purification of infectious Zika virus particles, comprising the steps of:

- 25 (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
- 30 (c) further purifying the virus preparation (b) by one or more size exclusion methods such as (i) a sucrose density gradient centrifugation, (ii) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-

activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles, and/or (iii) size exclusion chromatography to obtain a virus preparation (c) comprising the infectious virus particles, wherein the residual host cell DNA of the virus preparation (c) is less than 100 ng/mL and the residual host cell protein and the residual aggregates of infectious virus particles of the final virus preparation (c) is less than 1 µg/mL.

R5. The process of R4, wherein the residual host cell DNA of the Zika virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.

R6. The process of any of R2 to 5, wherein the crude harvest (a) comprising Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

R7. The process of R6, wherein the one or more pre-purification step(s) comprises

(a) filtration using a filter having a pore size equal to or less than 0.2 µm; and/or

(b) digestion of host cell genomic DNA by enzymatic treatment; and/or

(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

R8. The process of any one of R2 to 7, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml.

R9. The process of any one of R2 to 8, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

R10. The process of any one of R6 to 9, wherein the one or more pre-purification step(s) prior to step (b) of any of R6 to 9 is performed using a filter having a pore size equal to or less than 1 µm, preferably 0.2 µm.

R11. The process of any one of R2 to 10, wherein the residual impurity of the virus preparation (c) is less than 10%.

R12. The process of any one of R2 to 11, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero-αHis cell line, a HeLa cell

line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

R13. The process of R12, wherein said cell line is a Vero cell line.

5 R14. The process of any one of R2 to 13, wherein the Zika virus is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

R15. The process of any one of R2 to 14, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

10 R16. The process of any one of R2 to 15, wherein said process resulting in final Zika virus preparation (c) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

R17. Use of the process according to any one of R1 to 16 for manufacturing a composition for immunization against a virus infection.

15 R18. The use according to R17, wherein the composition for immunization against a virus infection is an infection caused by a Zika virus.

R19. A composition comprising the virus particles obtainable or obtained by the process of any one of R2 to 16 for treating and/or preventing an infection.

CLAIMS

What is claimed is:

- 5 1. Use of an optimized sucrose gradient centrifugation for removal of protamine sulphate from purified infectious Zika virus particles.
2. The use according to claim 1, wherein said optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three further
10 layers of sucrose solutions with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose, a second sucrose solution with 35% (w/w) sucrose, and a third sucrose solution with a 50% (w/w) sucrose.
3. A process of purification of infectious Zika virus particles, comprising the steps of:
15 a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said Zika virus particles on a cell substrate;
b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus
20 preparation (b);
c) further purifying the Zika virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the Zika virus fraction; and wherein the protamine concentration is reduced by this step to the extent
25 that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05µg/mL.
4. The process of claim 4, wherein said optimized sucrose density gradient centrifugation
30 comprises a Zika virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose, a second sucrose solution with 35% (w/w) sucrose, and a third sucrose solution with a 50% (w/w) sucrose.

5. The process of claim 3 or 4, additionally comprising a further purification step of:
(d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the Zika virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the Zika virus particles.
6. The process of any of claims 3 to 5, wherein the residual host cell DNA content of the Zika virus preparation (c) is less than 10 ng/mL and the residual host cell protein content of the final Zika virus preparation (c) is less than 100 ng/mL.
7. The process of any of claims 3 to 6, wherein said crude harvest (a) comprising Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).
8. The process of claim 7, wherein the one or more pre-purification step(s) comprises
a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
b) digestion of host cell genomic DNA by enzymatic treatment; and/or
c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.
9. The process of any one of claims 3 to 8, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.
10. The process of any one of claims 3 to 9, wherein the enrichment of infectious Zika virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.
11. The process of any one of claims 8 to 10, wherein the one or more pre-purification step(s) prior to step (b) of any of claims 8 to 11 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .
12. The process of any one of claims 3 to 11, wherein the residual impurity of the Zika virus preparation (c) is less than 10%.

13. The process of any one of claims 3 to 12, wherein the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line,
5 a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.
14. The process of claim 13, wherein said cell line is a Vero cell line.
- 10 15. The process of any one of claims 3 to 14, wherein said infectious Zika virus particle is an infectious Zika virus particle that is a live virus, a live attenuated virus, a chimeric virus, a modified live virus, or a recombinant live virus.
16. The process of any one of claims 3 to 15, wherein the Zika virus comprises SEQ ID NO: 72
15
17. The process of any one of claims 3 to 16, wherein said process resulting in final Zika virus preparation (c) or (d) is followed by an inactivation step, wherein the Zika virus is inactivated preferably by formaldehyde.
- 20 18. Use of the process according to any one of claims 3 to 17 for manufacturing a composition for immunization against a Zika virus infection.
- 25 19. A composition comprising the Zika virus particles obtainable or obtained by the process of any one of claims 3 to 17 for treating and/or protecting from a Zika virus infection.
- 30 20. A Zika virus vaccine comprising an inactivated Zika virus particle grown on Vero cells, wherein the Zika virus vaccine is able to confer seroprotection on at least 70% of subjects that are administered the Zika virus vaccine and comprises minor amounts of protamine sulphate, preferably below the detection limit when measured with HPLC (below LOD) but still detectable by mass spectroscopy; i.e., trace amounts of PS and/or fragments thereof.
- 35 21. The Zika virus vaccine of claim 20, wherein the Zika virus vaccine is able to confer seroprotection on at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of subjects that are administered the Zika virus vaccine, preferably on at least 80% of subjects.

22. The vaccine of claim 20 or 21, wherein said Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 and able to pack a virulent Zika virus.
23. The vaccine of any one of claims 20 to 22, wherein said Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.
24. The vaccine of any one of claims 20 to 23, wherein said Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.
25. The vaccine of any one of claims 20 to 24, further comprising an adjuvant.
26. The vaccine of claim 25, wherein said adjuvant is an aluminum salt adjuvant.
27. The vaccine of claim 26, wherein said aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.
28. The vaccine of claim 26, wherein said aluminum salt adjuvant is aluminium hydroxide with less than 1.25 ppb Cu based on the final pharmaceutical composition comprising the Zika virus.
29. The vaccine of any one of claims 20 to 28, further comprising one or more pharmaceutically acceptable excipient(s).

1/23




Figure 1

2/23




Figure 2

3/23

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
DWV 1.NC 001477.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
DWV 1681.NC 001474.2	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
DWV 3.NC 001475.2	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
DWV 4.NC 002640.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
JEV SA14-14-2.AF315119.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
JEV SA14-14-2.D90195.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
JEV SA14.D90194.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
JEV virus.M55506.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
JEV virus.NC 001437.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
TEV virus.NC 001672.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
WNV 956.NC 001563.2	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
WNV Chin-01.AY490240.2	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
WNV NY99 isol-385-99.NC 009942.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
YFV 17D vaccine strain.NC 002031.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
YFV ASIB.AY640589.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
YFV Pasteur 17D-204.X15062.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
YFV vaccine strain 17D-213.U17067.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
ZWV MR766-NIID.LC002520.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
ZWV MR 766.AY632535.2	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
ZWV MR 766.NC 012532.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
ZWV ZikaSPH2015.KU321639.1	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0

% Identity and higher

 % Identity and higher

 % Identity and higher

Figure 3

4/23




Figure 4

5/23




Figure 5

6/23

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
DVV 1.NC 001477.1	0	68.7	77.4	83.8	49.7	49.7	50.1	49.9	50.5	38.3	51.5	50.5	50.9	43.0	43.8	43.0	43.2	57.3	57.9	58.4	58.4	57.1
DVV 16681.NC 001474.2	1	68.7	77.4	83.8	46.7	46.7	47.1	46.9	47.5	38.9	48.4	47.6	47.6	43.6	44.4	43.6	43.6	53.6	53.8	54.2	54.2	53.8
DVV 3.NC 001475.2	2	77.4	68.7	77.4	48.0	48.0	48.2	48.2	48.6	38.2	46.8	46.7	46.3	41.6	42.2	41.6	41.7	57.3	57.7	58.2	58.2	57.1
DVV 4.NC 002640.1	3	63.8	64.0	62.8	47.5	47.5	47.7	47.5	48.1	39.7	49.6	49.6	49.8	40.0	40.6	40.0	40.0	55.8	56.4	56.4	56.4	55.8
JEV SA14-14-2.AF315119.1	4	49.7	46.7	48.0	47.5	49.0	49.8	49.8	49.8	39.6	75.3	75.3	75.3	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV SA14-14-2.D90195.1	5	49.7	46.7	48.0	47.5	49.8	49.8	49.8	49.8	39.8	75.3	75.3	75.3	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV SA14.D90194.1	6	50.1	47.1	48.2	47.7	49.0	49.8	49.8	49.8	40.0	77.5	77.5	77.5	43.3	43.3	43.3	43.3	54.4	55.4	55.2	55.2	54.4
JEV virus.M55506.1	7	49.9	46.9	48.2	47.5	49.8	49.8	49.8	49.8	40.0	77.3	77.3	77.3	43.3	43.3	43.3	43.3	54.2	55.2	55.0	55.0	54.2
JEV virus.NC 001437.1	8	50.5	47.5	48.6	48.1	49.8	49.8	49.8	49.8	40.4	78.0	78.4	78.6	43.5	43.5	43.5	43.5	54.8	55.4	55.2	55.2	54.8
TEV virus.NC 001672.1	9	38.3	38.9	38.2	39.7	39.6	39.8	40.0	40.4	40.0	41.3	41.6	41.0	42.3	41.9	42.3	42.3	39.9	39.9	39.6	39.6	39.9
WNV 956.NC 001563.2	10	51.5	48.4	46.8	49.6	46.7	47.5	47.5	47.5	41.3	94.6	94.6	94.0	43.8	43.6	43.8	43.8	55.0	55.0	54.8	54.8	55.0
WNV Chin-01.AV490240.2	11	50.5	47.6	46.7	49.6	46.5	47.7	47.8	47.8	41.6	94.6	94.6	94.0	43.9	43.5	43.9	43.9	54.4	54.2	54.0	54.0	54.4
WNV NY99 isol-385-99.NC 009942.1	12	50.9	47.6	45.3	49.8	46.7	46.9	47.8	47.8	41.0	94.0	94.0	94.0	43.9	43.5	43.9	43.9	54.0	53.8	53.8	53.8	54.0
YFV 17D vaccine strain.NC 002031.1	13	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	43.5	43.5	43.5	43.8	42.0	43.4	43.5	43.5
YFV ASIB.AY640589.1	14	43.8	44.4	42.2	40.6	42.9	42.9	43.3	43.3	43.5	41.9	43.6	43.5	43.5	43.5	43.5	43.5	43.8	42.4	43.8	43.9	43.9
YFV isol-Pasteur 17D-204.X15062.1	15	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	43.5	43.5	43.5	43.8	42.0	43.4	43.5	43.5
YFV vaccine strain 17D-213.U17067.1	16	43.2	43.6	41.7	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	43.5	43.5	43.5	43.8	42.0	43.4	43.5	43.5
ZVVB.H818995.KU365777.1	17	57.3	53.8	57.3	55.8	54.0	54.0	54.4	54.2	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	98.8	98.8	98.4	98.4	98.8
ZV MR766-NIID.LC002520.1	18	57.9	53.8	57.7	56.4	54.8	54.8	55.4	55.2	39.9	55.0	54.2	53.8	43.4	43.8	43.4	43.4	98.8	98.8	98.8	98.8	98.6
ZV MR 766.AY632535.2	19	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	98.4	98.8	98.8	98.8	98.2
ZV MR 766.NC 012532.1	20	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	98.4	98.8	98.8	98.8	98.2
ZV ZikaSPH2015.KU321639.1	21	57.1	53.8	57.1	55.8	54.0	54.0	54.4	54.2	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	98.8	98.8	96.2	96.2	98.0

 50 % Identity and higher
 60 % Identity and higher
 70 % Identity and higher

Figure 6

292 AH	IG1TD	IEVHG	SAT	30K	VWAPD	SLI	ISUETVAIDGP	EA	KV	YN	VLTHVKINDK	ST	CAHIAAEHGGNA	RTYS	SLVT	AKFT	41			
292 AH	IG1TD	IEVHG	SAT	30K	VWAPD	SLI	ISUETVAIDGP	EA	KV	YN	VLTHVKINDK	ST	CAHIAAEHGGNA	RTYS	SLVT	AKFT	41			
292 AH	IG1TD	IEVHG	SAT	30K	VWAPD	SLI	ISUETVAIDGP	EA	KV	YN	VLTHVKINDK	ST	CAHIAAEHGGNA	RTYS	SLVT	AKFT	41			
292 AH	IG1TD	IEVHG	SAT	30K	VWAPD	SLI	ISUETVAIDGP	EA	KV	YN	VLTHVKINDK	ST	CAHIAAEHGGNA	RTYS	SLVT	AKFT	41			
307 FN	LGMSN	IEAS	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
307 FN	LGMSN	IEAS	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
307 FN	LGMSN	IEAS	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
307 FN	LGMSN	IEAS	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
307 FN	LGMSN	IEAS	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
294 MR	IGVSN	IEVSG	W	DV	HG SV	THAKD	TLIELKTEVNP	VL	KL	IE	KISNTTDSR	TO	EATLVEOODTIV	RTFV	SLIT	AKFK	413			
287 MR	IGMSN	IEVES	SG	W	DV	THAKK	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
313 MR	GVGN	IEVES	SG	W	DV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
292 SR	THLEN	IEVST	Q	TLV	LG SV	ITRAG	SHWEDAIYQNP	KT	EY	LL	KISDTKVAAP	TO	EATLVEOODTIV	RTFV	SLIT	AKFK	413			
306 FN	LGMSN	IEVES	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
306 FN	LGMSN	IEVES	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
306 FN	LGMSN	IEVES	ATW	DLV	GD SL	INAND	TLVRMINIEASOL	EV	SY	YH	SVTDISTVAR	TT	CAHIEKRADSSV	QGFT	SLVT	AKFS	426			
326 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
326 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
326 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
326 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
326 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
308 IR	IGVSN	IEVSG	W	DV	HG SV	THAKQ	TLFEIKTEAQ	PL	KY	IE	KLNTTITTSR	TO	EPSLNEEODKRFV	SHSV	GLVT	AMFR	406			
412	--AKSM	SLFEVD	OTK10	VIRAQ	VBKOE	-----	NWNTD	IKTLKFDAL	SGSOE	AEF	IGY	KATLE	OVOTAVDFGHSYIAEMEK	-----	ESW	DRQ	AO	LT	QSGSGG	514
412	--AKSM	SLFEVD	OTK10	VIRAQ	VBKOE	-----	NWNTD	IKTLKFDAL	SGSOE	AEF	IGY	KATLE	OVOTAVDFGHSYIAEMET	-----	ESW	DRQ	AO	LT	QSGSGG	514
412	--AKSM	SLFEVD	OTK10	VIRAQ	VBKOE	-----	NWNTD	IKTLKFDAL	SGSOE	AEF	IGY	KATLE	OVOTAVDFGHSYIAEMET	-----	ESW	DRQ	AO	LT	QSGSGG	514
412	--AKSM	SLFEVD	OTK10	VIRAQ	VBKOE	-----	NWNTD	IKTLKFDAL	SGSOE	AEF	IGY	KATLE	OVOTAVDFGHSYIAEMET	-----	ESW	DRQ	AO	LT	QSGSGG	514
427	--TSKA	IGRTIOPENIK	EVGIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
427	--TSKA	IGRTIOPENIK	EVGIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
427	--TSKA	IGRTIOPENIK	EVGIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
427	--TSKA	IGRTIOPENIK	EVGIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
427	--TSKA	IGRTIOPENIK	EVGIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
417	--KMKMG	KVQIOPENLE	TIIVTP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
407	--KMKMG	KVQIOPENLE	TIIVTP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
414	--SGKI	TGNLQI	LENLE	TIIVTP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
433	--LEPI	LEGKVQY	LENLE	TIIVTP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
414	--LEPI	LEGKVQY	LENLE	TIIVTP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
412	EAKK	KATGHY	DANKIV	TVKVEP	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
428	--TKATG	WII	QIOPENIK	EVAIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
426	--TKATG	WII	QIOPENIK	EVAIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
426	--TKATG	WII	QIOPENIK	EVAIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
426	--TKATG	WII	QIOPENIK	EVAIFV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537	
446	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
446	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
446	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
446	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
446	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		
428	--SKMTG	KSIOPENLE	RIMLSV	-----	TTTSENHGNYS	AOVGASOAKFT	TVTPHAPS	ITLKGDY	EVTLDS	EPSP	LNTEAFYVNTVGS	-----	KSLF	HRE	FA	LA	TPSSST	537		

Figure 7 (Part 2 of 3)

9/23

748	M	S	A	V	L	I	W	V	G	I	N	T	R	N	M	T	M	S	M	I	L	V	G	V	I	M	M	F	L	S	L	G	V	G	
748	M	S	A	V	L	I	W	V	G	I	N	T	R	N	M	T	M	S	M	I	L	V	G	V	I	M	M	F	L	S	L	G	V	G	
748	M	S	A	V	L	I	W	V	G	I	N	T	R	N	M	T	M	S	M	I	L	V	G	V	I	M	M	F	L	S	L	G	V	G	
748	M	S	A	V	L	I	W	V	G	I	N	T	R	N	M	T	M	S	M	I	L	V	G	V	I	M	M	F	L	S	L	G	V	G	
770	M	S	A	L	L	L	M	M	G	V	N	A	R	D	R	S	I	A	L	A	F	L	A	T	G	G	V	L	V	F	L	A	T	N	H
770	M	S	A	L	L	L	M	M	G	V	N	A	R	D	R	S	I	A	L	A	F	L	A	T	G	G	V	L	V	F	L	A	T	N	H
770	M	S	A	L	L	L	M	M	G	V	N	A	R	D	R	S	I	A	L	A	F	L	A	T	G	G	V	L	V	F	L	A	T	N	H
770	M	S	A	L	L	L	M	M	G	V	N	A	R	D	R	S	I	A	L	A	F	L	A	T	G	G	V	L	V	F	L	A	T	N	H
770	M	S	A	L	L	L	M	M	G	V	N	A	R	D	R	S	I	A	L	A	F	L	A	T	G	G	V	L	V	F	L	A	T	N	H
7752	I	G	I	L	L	T	W	L	G	L	N	S	R	S	T	S	L	S	M	T	C	I	A	V	G	M	V	T	L	Y	L	G	V	M	Q
745	I	G	V	I	T	W	I	G	M	N	S	R	S	T	S	L	S	V	T	L	V	L	V	G	I	V	T	L	Y	L	G	V	M	Q	
771	I	G	F	L	V	L	I	G	T	N	S	R	N	T	S	M	A	M	T	C	I	A	V	G	I	T	L	F	L	G	F	T	Q		
750	I	G	V	L	L	T	W	I	G	L	N	S	K	N	T	S	M	S	F	S	C	I	A	I	G	I	T	L	Y	L	G	A	V	Q	
751	L	G	V	A	L	L	L	L	L	L	L	M	R	N	P	T	M	S	M	S	F	L	L	A	G	G	L	V	L	A	M	T	L	G	V
766	L	G	A	L	L	M	G	I	N	A	R	D	R	S	I	A	M	T	F	L	A	V	G	G	V	L	L	F	L	S	V	N	H		
770	L	G	A	L	L	M	G	I	N	A	R	D	R	S	I	A	L	T	F	L	A	V	G	G	V	L	L	F	L	S	V	N	H		
770	L	G	A	L	L	M	G	I	N	A	R	D	R	S	I	A	L	T	F	L	A	I	G	G	V	L	L	F	L	S	V	N	H		
793	I	G	T	L	L	V	M	L	G	L	N	T	K	N	G	S	I	S	L	T	C	L	A	L	G	G	V	M	I	F	L	S	T	A	S
793	I	G	T	L	L	M	M	L	G	L	N	T	K	N	G	S	I	S	L	M	C	L	A	L	G	G	V	L	I	F	L	S	T	A	S
789	I	G	T	L	L	V	M	L	G	L	N	T	K	N	G	S	I	S	L	T	C	L	A	L	G	G	V	M	I	F	L	S	T	A	S
789	I	G	T	L	L	V	M	L	G	L	N	T	K	N	G	S	I	S	L	T	C	L	A	L	G	G	V	M	I	F	L	S	T	A	S
775	I	G	T	L	L	M	M	L	G	L	N	T	K	N	G	S	I	S	L	M	C	L	A	L	G	G	V	L	I	F	L	S	T	A	S

YFV_AS/BI.AY640589.1/292-784
YFV_17D_vaccine_strain_NC_002031.1/292-784
YFV_vaccine_strain_17D-213.U17067.1/292-784
YFV_isol-Pasteur_17D-204.X15062.1/292-784
IEV_SA14.D90194.1/307-806
IEV_virus_NC_001437.1/307-806
IEV_virus.M55506.1/307-806
IEV_SA14-14-2.AF315119.1/307-806
IEV_SA14-14-2.D90195.1/307-806
DWW_1_NC_001477.1/294-788
DWW_16681_NC_001474.2/287-781
DWW_4_NC_002640.1/313-807
DWW_3_NC_001475.2/294-786
TEV_virus_NC_001672.1/292-787
WNV_956_NC_001563.2/306-802
WNV_NY99_isol-385-99_NC_009942.1/306-806
WNV_Chin-01.AY490240.2/306-806
ZVV_MR766-NIID.LC002520.1/326-829
ZVV_ZikaSPH2015.KU321639.1/326-829
ZVV_MR_766_NC_012532.1/326-825
ZVV_MR_766.AY632535.2/326-825
ZVV_BeH815995.KU365777.1/308-811

Figure 7 (Part 3 of 3)

10/23




Figure 8

11/23




Figure 9A




Figure 9B

12/23






Figure 10



- + Similar virus concentration in harvests Day 2, Day3, Day 7; lower virus concentration in harvest Day 5
- + Day 2 and Day 3 harvests contained more HCP than Days 5/7 (correlates with observed CPE)
- + Minor amount of virus multimers observed

Figure 11







Figure 13

Lane	Sample
1	Molecular weight Marker
2	JEV Sucrose Gradient Pool (Reference)
3	Zika Harvest pool (day 2,3,5,7)
4	Zika Harvest pool (day 2,3,5,7) concentrated 300x
5	Zika Harvest pool (day 2,3,5,7) concentrated 300x + Protamine sulfate
6	Ultrafiltration Permeate
7	SGC Bottle 1, Fraction 4
8	SGC Bottle 1, Fraction 5
9	SGC Bottle 1, Fraction 6
10	SGC Bottle 1, Fraction 7
11	SGC Bottle 1, Fraction 8
12	SGC Bottle 1, Fraction 9
13	SGC Bottle 1, Fraction 10
14	SGC Bottle 1, Fraction 11
15	SGC Bottle 1, Fraction 12
16	SGC Bottle 1, Fraction 13
17	SGC Bottle 1, Fraction 14
18	SGC Bottle 1, Fraction 15
19	SGC Bottle 1, Fraction 16
20	SGC Bottle 1, Fraction 17
21	SGC Bottle 1, Fraction 18
22	SGC Bottle 1, Fraction 19
23	SGC Bottle 1, Fraction 20
24	SGC Bottle 1, Fraction 21
25	SGC Bottle 1, Fraction 22
26	SGC Bottle 1, Fraction 23



Pooled fractions F10-F14
(10mL total volume pere bottle)

Figure 14

Comparison of harvest schedules




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/082666A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/12 C07K14/005
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2016/145149 A1 (THE US SECRETARY OF THE ARMY ON BEHALF OF THE WALTER REED ARMY INST OF) 15 September 2016 (2016-09-15) page 5, lines 8-17 page 14, paragraph 37 - page 15, paragraph 40 page 17, paragraph 48 page 19, paragraph 52; claims 1-19 ----- -/--	1-29



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

31 March 2017

Date of mailing of the international search report

21/04/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sommer, Birgit

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/082666

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COX B D ET AL: "Predicting Zika virus structural biology: Challenges and opportunities for intervention", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY., vol. 24, no. 3-4, 1 August 2015 (2015-08-01), pages 118-126, XP055328128, GB ISSN: 0956-3202, DOI: 10.1177/2040206616653873 the whole document	1-29
A,P	COHEN J: "The race for a Zika vaccine is on", SCIENCE, vol. 351, no. 6273, 5 February 2016 (2016-02-05), pages 543-544, XP055360676, ISSN: 0036-8075, DOI: 10.1126/science.351.6273.543 the whole document	1-29
Y	SRIVASTAVA A K ET AL: "A purified inactivated Japanese encephalitis virus vaccine made in vero cells", VACCINE, vol. 19, no. 31, 14 August 2001 (2001-08-14), pages 4557-4565, XP027321987, ISSN: 0264-410X [retrieved on 2001-08-14] abstract page 4559, left-hand column, paragraph 3 - page 4560, left-hand column, paragraph 2 page 4564, left-hand column, paragraph 2	1-29
Y	US 6 309 650 B1 (KIM HYUN SU ET AL) 30 October 2001 (2001-10-30) examples 3,4; table 3	1-29
A	KOFLER R M ET AL: "CAPSID PROTEIN C OF TICK-BORNE ENCEPHALITIS VIRUS TOLERATES LARGE INTERNAL DELETIONS AND IS A FAVORABLE TARGET FOR ATTENUATION OF VIRULENCE", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 7, 1 April 2002 (2002-04-01), pages 3534-3543, XP001073714, ISSN: 0022-538X, DOI: 10.1128/JVI.76.7.3534-3543.2002 abstract, materials and methods;	1-29
	-/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2016/082666

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	LAROCCA R A ET AL: "Vaccine protection against Zika virus from Brazil", NATURE, vol. 536, no. 7617, 28 June 2016 (2016-06-28), pages 474-478, XP055314483, United Kingdom ISSN: 0028-0836, DOI: 10.1038/nature18952 abstract page 475, right-hand column, last paragraph - page 476, left-hand column, paragraph 1 -----	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/082666

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016145149	A1	15-09-2016	NONE

US 6309650	B1	30-10-2001	AU 748730 B2 13-06-2002
		CA 2301000 A1 11-03-1999	
		CN 1272879 A 08-11-2000	
		DE 69837211 T2 06-12-2007	
		DE 122009000037 I1 05-11-2009	
		DK 1025209 T3 25-06-2007	
		DK 1604685 T3 18-06-2012	
		EP 1025209 A1 09-08-2000	
		EP 1604685 A2 14-12-2005	
		ES 2281929 T3 01-10-2007	
		ES 2382946 T3 14-06-2012	
		JP 4161017 B2 08-10-2008	
		JP 2001514844 A 18-09-2001	
		MY 129773 A 30-04-2007	
		NL 300391 I1 03-08-2009	
		NZ 503522 A 29-06-2001	
		US 6309650 B1 30-10-2001	
		WO 9911762 A1 11-03-1999	
